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Toll-like receptors (TLRs) are pattern recognition receptors that upon detection of pathogen-
associated molecular patterns activate innate immune cells. TLRs localised in the endosomal 
compartment are specialised in recognising nucleic acid molecules and instruct adaptive 
immune responses towards a Th1 phenotype with strong cytotoxic T cell effector functions. 
Synthetic agonists of endosomal TLRs (TLR3, TLR7/8 or TLR9) were shown to promote anti-
tumour immune responses when administered to the tumour site, with imiquimod (TLR7 
agonist) being approved for topical administration in basal cell carcinoma and stage zero 
melanoma. However, when administered systemically, endosomal TLR agonists induce broad 
immune activation that leads to adverse reactions, preventing their use for non-topical 
administration. Novel strategies for targeted delivery of TLR agonists to the tumour tissue may 
allow overcoming these limitations. 
This study explores different methods of linking endosomal TLR agonists to Trastuzumab, a 
clinically used HER2-specific antibody, to achieve targeted delivery to HER2-expressing 
tumour tissue. We investigate the feasibility of the approach and its efficiency in promoting 
anti-tumour immune responses. We engineered and expressed a novel fusion antibody with 
the nucleic acid binding, cationic peptide LL37. To achieve this, we investigated how a variety 
of linkers used in fusion protein design impact folding and assembly of our fusion antibody. 
Additionally, we evaluated methods of biochemical conjugation of Trastuzumab to the TLR9 
agonist CpG. We showed that the properties of each moiety, and the conjugation chemistry 
impact on the functionality of the resulting biochemical conjugates. 
To characterise both conjugates and complexes and their effect on immune responses, we 
established and adapted a variety of physicochemical and in vitro assays. To evaluate the 
efficiency of conjugates and complexes in vivo, we have developed a human HER2-expressing 
lung tumour model in immunocompetent mice, using human HER2 transgenic B16 melanoma 
cells, syngeneic to the C57BL/6 background. Data so far, illustrated possible advantages, but 
also important limitations of each approach. Specifically, in contrast with conjugates, 
complexes did not persist in serum. Trastuzumab-CpG conjugates generated using site-
specific conjugation technologies enhanced anti-tumour T cell responses and moderately 
delayed tumour growth. This was not observed for conventional conjugates, indicating that 
appropriate conjugation technology is required for conjugate functionality. 
Due to the specific in vivo profile of conjugates, further investigations of their effects, 
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OVA - ovalbumin 
P 
PBMC - peripheral blood mononuclear cell 
PCR - polymerase chain reaction 
pDC – plasmacytoid dendritic cells 
PIPE - polymerase incomplete primer extension 
poly I:C - Polyinosinic-polycytidylic acid 
polyUs21 – 21-mer single stranded phosphorothioated polyuridylic acid 
R 
RD – resolution metric 
ROI – region of interest 
RT – room temperature 
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RV – reverse  
S 
SD – standard deviation 
SDS-PAGE – dodecyl sulphate and polyacrylamide gel electrophoresis 
SEM – standard error of mean 
SEC – size exclusion chromatography 
SFM – serum-free medium 
SFFV - spleen focus-forming virus 
SIN – self-inactivating virus 
SMCC - succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate 
ssRNA – single stranded RNA 
T 
TCEP - tris(2-carboxyethyl)phosphine 
TC – tissue culture 
TLR – toll-like receptor 
Tm – melting temperature 
TNF-α – tumour necrosis factor alpha 
Tr – Trastuzumab 
Tr(TH) – Trastuzumab with THIOMAB mutations 
Tr-LL37 – Trastuzumab-LL37 (without linker) 
Tr-H2-LL37 – Trastuzumab-H2-LL37 
Tr-H3-LL37 – Trastuzumab-H3-LL37 
Tr-H4-LL37 – Trastuzumab-H4-LL37 
Tr-MCC-CpG – Trastuzumab CpG non-specific conjugate generated with SMCC 
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TRP-1 - tyrosinase related protein-1 
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Immunotherapy has revolutionised the clinical management of multiple cancer types, bringing 
long-lasting benefits to groups of patients with tumours that were previously considered 
untreatable. Currently, distinct classes of immunotherapies are approved for treatment of 
selected tumour indications, and include immune checkpoint inhibitors, bispecific antibodies 
and cell-based therapies. These drugs demonstrate the potential of the immune system to 
control tumour growth. Despite these enormous strides in cancer treatment, there are, however, 
many patients whom do not benefit from immunotherapy, either due to lack of efficacy or 
substantial, sometimes even life-threatening adverse effects (Johnson, Chandra, and Sosman 
2018; Neelapu et al. 2018; Kennedy and Salama 2020). Therefore, further research efforts are 
currently underway to increase response rates, and minimise adverse effects (Khalil et al. 
2016; Tang et al. 2018). 
Progress in the field of tumour immunology has led to the important understanding that the 
tumour microenvironment is immunosuppressive and hinders anti-tumour immune responses. 
Local immunosuppression is mediated by tumour cells, stromal cells and immune cells (Chen 
and Mellman 2013). Therefore, developing therapies that act on immune cells to break local 
tumour immunosuppression is a promising strategy for cancer treatment. Among 
immunomodulatory molecules, the most successful class are immune checkpoint inhibitors. 
These are monoclonal antibodies anti-tumour T cells, leading to tumour regression in a 
percentage of treated patients. Currently, multiple other immunomodulators, acting on a 
variety of targets in the tumour microenvironment are explored for therapy, including agonists 
of endosomal toll-like receptors (TLRs) (Tang et al. 2018; Tang, Shalabi, and Hubbard-Lucey 
2018). Endosomal TLR agonists activate dendritic cells and other innate immune cells in the 
tumour microenvironment and have been shown to promote anti-tumour T cell responses and 
local inflammation in multiple animal models, as well as a few clinical trials (Iribarren et al. 
2016; Garcia-Martinez et al. 2018). 
As with other immunotherapies acting on immune cells in the tumour microenvironment, 
appropriate accumulation of endosomal TLR agonists to the tumour site is paramount for 
treatment efficacy, as well as avoiding immune activation in healthy tissues, which leads to 
adverse effects (Engel, Holt, and Lu 2011). Increasing evidence suggests that local 
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administration by topical application or direct intratumoral injection of endosomal TLRs, are 
promising therapeutic approaches (Marabelle et al. 2014; Smith et al. 2018; Murthy, Minehart, 
and Sterman 2017). With growing research interest for the approach, and to facilitate clinical 
development of intratumoral immunotherapy, the European Society for Medical Oncology has 
recently published a set of expert recommendations (Marabelle et al. 2018).  
Importantly, while endosomal TLR agonists show promise for intratumoral immunotherapy, 
not all patients have tumours that are safely accessible to direct injection. This can be due to 
small dimensions of metastases, inaccessible locations or bleeding risk (Marabelle et al. 2017; 
Marabelle et al. 2018). To circumvent these limitations, we set out to investigate the potential 
of antibody-based targeted delivery systems in fostering endosomal TLR agonist-based cancer 
immunotherapy. 
This chapter will describe endosomal TLR agonists and their potential in tumour 
immunotherapy, explaining the need for targeted delivery. Furthermore, we describe the use 
of recombinant antibodies as targeted delivery systems and our strategy in harnessing their 
properties to enable concentration of endosomal TLR agonists to the tumour 
microenvironment.  
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1.2 Endosomal toll-like receptors  
Toll-like receptors (TLRs) are a family of pattern recognition receptors (PRRs) of the innate 
immune system, that recognize a variety of pathogen-associated molecular patterns (PAMPs) 
and initiate immune responses (Medzhitov 2001; Takeda, Kaisho, and Akira 2003).  
All TLRs are membrane-bound proteins, and can be broadly divided in two subsets, based on 
cellular localization, either on the plasma membrane (TLR1, TLR2, TLR4, TLR5, TLR6, 
TLR10) or endosomal compartments (TLR3, TLR7, TLR8 and TLR9). In terms of PAMPs, 
cell surface TLRs recognize microbial membrane-bound ligands, such lipids, proteins or 
lipoprotein. Endosomal TLRs recognize nucleic acids (NA) of viruses and other endocytosed 
pathogens: double-stranded RNA (dsRNA) by TLR3, single-stranded RNA (ssRNA) by TLR7 
and 8 and double-stranded DNA (dsDNA) by TLR9 (Iwasaki and Medzhitov 2004; O'Neill, 
Golenbock, and Bowie 2013).  
TLRs are expressed by multiple immune cells including monocytes, macrophages, dendritic 
cells (DCs) and B cells, but select receptors are also expressed by non-immune cells including 
fibroblast (TLR3 and TLR4) and intestinal epithelial cells (TLR5) (Takeda and Akira 2005). 
Innate immune cells respond to TLR agonists by secreting proinflammatory cytokines 
(Medzhitov 2007). In addition to cytokine release, TLR stimulation induce maturation of 
dendritic cells which results in antigen presentation, TLR signaling bridges innate and adaptive 
immunity (Iwasaki and Medzhitov 2004). The profile of these adaptive immune responses 
depends on the type of PAMP and can be influenced by factors in the local environment as 
well (Liu 2001; Diebold 2009; Iwasaki and Medzhitov 2015). Importantly, endosomal TLRs 
have evolved primarily to detect viral infections and are specialized in inducing Th1 and 
cytotoxic T lymphocyte (CTL) responses, which are crucial for the clearance of virus-infected 
cells. These responses can also be exploited for the eradication of tumour cells (Iwasaki and 
Medzhitov 2015). 
1.2.1 Endosomal TLR signaling 
In terms of signaling, ligand binding to the endosomal leucin-rich-repeats domain of TLRs 
induces a conformational change in the cytoplasmatic Toll-like/IL-1 receptor (TIR) domain, 
which recruits adaptor molecules. TLR7, TLR8 and TLR9 use the adaptor MyD88 to initiate 
a signaling cascade resulting in activation of NF-κB, IRF-1, and AP-1 transcription factors, 
which in turn induce gene transcription of proinflammatory cytokines such as IL-12, TNF-α 
and IL-6 by myeloid dendritic cells (mDCs) and macrophages. IRF-5 induces production of 
INF-α. Additionally, in plasmacytoid dendritic cells (pDCs), MyD88 induces IRF7 as well 
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resulting in higher levels of secreted type I interferons. In contrast with TLRs 7, 8 and 9, TLR3 
recruits the adaptor TRIF and downstream signaling ultimately activates IRF3 and IFN-β 
production in mDCs and macrophages. TLR3 signaling can involve NF-κB activation and 
production of proinflammatory cytokines as well (Blasius and Beutler 2010; O'Neill and 
Bowie 2007). 
1.2.2 Immune responses induced by endosomal TLR signaling 
Endosomal TLRs are expressed by a variety of cells and mediate a series of immune responses. 
Importantly, cell expression patterns, while largely overlapping, are distinct in the mouse and 
human system (Iwasaki and Medzhitov 2004). Notably, TLR8 is inactive in mice 
(Alexopoulou, Desnues, and Demaria 2012). Endosomal TLR expression patterns are 
complex, and currently incompletely defined, with subsets of immune cells regulating 
endosomal TLR expression depending on the local environment (Akira, Uematsu, and 
Takeuchi 2006).  
A key feature of endosomal TLR signaling is triggering dendritic cell activation, which in turn 
induces adaptive immune responses (Manicassamy and Pulendran 2009; Iwasaki and 
Medzhitov 2015). In terms of endosomal TLR expression on DC subtypes, plasmacytoid DCs 
express TLR7 and 9, but not TLR3, while subtypes of myeloid DCs can express either or 
multiple endosomal TLR. Expression can differ between human and mouse equivalent subset 
of myeloid DCs (Edwards et al. 2003; Liu et al. 2002; Schreibelt et al. 2010). Upon endosomal 
TLR triggering, both human and mouse DCs undergo a maturation process characterized by 
antigen presentation of the ingested material on the major histocompatibility complex (MHC), 
upregulation of costimulatory molecules CD80 and CD86 and production of proinflammatory 
cytokines IL-12, TNF-α and IL-6. Notably, plasmacytoid dendritic cells and not myeloid DCs 
are the main source of IFN-α. The maturation process initiated by endosomal TLR signaling 
drives Th1 immune responses and the expansion of antigen-specific T cells (Diebold 2008a; 
Brencicova and Diebold 2013; Manicassamy and Pulendran 2009). Importantly, priming of 
functional cytotoxic T cell responses requires TLR triggering of DCs and interaction with 
helper T cells (Elgueta et al. 2009).  
Both human and mouse B cell subsets express endosomal TLRs and respond to their agonists. 
Only low levels of TLR7 and TLR9 were detected in naïve human B cells, while activated and 
memory cells showed substantially higher levels (Bernasconi, Onai, and Lanzavecchia 2003; 
Agrawal and Gupta 2011). Mouse B cells express TLRs 3, 7 and 9, at various levels among 
cell subtypes. To exemplify, mouse B-1a cells express significant levels of TLR7 and TLR9  
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(Gururajan, Jacob, and Pulendran 2007). In both human and mouse cells, expression of 
endosomal TLRs is up-regulated in response to BCR signaling and type I interferons (Bourke 
et al. 2003; Browne 2012). Both human and mouse B cells have been shown to produce 
cytokines IL-6, TNF-α and IL-10 in response to either TLR7 or TLR9 agonists (Pettengill et 
al. 2016; du Plessis et al. 2016; Barr et al. 2007). 
Endosomal TLR signaling is involved in the generation of B-cell responses, whether T-cell 
independent or T-cell dependent. In terms of T-cell independent responses, in vitro 
experiments showed that ligand binding to TLR7 or TLR9 induces IgM production by select 
mouse and human B cell subsets (Bekeredjian-Ding and Jego 2009; Rawlings et al. 2012). 
Mouse models of infection showed that both endosomal TLR signaling and B cell receptor 
(BCR) signaling are required for the generation of pathogen-specific T-cell independent IgM 
responses in vivo (Alugupalli et al. 2007; Rawlings et al. 2012).  
Regarding T-cell dependent antibody responses, multiple research groups showed that TLR 
signaling in both B cells and dendritic cells are required for class switching to a particular 
heavy-chain isotype and affinity maturation (Browne 2012; Hua and Hou 2013). TLR9 and 
TLR7 agonists have been shown to promote IgG2a, IgG2b and IgG3 production in mouse 
models of viral infection or vaccination (Lin, Gerth, and Peng 2004; Bekeredjian-Ding and 
Jego 2009; Rookhuizen and DeFranco 2014). However, when TLR7 agonist polyUs21 was 
used as vaccine adjuvant in vivo by others, no class switch preference for a particular isotype 
was noticed (Rajagopal et al. 2010). An increase in antibody production with no preference of 
B-cell class switching was reported by others in mice treated intranasally with a TLR9 agonist 
(Gallotta et al. 2018). These discrepancies suggest that B-cell class switch fine-tuning is 
complex and might be influenced by multiple stimuli or could vary with individual endosomal 
TLR agonists or administration routes.  
As mentioned above, endosomal TLRs engagement stimulates monocytes and macrophages 
as well (Barbalat et al. 2011). While expression of TLR7 is similar for mouse and human 
macrophages, TLR9 and TLR3 expression is characteristic to murine macrophages only, while 
TLR8 functionality is limited to human monocytes and macrophages (Anwar et al. 2019). 
Endosomal TLR signaling induces proinflammatory cytokine and chemokine production by 
macrophages (Blasius and Beutler 2010), as well as inducible nitric oxide synthase (iNOS) 
(Krieg 2002).  
Direct activation of immune cells by endosomal TLR triggering induces proinflammatory 
cytokine production. This in turn can indirectly activate other cells or support adaptive immune 
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responses (Iwasaki and Medzhitov 2004). For instance, IL-12 production by dendritic cells 
promotes Th1 and CTL responses (Trinchieri 2003). Another good example is the activation 
of human NK cells by type I interferons secreted by TLR9 triggered pDCs (Marshall et al. 
2006). Human macrophages can be polarized to M1 phenotype in environments dominated by 
high amounts of IFN-ɣ, which is produced in the context of Th1 immune responses (Murray 
2017).  
1.2.3 Agonists of endosomal TLRs  
In the context of infection, upon endocytic or phagocytic uptake of viruses and bacteria, 
microbe degradation leads to release of nucleic acids (NAs), such as double stranded DNA 
(dsDNA) with unmethylated CpG motifs recognized by TLR9, viral single stranded RNA 
(ssRNA) recognized by TLR7 and TLR8 and double stranded RNA (dsRNA) detected by 
TLR3 (Blasius and Beutler 2010).  
While it was originally thought that endosomal TLRs recognise microbe-specific nucleic acid 
sequences, it was later shown that the receptors do not distinguish between foreign and self- 
nucleic acids (Majer, Liu, and Barton 2017). In homeostatic conditions, self-nucleic acids do 
not access endosomal compartments to activate TLRs (Brencicova and Diebold 2013). Under 
certain conditions, however, self-nucleic acids can access the endosomes and activate 
endosomal TLRs. For instance, in lupus patients, which develop anti-DNA antibodies, DNA-
antibody complexes are internalized via Fc-mediated endocytosis, exposing self-DNA to 
TLR9 and triggering further inflammation (Hurst and von Landenberg 2008). The peptide 
LL37, which is overexpressed in psoriatic skin and other autoimmune conditions, has been 
shown to bind and deliver both self-DNA and self-RNA to endosomes, triggering TLR9 or 
TLR7 and 8, respectively (Ganguly et al. 2009; Lande et al. 2007). Therefore, discrimination 
between “self” and “non-self” molecules is mediated by access of agonists to the endosomal 
compartment, which can be breached under pathological conditions, leading to inflammation 
and promoting autoimmune responses. 
As mentioned above, studies have defined the nucleic acid requirements for endosomal TLR 
receptor binding, and this has further facilitated the development of synthetic agonists, which 
are of great interest for therapeutic use (O'Neill, Bryant, and Doyle 2009; Vanpouille-Box, 
Hoffmann, and Galluzzi 2019).  
Specifically, TLR3 binds dsRNA of minimum 40 base pairs in length without stringent 
sequence requirements (Botos et al. 2009). In terms of synthetic molecules, TLR3 detects and 
is activated by polyinosine-polycytidylic acid (polyI:C) (Alexopoulou et al. 2001). 
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TLR7 and human TLR8 recognize single stranded RNA (ssRNA). Under physiological 
conditions RNA does not access the endosomal compartment. This is achieved in viral 
infections, with recognition of viral single-stranded RNA (ssRNA) (Lund et al. 2004; Heil et 
al. 2004). To deliver self-RNA to endosomes, either transfection reagents (Diebold 2008b) or 
LL37 (Ganguly et al. 2009) can be employed. While many RNA molecules trigger TLR7 and 
human TLR8, a preference for uracil repeats in RNA has been noted. This allowed for the 
development of the synthetic TLR7 agonist polyUs21, which is a 21 bases long uracil 
homopolymer (Diebold et al. 2006; Diebold et al. 2004). In terms of secondary conformation, 
polyU homopolymers do not form double-stranded structures (Saenger 1984). To access the 
endosomal compartment and activate immune cells, polyUs21 needs to be administered in 
complex with transfection reagents (Diebold et al. 2006).  
In addition to the synthetic polyUs21, TLR7 and human TLR8 also respond to 
imidazoquinolines, such as imiquimod and resiquimod (R848), which are synthetic small 
molecules (Hemmi et al. 2002). Like all small molecules, imiquimod and resiquimod passively 
diffuse the cell membranes (Yang and Hinner 2015) and do not require special delivery 
methods to reach the endosomal compartment. The profile of immune responses, however, is 
distinct from polyUs21. In contrast with R848, polyUs21 induces IFN-α production by 
plasmacytoid DCs driving robust Th1 and CTL responses in mice (Rajagopal et al. 2010).   
Regarding TLR9 activation, research has shown that the sugar backbone phosphodiester (PD) 
2’ deoxyribose binds and activates TLR9 and this is enhanced by DNA bases. Conversely, the 
phosphorothioate (PS) modified 2’ deoxyribose backbone, which confers protection to 
synthesized oligodeoxynucleotides (ODN) from degradation by nucleases, binds but does not 
activate TLR9. Addition of CpG motifs to phosphorothioate backbones is required to induce 
potent TLR9 activation (Haas et al. 2008). These results explain the TLR9 activation mediated 
by DNA, including self-DNA (Boule et al. 2004; Blasius and Beutler 2010) and by CpG 
containing, phosphorothioate-modified oligodeoxynucleotides (ODN), where the CpG motifs 
are key to receptor activation and inversion to GpC abolishes activation almost completely 
(Krieg 2002). In addition to conferring resistance to degradation by nucleases, the PS 
backbone increases uptake of CpG-ODN into the endosomes of macrophages (Sester et al. 
2000).  
A wide range of CpG-ODN were developed, many specifically for use in tumour 
immunotherapy (Krieg 2007), and they can be broadly divided in three classes of CpG 
molecules. Class A CpG-ODN stimulate pDCs to produce higher levels of IFN-α, class B 
molecules are stronger stimulants of B cells, while class C CpG-ODN combines the effects of 
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the other two classes (Vollmer et al. 2004). The three classes of CpG are also distinct in terms 
of secondary structure. Class A CpG contain poly-G motifs which facilitate assembly in 
higher-ordered structures called G-tetrads. Class C CpG-ODN contain a palindrome in their 
sequence, resulting in assembly in duplexes. In contrast, class B CpG-ODN are reportedly 
monomeric under physiological conditions (Krieg 2006). These distinct structures drive 
differences in biological activity. Class A and class C CpG molecules, which form multimers, 
induce much higher levels of IFN-α in pDCs than class B molecules (Vollmer et al. 2004; 
Samulowitz et al. 2010; Hartmann et al. 2003).    
1.2.4 Endosomal TLR agonists in tumour immunotherapy 
Due to their specific immunomodulatory profile, synthetic agonists of endosomal TLRs have 
been explored as adjuvants, including for anti-tumour vaccines (Duthie et al. 2011). 
Importantly, endosomal TLR agonists have also been studied as drugs with potential in cancer 
immunotherapy (Molenkamp et al. 2007; Aranda et al. 2014; Iribarren et al. 2016).  
Vaccine adjuvants 
Regarding the use of endosomal TLR agonists as vaccine adjuvants, CpG-ODNs are presently 
the most successful. An abundance of studies focused on CpG molecules, due to their potency 
in generating antigen specific Th1 and CTL responses, as well as robust, rapid antibody 
responses (Bode et al. 2011). Notably, CpG 1018 is used as adjuvant in the FDA approved 
hepatitis B vaccine Heplisav-B™ (Campbell 2017). Data pooled from a total of four 
randomised controlled trials showed that 90.0-100.0% of subjects receiving the CpG-
containing Heplisav-B™ developed protective antibodies, compared to 70.5%-90.2% of 
subjects using the original anti-hepatitis B vaccine Engerix-B (Schillie et al. 2018).   
CpG was used as adjuvant within human vaccines for cancer as well. In two independent 
clinical trials, vaccination with NY-ESO-1 peptide, montanide and CpG induced expansion of 
CD4+ T cells and CD8+ T cells in NY-ESO-1-expressing melanoma patients. This finding is 
especially important since most vaccines do not expand T cell responses required for clearing 
tumour cells (Valmori et al. 2007; Fourcade et al. 2008). Interestingly, a similar vaccination 
approach using NY-ESO-1 peptide intradermally and topical Imiquimod induced protein 
specific CD4+ T cells, but no CD8+ T cells in melanoma patients (Adams et al. 2008). The 
reasons for this are not clear and might be due to differences in administration route or agonist 
potency.  
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Importantly, both preclinical (Nierkens et al. 2008; Maurer et al. 2002) and clinical data 
(Cooper et al. 2004; Campbell 2017) support the notion that antigen and adjuvant (CpG) 
administration at the same site massively increases antigen-specific immune responses.  
As with most tumour vaccines (Guo et al. 2013), the tumour-specific cytotoxic T cells 
generated through vaccination with tumour proteins or peptides and endosomal TLR agonists 
did not generally infiltrate tumours and did not induce tumour regression (Appay et al. 2006). 
The potential of tumour vaccines is currently investigated in combination with other 
immunotherapies, such as immune checkpoint inhibitors (Hollingsworth and Jansen 2019; 
Guo et al. 2013).  
Tumour immunotherapies 
a) Preclinical evidence 
An extensive body of preclinical evidence studied endosomal TLR agonists as drugs for their 
potential in immunotherapy. A PubMed database (https://www.ncbi.nlm.nih.gov/pubmed/) 
search using the keywords “polyI:C” AND “tumor” AND “immunotherapy” AND “mice” 
returned 112 individual journal articles. When the same search was performed using the 
keywords “TLR7” AND “agonist” instead of polyI:C, the sech returned 89 journal articles. 
Impressively, the search using “CpG” AND “tumour” AND “immunotherapy” AND “mice” 
returned 545 individual journal articles. Considering that these databases are not all-inclusive, 
the possibility of counting studies that employed two or more of the mentioned agonists and 
other possible biases induced by the choice of keywords, the number are not exact. These 
searches illustrate, however, the abundance of preclinical animal studies that employed 
endosomal TLR agonists for immunotherapy. 
In terms of delivery systems, a great number of studies have employed intratumoral 
administration (IT), while others used targeted delivery approaches such as nanocarriers. The 
following exemplified elegant preclinical studies demonstrate the anti-tumour efficacy of 
endosomal TLR agonists in a variety of tumour mouse models:  
TLR3 agonist poly(I:C), given IT, was efficient in reactivating pre-existing anti-tumour T cell 
responses which controlled tumour growth in a mouse model of mesothelioma (Currie et al. 
2008). More recently, a study showed that combination therapy of IT poly(I:C) and anti-PD-1 
induced T cell mediated control in a B16-OVA melanoma model, which responds poorly to 
immune checkpoint blockade (Nagato et al. 2014). Another study using B16-OVA melanoma 
tumours demonstrated the anti-tumour efficacy of intratumoral B0-122, a nanoplexed form of 
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poly(I:C) complexed with polyethylenimine (PEI). Dendritic cell maturation was paramount 
for tumour specific CD8+ T cell responses and tumour growth control. These effects further 
synergised with systemic anti-PD-L1 or anti-CD137 antibodies. (Aznar et al. 2019).  
TLR7/8 agonist 3M-052, an imidazoquinolin, induced anti-tumour immune responses when 
administered intratumorally in a B16F10 melanoma mouse model (Singh et al. 2014). Similar 
immune-mediated delay of tumour growth was observed with another TLR7 agonist small 
molecule, SZU101, in a 4T1 mouse model of breast cancer (Diao et al. 2016) and with 
resiquimod in mouse models of pancreatic cancers (Michaelis et al. 2019). A novel TLR7/8 
agonists MEDI9197, with improved retention at the injected tumour site, showed even stronger 
anti-tumour effects when administered intratumorally, but not subcutaneously in mouse 
models of melanoma (B16F10), breast cancer (4T1) and colon cancer (MC-38). Anti-tumour 
efficacy was further improved by combination treatment with anti-OX40 antibodies (Mullins 
et al. 2019). These studies illustrate anti-tumour effects can be achieved with multiple TLR7 
agonists and that retention of small molecules at the tumour site might lead to improved 
responses, either alone or in combination with other immunotherapies. 
TLR9 agonists CpG molecules were studied as well. In a mouse model of lymphoma, T cell 
immunity and tumour growth control has been observed with IT CpG used as monotherapy 
(Lonsdorf et al. 2003). Treatment with CpG in combination with in situ tumour destruction by 
cryoablation induced anti-tumour T cell immunity driving regression of B16OVA tumours. 
Dendritic cell maturation, which primed CD8+ CTLs driving anti-tumour effect was 
substantially increased when CpG was administered locally, peritumorally, compared to 
systemic administration (Nierkens et al. 2009). In this model, collaboration between pDCs and 
mDCs was essential for anti-tumour efficacy (Nierkens et al. 2011). These results are in line 
with studies we described above showing that co-administration of antigen and adjuvant at the 
same site boosts anti-tumour immunity.  
The capacity of CpG molecules to induce anti-tumour T cell responses, provided a strong 
rational for combination treatment with immune checkpoint inhibitors. In mouse models of 
colon carcinoma (CT26 and MCA38) and breast adenocarcinoma (TSA), which respond 
poorly to anti-PD-1 therapy, treatment with IT CpG reversed this resistance. When only one 
tumour site was treated IT with CpG and systemic anti-PD-1 in mice bearing two subcutaneous 
tumour nodules, tumour rejection was also observed at untreated sites in a percentage of mice 
(Wang et al. 2016). Another group showed similar anti-tumour efficacy of intratumoral CpG 
in combination with another immune checkpoint inhibitor, anti-OX40. Again, the treatment 
promoted anti-tumour immune responses in multiple mouse models (Sagiv-Barfi et al. 2018). 
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To summarise, for each of the endosomal TLRs, there is converging preclinical evidence 
illustrating the anti-tumour efficacy of their agonists, either alone, or in combination with other 
therapies. This was shown for multiple transplantable tumour mouse models. The anti-tumour 
effect was mediated by local activation of antigen presenting cells, promoting CTL responses. 
These studies suggest that administration of endosomal TLR agonist at the tumour site 
promote and even induce anti-tumour immune responses that control tumour growth.  
b) Clinical trials 
The success of multiple endosomal TLR agonists in preclinical settings supported their 
evaluation as cancer immunotherapies in the clinical setting in combination with other agents.  
Historically, agonists of endosomal TLRs have been investigated in clinical trials for systemic 
administration and showed no therapeutic benefit to patients. Furthermore, a plethora of 
immune-mediated adverse effects was observed (Schmidt 2007; Weber et al. 2009; Hirsh et 
al. 2011). As described above, preclinical advances have led to the understanding that local 
administration of endosomal TLR agonists underpins anti-tumour immune responses 
(Nierkens et al. 2009). In subsequent studies, where TLR agonists were administered 
intratumorally, these drugs showed promise, reigniting research efforts (Anwar et al. 2019). 
These results from clinical trials support the notion that accumulation of endosomal TLR 
agonists at the tumour site is paramount for anti-tumour effects and systemic administration 
does not achieve this. 
Local administration of endosomal TLR agonists shows promising anti-tumour responses in 
patients. Notably, topical administration of the lipophilic Imiquimod is approved for treatment 
of superficial skin tumours such as basal cell carcinoma (NICE NG14, 2015). Direct injection 
of the CpG molecule SD-101 into the tumour itself, in combination with local low-dose 
radiation resulted in infiltration of cytotoxic T cells into the injected tumour microenvironment 
which was associated favourable clinical responses in patients with indolent lymphoma. 
Moreover, tumour regression was observed at treated sites (26 out of 29 patients) and at distant, 
non-treated sites (24 out of 29 patients) (Frank et al. 2018). Intratumoral therapy with SD-101 
in addition to systemic PD-1 blockade was safe in patients with metastatic melanoma and 
induced local anti-tumour immune responses (Ribas et al. 2018). Studies have shown that that 
intratumoral injection of CpG class B activates both pDCs and mDCs in the sentinel lymph 
node in patients with melanoma (Molenkamp et al. 2007; Koster et al. 2017). Moreover, 
treatment with CpG class B offered protection against melanoma recurrence (Koster et al. 
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2017). Many more clinical studies evaluating endosomal TLR agonists for intratumoral 
immunotherapy are underway, with (Anwar et al. 2019) providing a comprehensive list. 
This current landscape of clinical studies involving endosomal TLR agonists for cancer 
immunotherapy illustrates the need for appropriate delivery methods to the tumour tissue. 
Intratumoral immunotherapy is gaining clinical momentum, since such approaches show 
promise in priming local tumour specific immunity, while limiting the access of 
immunotherapies to healthy tissue, thus minimising adverse effects (Marabelle et al. 2014; 
Murthy, Minehart, and Sterman 2017; Hamid, Ismail, and Puzanov 2019). While interest in 
this approach is increasing, not all patients can benefit from it, since not all tumour are safely 
accessible to direct injection, due to location, small dimensions or importantly, bleeding risk 
(Marabelle et al. 2018; Marabelle et al. 2017). These limitations could be circumvented by 
alternative drug administration methods that lead to predominant accumulation of therapies at 
the tumour site, while sparing healthy tissue. 
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1.3 Targeted delivery  
Targeted drug delivery defines the concentration of a drug, independently of administration 
route into targeted sites, for instance tumour lesions, while sparring healthy tissues. While 
some authors include local administration under targeted drug delivery methods (Torchilin 
2000), others distinguish it from targeted drug delivery (Murthy, Minehart, and Sterman 2017). 
Specialised targeted drug delivery systems are of significant interest for cancer therapy. 
Representatives are nanocarriers, for instance liposomes, microspheres and nanoparticles and 
antibody-based systems, where monoclonal antibodies recognising tumour tissue antigens are 
used as vehicles to transport and concentrate other drugs to the tumour tissue (Mitragotri, 
Burke, and Langer 2014; Schrama, Reisfeld, and Becker 2006; Rosenblum et al. 2018). The 
use of liposomes and other nanocarrier technologies for delivery of CpG and other endosomal 
TLRs does not fall under the scope of this work and was described elsewhere (Engel, Holt, 
and Lu 2011; Zhuang et al. 2019). Here, we only focus on the use of antibodies as vehicles for 
targeted drug delivery to the tumour tissue. 
Monoclonal antibodies targeting membrane-bound tumour associated antigens have been 
developed for tumour therapy, with several agents approved for clinical use including 
Trastuzumab (anti-HER2), Cetuximab (anti-EGFR), Rituximab (anti-CD19) and 
Alemtuzumab (anti-CD52) (Weiner, Dhodapkar, and Ferrone 2009; Levene, Singh, and 
Palmieri 2005). One intrinsic property of anti-tumour antibodies is to concentrate into the 
tumour tissue. Positron emission tomography (PET) or PET/CT studies using labelled anti-
tumour antibodies administered to tumour patients enable visualisation of antibody 
accumulation into tumour tissues (Menke-van der Houven van Oordt et al. 2015; Mortimer et 
al. 2014; Mortimer et al. 2018). Another useful property of anti-tumour monoclonal antibodies 
is the extended half-life of several days characteristic to all IgG antibodies (Keizer et al. 2010). 
Importantly, full-length anti-tumour monoclonal antibodies interact with immune cells and 
complement fractions mediating effector functions (Weiner, Dhodapkar, and Ferrone 2009). 
1.3.1 Anti-tumour antibodies interact with immune cells in the tumour 
microenvironment 
Anti-tumour monoclonal antibodies typically interact with tumour cells via the antigen binding 
site and with Fc receptors on immune cells via the antibody Fc domain. The antigen binding 
site mediates homing to tumour cells and inhibits tumour growth and survival signals for 
antibodies such as Trastuzumab and Cetuximab which are specific for the growth factor 
receptors HER-2 and EGFR, respectively (Weiner, Dhodapkar, and Ferrone 2009; Marcucci 
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et al. 2013). Monoclonal antibodies targeting tumour associated antigens are typically of the 
human IgG1 isotype. It was shown that both the amino acid sequence of the Ig Fc domain and 
the Fc-associated glycan structure determine the interactions with Fcγ receptors (FcγRs) on 
immune cells and impact on the evoked effector responses (Shields et al. 2001; Lazar et al. 
2006; Bournazos and Ravetch 2015).  
Among IgG subclasses, human IgG1 antibodies have the highest affinity for activating FcγRs, 
and therefore exhibit the highest cytotoxic activity in vivo. Induced responses include 
antibody-dependent cytotoxicity (ADCC) mediated mostly by NK cells and antibody-
dependent phagocytosis (ADCP) mediated by a variety of cells including macrophages (Shi et 
al. 2015; Petricevic et al. 2013; Bournazos and Ravetch 2017). DCs express FcγRs and 
efficiently take up antibody coated tumour cells (Dhodapkar and Dhodapkar 2005). A complex 
regulatory system which can be influenced by immunomodulatory molecules in the local 
environment determine if FcγR mediated uptake results in immunogenic or tolerogenic 
responses (Dhodapkar, Dhodapkar, and Palucka 2008). It has been shown that in some patients 
with HER2-positive breast cancer, treatment with Trastuzumab can induce anti-HER2 CD4+ 
T cell responses and augment anti-HER2 B cell responses (Taylor et al. 2007; Knutson et al. 
2016). The effector functions mediated via Fc-FcγRs have been shown to play an important 
role in the therapeutic activity of anti-tumour monoclonal antibodies such as Trastuzumab 
(Weiner, Dhodapkar, and Ferrone 2009; Bianchini and Gianni 2014). 
The aforementioned clinically used antibodies, and others, have been explored as “vehicles” 
for targeted delivery to tumours of a variety of molecules with low efficacy to toxicity ratio 
(Schrama, Reisfeld, and Becker 2006). Antibody-based targeted delivery systems are typically 
generated via antibody engineering to generate fusion antibodies with other proteins or 
peptides, or through biochemical conjugation.  
 1.3.2 Fusion antibodies 
Antibody engineering technologies have been employed to fuse other protein moieties to 
antibodies or antibody fragments targeting accessible tumour antigens. The scope was to 
facilitate accumulation of other proteins or peptides to the tumour tissue. This strategy was 
employed for the delivery of potent protein molecules such as cytokines to generate antibody-
cytokine fusion proteins, also named immunocytokines. Antibody-fusion cytokines have been 
developed with a variety of cytokines and using different antibody formats, such as full-length 
antibodies or antibody fragments (Kontermann 2012; Young, Morrison, and Timmerman 
2014), with ample literature describing their efficacy in preclinical tumour models. The 
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clinical development of antibody-fusion cytokines is only starting to accelerate and their 
efficacy in cancer treatment remains to be determined (Hutmacher and Neri 2019; Murer and 
Neri 2019).   
1.3.3 Antibody conjugates 
In contrast with antibody engineering technologies that allow for fusion of peptides and 
proteins to anti-tumour antibodies, biochemical conjugation enables binding of a variety of 
molecular structures. Antibody conjugates were generated with chemotherapeutic drugs 
(Diamantis and Banerji 2016), radioisotopes (Smaglo, Aldeghaither, and Weiner 2014) and 
enzymes (Sharma and Bagshawe 2017). 
The term antibody-drug conjugates (ADC) typically refers to antibody conjugates with small 
molecules, most often chemotherapeutic drugs, that due to high toxicity are not safe for 
systemic administration. In terms of generating and characterising antibody conjugates most 
of the knowledge and expertise are derived from the expanding field of antibody-drug 
conjugates, which are of great interest for cancer therapy (Zolot, Basu, and Million 2013; 
Chau, Steeg, and Figg 2019).  
The typical mechanism of action of ADCs involves three steps. First, the ADC recognises 
antigens on the surface of tumour cells via the antibody moiety. Then, the ADC is internalised, 
and the payload is released from the antibody. Once the payload is released, it can exert its 
cytotoxic function. Most payloads in clinical development are small molecules, and therefore 
able to pass through membranes once released from the ADC and access different cellular 
compartments (Bakhtiar 2016; Hoffmann et al. 2018). 
Generally, antibody conjugates are formed of an antibody or antibody fragment, linker and 
payload, each of them determining the properties of the conjugate. Ideally, the antibody would 
recognise with high affinity a target tumour antigen with high expression levels on tumour 
cells but not healthy tissues (Thomas, Teicher, and Hassan 2016). Many ADCs are directed 
against tumour associated antigens such as HER2, CD20, CD19, CD79b, using antibodies 
such as Trastuzumab and Rituximab. However, most membrane-bound tumour associated 
antigens currently described are not exclusive to tumour cells, but are also expressed on 
healthy tissues, which leads to adverse effects of the ADC (McCombs and Owen 2015; 
Smaglo, Aldeghaither, and Weiner 2014). Moreover, targets such as HER2 are slow 
internalising (Hommelgaard, Lerdrup, and van Deurs 2004; Wallberg and Orlova 2008), which 
likely limits delivery of high amounts of cytotoxic drug. To circumvent these issues, ample 
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research is underway to define more suitable ADC targets and generate targeting antibodies 
(Damelin et al. 2015).  
Aside from target selection, the antibody format should be considered as well. Full-length 
antibodies of the IgG1 isotype have higher half-life and mediate effector functions such as 
ADCC and ADCP, which can be transferred to the ADC, provided that the conjugation 
chemistry does not alter these properties. For instance, the approved ADC trastuzumab-
emtansine (Kadcyla®) is ADCC competent (Barok et al. 2011; Phillips et al. 2014). In addition 
to mediating effector functions, Fc-FcγR interactions have the potential to mediate 
internalisation of ADCs into immune cells, inducing off-target toxicity. To exemplify, uptake 
of trastuzumab-emtansine (Kadcyla®) though Fc interactions into megakaryocytes has been 
proposed as mechanism of action for the induced thrombocytopenia (Uppal et al. 2015; Zhao 
et al. 2017). In contrast, antibody fragments have much shorter half-life and no effector 
functions. Multiple studies using ADCs generated with antibody fragments showed poor in 
vitro efficacy (Richards 2018).   
In terms of suitable payloads for ADC generation, the requirements are solubility, serum 
stability and importantly, amenability to conjugation without loss of function (McCombs and 
Owen 2015). 
Ample research studied developed various conjugation chemistries and linkers for the 
generation of ADCs. Linkers, also named cross-likers by some authors, are typically 
heterobifunctional, with two individual groups reacting with discrete functional groups on the 
antibody and payload (Mattson et al. 1993). Two broad categories of linkers exist, cleavable 
and non-cleavable. Pertaining to their name, cleavable linkers can be degraded by biochemical 
cues. Based on the mechanism, they can be further divided into acid-label linker, protease 
sensitive linkers and reducible (disulphide) linkers. Conversely, non-cleavable linkers rely on 
the degradation of the antibody for release of the payload (Jain et al. 2015; Bakhtiar 2016). 
While cleavable linkers seem to release the cytotoxic small molecule more easily, they are also 
less stable in serum. In contrast, non-cleavable linkers have no effect on neighbouring tumour 
cells that do not express the antigen but have higher stability in serum. In the context of solid 
tumours, this has been shown to contribute to higher efficacy (Parslow et al. 2016). For 
instance, trastuzumab-emtansine generated using the non-cleavable heterobifunctional cross-
linker succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) showed 
higher serum persistence, and was more efficient than counterparts generated with reducible 
linkers (Lewis Phillips et al. 2008). 
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The properties of the resulting conjugate depend on the conjugation chemistry as well. 
Conjugation chemistries are typically described in literature as non-specific, to native amino 
acid residues on the antibody surface and site-specific, where conjugation is limited to selected 
site in the antibody (Chau, Steeg, and Figg 2019).  
Non-specific conjugation occurs to reactive side chains such as amino groups of lysine or thiol 
groups of cysteine on the surface of IgG antibodies. An extensive body of evidence shows that 
these preparations are heterogenous, containing a spectrum of species, from antibodies with 
no payload to antibodies with a degree of conjugation that impairs antibody activity (Behrens 
and Liu 2014; McCombs and Owen 2015). For antibodies incorporating maleimide-thiol 
bonds, and additional issue of serum stability was reported, due to transfer of the payload to 
34-cysteine in serum albumin (Alley et al. 2008). Naturally, this results in reduced efficacy 
and higher adverse effects mediated by non-targeted release of drug. The phenomenon was 
shown for SMCC-generated conjugates as well (Dere et al. 2013). To circumvent these 
problems, the field is moving towards generating site-specific conjugates. Some publications 
name non-specific conjugation techniques “conventional”, to distinguish them from novel 
generation technologies (Dan et al. 2018; Sochaj, Swiderska, and Otlewski 2015). These 
include, but are not limited to engineering amino acids in the antibody structure and 
conjugating payloads to antibody glycans (Behrens and Liu 2014; Deonarain et al. 2015). 
Importantly, such conjugates showed improved performance in animal models and are 
currently under clinical investigation (Beck et al. 2017). One of the big questions is to what 
extent can novel ADCs improve upon the low therapeutic benefit of currently approved ADCs 
such as trastuzumab-emtansine (Kadcyla®).  
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1.4. LL37 peptide and endosomal TLR signaling 
1.4.1 LL37 peptide function and implication in autoimmune diseases 
As described in section 1.2.3, endosomal TLR receptors do not distinguish between self and 
foreign nucleic acids. Triggering of TLR agonists is therefore controlled through access to the 
endosomal compartment. Self-nucleic acids such as DNA and RNA released from cells do not 
access the endosomal compartment under physiological conditions. Responsible mechanisms 
include degradation by DNases and RNases and sequestration of nucleic acids via association 
with other cellular components (Brencicova and Diebold 2013). It is now accepted that in 
autoimmune diseases such as psoriasis and systemic lupus erythematosus (SLE), access of 
self-DNA or self-RNA to the endosomes, contributes to development and exacerbation of 
autoimmunity (Blasius and Beutler 2010; Barbalat et al. 2011; Roers, Hiller, and Hornung 
2016). One method of translocating self-nucleic acids to the endosomal compartment to access 
TLRs involves complex formation with LL37, a cationic peptide, which is the C-terminal 
fragment of hCAP18, the only human cathelicidin (Durr, Sudheendra, and Ramamoorthy 
2006).  
Initially, LL37 was described as an antimicrobial peptide produced by proteolytic cleavage of 
hCAP18 in response to microbial infection. LL37 expression was described for cells that form 
part of barrier tissues: epithelial cells in the gastro-intestinal tract and skin, as well as specific 
immune cells (neutrophils, monocytes mast cells, macrophages, dendritic cells and NK cells) 
(Xhindoli et al. 2016). Due to its cationic and amphipathic properties, LL37 can form pores in 
membranes of bacteria and viruses, acting as an antimicrobial. Cholesterol in mammalian cell 
membranes hinders the pore-forming activity of LL37, impairing cytotoxicity. However, it is 
unclear whether the protective effect of cholesterol can be overcome by increased doses of 
LL37, or the peptide can regulate cell-death in discrete cell populations (Kahlenberg and 
Kaplan 2013). 
While expression of LL37 is tightly regulated under normal condition, psoriatic skin and SLE 
cutaneous lesions show upregulated LL37 levels. Genetic predisposition and local 
inflammation have been proposed to cause this increased LL37 expression (Kahlenberg and 
Kaplan 2013). At these sites, the cationic LL37 can form complexes with both self-DNA 
(Lande et al. 2007) and self-RNA (Ganguly et al. 2009) released from injured cells. LL37 has 
been shown to protect self-nucleic acids from degradation by endonucleases and transport 
them to the endosomal compartment of monocytes and pDCs, where they interact with TLR7 
and TLR9, triggering inflammation. An important hallmark of LL37 induced inflammation is 
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IFN-I produced by pDCs, which in turn, boosts antigen presentation by mDC (Ganguly et al. 
2009), and augments NK cell function as well (Pinegin et al. 2015). LL37 was shown to play 
a role in the progression of psoriasis and SLE (Ganguly et al. 2009; Lande et al. 2007). 
Importantly, there are other mechanisms that can transport self-nucleic acids to endosomes in 
the context of autoimmune diseases. Notably, SLE is characterized by the presence of anti-
nuclear antibodies. These antibodies form circulating antibody-nucleic acid immune 
complexes, which gain access to endosomes via FcɣRIII-mediated endocytosis (Barrat et al. 
2005; Means et al. 2005). 
In addition to immune-mediated effects, LL37 has other biological functions. Among them, 
the cationic nature of LL37 allows for binding and neutralization of LPS. Additionally, LL37 
promotes wound healing of chronic ulcers via incompletely described mechanisms (Suzuki et 
al. 2016; Hu et al. 2016). A substantial number of studies investigated the direct effect of LL37 
on cancer cell proliferation and biology. Interestingly, LL37 can promote growth of some 
tumours or induce direct tumour cell death in a variety of cancer cells and tumour mouse 
models. These effects were tumour-specific (Chen et al. 2018; Piktel et al. 2016; Kuroda et al. 
2015). Studies attempting to define LL37 receptors on tumour cells and how they mediate 
LL37 function are still in infancy and technically challenging, as LL37 associates with 
membranes as a result of amphipathicity. 
1.4.2 LL37 in immunotherapy  
In terms of therapeutic use, LL37 remains under investigation for a variety of its functional 
properties such as its direct anti-tumour effect, its immunomodulatory activity, its 
antimicrobial function and its wound healing properties. The immunostimulatory activity of 
LL37 complexed with nucleic acids, if efficiently harnessed, could improve anti-tumour 
immune responses, by triggering endosomal TLRs. Research exploring this is relatively 
sparse. We include here a description of relevant data so far. 
Pre-clinical data demonstrated that LL37 binds also to synthetic nucleic acids such as CpG 
and poly(I:C), mediating DC activation (Ganguly et al. 2009). This includes CpG molecules 
with phosphodiester backbone, which in free form are prone to degradation by endonucleases 
and, therefore, difficult to apply for therapeutic use (Hurtado and Peh 2010). Adding LL37 to 
differentiation media, led to monocyte derived DCs with superior function in promoting Th1 
responses in vitro (Davidson et al. 2004). A recent study showed that treatment with LL37 and 
nucleic acid TLR agonists increased the functionality of DCs in promoting anti-tumour T cell 
responses both in vitro and in vivo (Findlay et al. 2019).  
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Only very few studies tested the benefit of LL37-induced inflammation in tumour models. In 
a mouse model of ovarian carcinoma, LL37 boosted anti-tumour immune responses induced 
by CpG (Chuang et al. 2009). In a mouse model of melanoma, LL37 injected into the tumour 
tissue binds DNA released from dying cells and delivers it to the endosomes of tumour 
associated pDCs, enhancing anti-tumour immunity through TLR signaling (Gillet et al. 2012).  
The approach of LL37 for intra-tumoral injections has been investigated in a phase I clinical 
trial for melanoma patients with cutaneous metastases (NCT02225366). The major limitation 
of the study was the low number of participants enrolled (only 4). A case report has been 
published, highlighting the severe dermatological toxicity at tumour-free sites observed with 
intratumoral LL37 therapy in a patient with good clinical response (Dolkar et al. 2018). While 
this confirms the proinflammatory effect of LL37 linked with clinical response, the report also 
emphasises that similarly with other immunotherapies, LL37 also induces inflammation in 
tumour-free tissues, leading to adverse effects.   
Current literature highlights the rational for exploring LL37, alone or complexed with nucleic 
TLR agonists for the promotion of anti-tumour immunity. As with other TLR signaling 
approaches, LL37 needs to reach the tumour tissue, whether alone, to enable the 
immunostimulatory activity of self-nucleic acids, or complexed with TLR agonists. 
Conversely, LL37 has additional biological function, which include anti-tumour, but also pro-
tumour properties. These effects seem to be tumour specific. Awareness of additional 
functions of LL37 is important, as they might be playing a role in individual experimental 
settings.   
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1.5 Expected effects of antibodies and endosomal TLR agonists in the tumour 
microenvironment 
Anti-tumour monoclonal antibodies were shown to concentrate and efficiently deliver other 
molecules into the tumour tissue (Parslow et al. 2016; Teicher and Chari 2011). For this study 
we explore delivery of endosomal TLR agonists to the tumour tissue and their effects on the 
tumour microenvironment. At the tumour tissue, antibodies interact with tumour cells, through 
the antigen-binding site and with immune cells, via the Fc region. Dendritic cells were shown 
to take up antibody-coated tumour cells (Dhodapkar, Dhodapkar, and Palucka 2008). Addition 
of endosomal TLR agonists at the site of this interaction will enhance maturation of DCs and 
presentation of tumour-specific antigens. Antibody-dependent phagocytosis mediated by an 
antibody linked to endosomal TLR agonists may lead to activation of other cells such as 
macrophages. At the tumour site, endosomal TLR agonists were shown to switch of 
macrophages from a M2 protumorigenic to a M1 tumoricidal phenotype and control tumour 
growth in mice (Rodell et al. 2018; Liu et al. 2016; Vidyarthi et al. 2018). 
Previous studies showed that Fc-mediated effects such as antibody-dependent cytotoxicity 
contribute to tumour cell death, also making tumour antigens available for recognition by the 
immune system (Weiner, Dhodapkar, and Ferrone 2009). In this context as well, the 
availability of endosomal TLR agonists at the tumour tissue would be of advantage, triggering 
DC maturation and ultimately boosting anti-tumour T cell responses.  
The immune activation profile of endosomal TLR agonists and the intrinsic property of 
antibodies to bridge tumour and immune cells provide a strong rationale for the generation of 
an antibody-based targeted delivery system to boost anti-tumour immune responses. 
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1.6 Hypothesis, experimental setup and objectives 
Our hypothesis is that antibodies can be exploited as vehicles for targeted delivery of 
endosomal TLR agonists to the tumour tissue and will result in promotion of anti-tumour 
immunity. We ask if this approach is feasible and efficient in inducing anti-tumour responses 
in a proof of principle study. 
As a model antibody, we use Trastuzumab, a monoclonal human IgG1 antibody, clinically 
used for treatment of HER2-positive breast (Hudis 2007) and gastric cancers (Gunturu et al. 
2013). Starting with this antibody we explored two individual strategies of targeted delivery 
(Fig. 1.1). One is to generate a fusion antibody with the nucleic acid peptide LL37 (Fig.1.1 A), 
which complexes nucleic acid endosomal TLR agonists and facilitates delivery to the 
endosome (Lande et al. 2007; Ganguly et al. 2009). The other approach is to use conjugation 
chemistries developed in the field of antibody-drug conjugates to generate Trastuzumab 
conjugates with endosomal TLR agonists (Fig. 1.1 B).  
To enable evaluation of Trastuzumab based fusion antibodies and conjugates, an ideal mouse 
model would offer both selective human HER2 expression on tumour cells and an intact 
immune system. This would allow us to explore antibody engineering and conjugation 
techniques using Trastuzumab rather than an equivalent mouse antibody. Importantly, human 
IgG1 antibodies interact with Fc receptors on mouse cells as well, and the pattern of binding 
and effector functions is comparable to mouse IgG2a/c, which is the most active mouse 
antibody in terms of antibody-mediated immune effects (Overdijk et al. 2012). Considering 
all this, we set out to generate human HER2-transgenic B16 melanoma cells and explore their 
growth into syngeneic C57/BL6 mice. 
To summarise, our main objectives for this proof of principle study are: 
a) To establish a mouse model using human HER2-transgenic B16 melanoma cells; 
b) To explore fusion of LL37 to Trastuzumab and evaluate if the resulting fusion 
antibody forms complexes with nucleic acid endosomal TLR agonists and delivers 
them to the tumour tissue; 
c) To explore biochemical conjugation of Trastuzumab with endosomal TLR agonists 
and assess their capacity to promote anti-tumour immune responses. 
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Fig. 1.1. Proposed strategies to link nuclei acid TLR agonists to antibodies. A. Complex formation 
of nucleic acid TLR agonists with the cationic peptide LL37 fused with Trastuzumab. B. Biochemical 











Materials and Methods  
 




2.1 Cell culture 
Tissue culture (TC) general reagents: 
RPMI 1640 [+] Glutamine (Gibco) 
PBS: 1x DPBS [-] CaCl2, [-] MgCl2 (Gibco) 
Fetal calf serum (FCS), heat inactivated (Biosera) 
Penicillin 10000 U/ml + Streptomycin 10mg/ml (Gibco)  
Ethylenediaminetetraacetic acid 0.5M (EDTA) (Sigma) 
Trypsin-EDTA Solution 0.25% (Sigma-Aldrich)  
β-Mercaptoethanol 50mM (2-ME) (Gibco)  
Tripan Blue 0.4% (Gibco)  
Neubauer counting chamber (Fisher Scientific) 
Cell lines and cell culture conditions: 
All adherent cell lines, either mouse (Table 2.1) or human (Table 2.2) were cultured in RPMI 
1640 with Glutamine (Gibco) supplemented with 10% FCS and 100U/ml penicillin and 
100μg/ml streptomycin (hence referred to as complete R10). Cells were passaged every 2-3 
days, depending on doubling time. B16 and derived cell lines were detached using pre-warmed 
PBS + 0.5mM EDTA (hence called PBS-EDTA), while all other cell lines were detached using 
Trypsin-EDTA (Sigma-Aldrich). All adherent cells were cultured at 37ºC, 5% CO2 in a tissue 
culture incubator.  
Mouse cell line Description Source 
B16 Melanoma CRUK Cell services 
B14.3 B16 cells transduced with GFP-OVA 
encoding retrovirus 
Generated by Sandra S. Diebold 
B14.3 luciferase B14.3 cells transduced with 
luciferase* encoding lentivirus 
Generated by Sandra S. Diebold 
RAW 264.7 Abelson Murine Leukemia Virus-
Induced Macrophage Tumor 
CRUK Cell services 
Table 2.1. Cell lines of mouse origin. OVA - ovalbumin; GFP - green fluorescent protein; * Rinella 
luciferase  
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Human cell line Type Source 




kind gift from Ross Hawkins, NIBSC 
SKBr3 Breast adenocarcinoma NIBSC cell bank 
SKOV3 Ovarian adenocarcinoma ATCC®-HTB-74 
JIMT-1 Breast carcinoma DSMZ – ACC589 
T47D Breast ductal carcinoma 
kind gift from James N. Arnold, King’s College 
London 
MCF-7 Breast adenocarcinoma 
kind gift from James N. Arnold, King’s College 
London 
MDA-MB-231 Breast adenocarcinoma kind gift from Ross Hawkins, NIBSC 
MDA-MB-468 Breast adenocarcinoma kind gift from Sophie Papa, King’s College London 
Table 2.2. Tumour cell lines of human origin. 
Primary cells of either mouse or human origin including murine bone-marrow derived 
dendritic cells (BMDCs) and human monocyte-derived dendritic cells were cultured using 
complete R10 supplemented with 50µM β-Mercaptoethanol.  
For antibody-dependent cellular cytotoxicity (ADCC) assays, the Human Natural Killer Cell 
Line No-GFP-CD16.NK-92 cell line (high affinity; 176V) was purchased from ATCC® (code 
PTA-6967) and cultured in MyeloCult H5100 media (STEMCELL Technologies) 
supplemented with 100 IU/ml fresh human IL-2 (tissue culture grade, Miltenyi Biotech) at 
37ºC, 7% CO2.   
For lentivirus production, HEK293T cells were generously provided by Mary Collins, cultured 
in complete R10 at 37ºC, 5% CO2, dissociated using PBS-EDTA and passaged every other 
day. 
For recombinant antibody production, suspension cell lines FreeStyle 293TM (Life 
technologies) or ExpiCHOTM (Life Technologies) cells were cultured in their respective media 
purchased from the manufacturer (FreeStyleTM 293 expression medium and ExpiCHOTM 
medium, respectively), maintained at 37ºC, 8% CO2, and 125-150 rotations per minute (rpm) 
in a tissue culture incubator and passaged every 2-3 days at a density of 0.2x 106 cells/ml.   
All cells were regularly tested for Mycoplasma by PCR (EZ-PCR Mycoplasma Test Kit, 
Geneflow Limited). Most of the Mycoplasma testing assays were performed by Miltiades 
Stylianou, NIBSC. 
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2.2 Polymerase Incomplete Primer Extension (PIPE) cloning 
Materials: 
Q5® High Fidelity polymerase (New England BioLabs) 
Q5® Reaction Buffer (New England BioLabs) 
Q5® High GC Enhancer (New England BioLabs) 
Nucleotide mix dNTP (New England BioLabs) 
DpnI (New England BioLabs) 
CutSmart buffer (New England BioLabs) 
Agarose, electrophoresis grade (Life Technologies) 
Low melting point agarose (SeaKem GTG Agarose from Lonza) 
Quick-Load® Purple 1 kb Plus DNA Ladder (New England BioLabs) 
Gel Loading Dye, Purple (6X) (New England BioLabs) 
SYBR Safe DNA Dye (Invitrogen) 
Wizard SV gel and PCR clean-up system (Promega) 
QIAquick PCR Purification Kit (Qiagen) 
Hygromycin 100mg/ml (Invivogen) 
Ampicillin (Sigma-Aldrich)  
XL-1 Blue Competent bacteria (for routine cloning), ≥ 1 x 108 transformants/µg (Agilent 
Genomics) 
Plasmids – see appendices for full sequence and annotations:  
pVITRO-Trastuzumab-IgG1/κ (Addgene plasmid # 61883; http://n2t.net/addgene:61883; 
RRID:Addgene_61883) were purchased from Addgene; originally generated in Andrew 
Beavil‘s laboratory at King’s College London.  
pVITRO-397-LL37 plasmid was generated by Sandra S. Diebold, NIBSC. 
pcDNA3-HER2WT was purchased from Addgene (Addgene plasmid # 16257; 
http://n2t.net/addgene:16257; RRID:Addgene_16257); originally generated in Mien-Chie 
Hung’s laboratory. 
pSIN-SFFV-luc2 was a gift from Kam Zaki, NIBSC. 
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Sequencing primers: 
Primer Primer sequence 5’→ 3’ Use 
FW SFFV AGCTCTATAAAAGAGCTCAC  
pSIN-SFFV plasmid; to sequence the insert, 




pSIN-SFFV plasmid; to sequence from the 




pVITRO-Trastuzumab and derived plasmids; 
to sequence from the end of the heavy chain 




pVITRO-Trastuzumab and Isotype control; to 





pVITRO-Trastuzumab and Isotype control; to 




sequence from the end of the light chain in 
reverse 
Table 2.3. Sequencing primers verification of plasmid sequences. FW - forward; RV – reverse. 
2.2.1 Description of PIPE cloning method: 
PIPE cloning primer pairs (Tables 2.3, 2.4 and 2.5) were designed for the amplification of the 
insert and backbone fragments for each pVITRO plasmids as previously described (Dodev et 
al. 2014). Each primer contained a 5’-end of minimum 10 base pairs (bp) overlapping with the 
adjacent fragment. All sequences for reverse primers shown in tables were reversed and 
complemented before ordering. PCR fragments containing 5’ overhangs were amplified using 
Q5 high fidelity DNA polymerase (New England BioLabs).  
PCR reactions included 35 cycles of: 
- denaturation for 10 sec  
- annealing for 30 sec at temperatures depending on the primer pair and 
- extension at 72ºC for 30-150 sec depending on the size of the generated fragment (~30 
sec per 1kb of sequence), followed by  
- a final extension step at 72ºC for 5 min and cooldown at 8ºC. 
PCR products were cleaned up using QIAquick PCR Purification Kit (Qiagen) according to 
the manufacturer’s specifications and were eluted in H2O. Subsequently, PCR products were 
treated for one hour with 20U DpnI enzyme in CutSmart Buffer (New England Biolabs) to 
digest the templates. Fragments of at least 300bp were run on 1% low melting point agarose 
gels, while PCR fragments smaller than 300 bp were run on 2% agarose gels. The desired 
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bands were excised, purified with Wizard SV gel and PCR clean-up system (Promega) and 
eluted in H2O.  
For transformation, 100ng of insert fragment was incubated for 30 min with 100ng of each of 
the pVITRO backbone fragments and then transformed into 70µl XL-1 Blue competent 
bacteria (Agilent Genomics) pre-incubated on ice with 1.2µl 1.42M 2-ME using the heat-
shock method. Bacteria were incubated for 2 min at 42°C, 630µl SOCS medium was added 
and suspensions were incubated for 1 h at 37°C in a Thermomixer shaking at 750rpm. Upon 
incubation, the bacterial suspension was briefly spun and 500µl supernatant was removed. The 
bacterial pellet was resuspended in the remaining 200µl and the transformed bacteria were 
plated on Luria Broth Agar plates either containing 100μg/ml Hygromycin or 50μg/ml 
Ampicillin as appropriate. The Agar plates were incubated over night at 37°C in a bacterial 
incubator. The next day, antibiotic-resistant clones were picked and expanded in 5ml LB broth 
containing the appropriate antibiotic. Plasmid was isolated from 3ml bacterial suspension by 
alkaline lysis (see Section 2.3). Optionally, plasmid DNA was analysed for the presence of 
insert, either by PCR or digestion with restriction enzymes cleaving sites present in the insert 
only. Plasmids expressing the insert or untested plasmids were sent for sequencing to Eurofin 
Genomics using appropriate primers (Table 2.3) to verify correct assembly of the fragments 
and identify possible point mutations.  
 
2.2.2 Generation of pSIN-SFFV-HER2WT 
In order to produce a lentivirus encoding human HER2 (hence referred to as HER2), the 
sequence for HER2 was subcloned from the pcDNA3-HER2WT vector into the transgene 
pSIN-SFFV vector using the steps for PIPE cloning described in section 2.2.1. Conditions for 
PCR reactions depending on the optimal melting temperature of primers (Tm) or size of the 
generated fragment (extension time) are shown in Table 2.4. 
 
  
Chapter 2 Materials and methods 
54 

















bb frag A 















Table 2.4.  List of primers designed and used for PIPE cloning of pSIN-SFFV-HER2. pcDNA3-HER2WT 
plasmid was used as template to clone the HER2 fragment. pSIN-SFFV-luc2 plasmid was the template 
used to generate pSIN bb frag A and B. (rv) bp – base pairs; bb frag – backbone fragment; fw – forward; 
rv-reverse; GC enh – high GC enhancer was used.  
These three generated PCR fragments were used for cloning as described above. Plasmid 
preparations from expanded single bacterial colonies were evaluated for the presence of human 
HER2 by digestion with 10U/μg DNA of restriction enzymes EcoRI (in NEBuffer EcoRI) and 
separately KpnI (in NEBuffer 1). Digested plasmid was mixed with gel loading dye and 
analysed on a 1% agarose gel stained with SYBR Safe DNA Stain (Invitrogen). Plasmids 
showing bands migrating as expected compared to the DNA ladder on the gel were sequenced 
(Eurofin Genomics) using appropriate primers described in Table 2.3. 
 
2.2.3    Generation of pVITRO-Trastuzumab-LL37 IgG1/κ 
The LL37 insert was cloned from the pVITRO-397-LL37 plasmid into the pVITO-
Trastuzuman-IgG1/κ plasmid by PIPE cloning as described before (See Table 2.5 for primers 
and PCR conditions; see Appendix E for pVITRO vector map, Appendix F for annotated 
sequence and appendix G for nucleotide sequence of LL37). LL37 was inserted after the 
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TTCC 69°C 120 sec 
distLL37.rv CTTGGAGCGAACGACCTAC 
pVITRO 
bb frag A 






bb frag B 
IgGBBfrB_ fw CTTGGAGCGAACGACCTAC 
64°C 120 sec 
ratIgG-bb.rv TATCCCTAATACCTGCCACC 
Table 2.5. Primers designed for PIPE cloning of LL37 in pVITRO-Trastuzumab IgG1/κ.  The LL37 
fragment was cloned using pcDNA3-LL37 template. pVITRO bb frag A and B were generated using 
pVITRO-Trastuzumab IgG1/κ plasmind template. bp – base pairs; bb frag – backbone fragment; fw – 
forward; rv-reverse; GC enh – high GC enhancer was used. LL37 sequence is underlined. 
To verify insertion of LL37 in plasmid preparations generated from Hygromycin-resistant 
bacterial colonies, primers specific for the LL37 insert were used in a PCR reaction with the 
following cycling conditions: 
1x 98°C  30 sec 
  30x 98°C  10 sec 
   54°C  30 sec 
   72°C  30 sec 
  1x 72˚C  5 min 
   8°C  forever 
Primer Primer sequence 5’→ 3’ 
LL37_FW GAAAGCTTGAATTCCTGCTGGGTGATTTCTTCCGG 
LL37_RV ACTCGAGGATCCGGACTCTGTCCTGGGTACAAGAT 
Table 2.6. Primers for screening of the generated clones, with sequence specific for LL37 underlined. 
PCR samples were analysed by agarose gel electrophoresis (1.5% gel). Plasmids encoding 
LL37 were sequenced using the pVITRO-FcF4 primer to confirm the identity of the sequence.
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Inserting linkers between the C-terminus of Trastuzumab heavy chain and the LL37 peptide 
Long oligos (Extremers): 
H3 sense oligo: CTGGAGGCCGAGGCCGCCGCCAAGGAGGCCGCCGCCAAGGAGG 
CCGCCGCCAAGCTGGAG 
H3 antisense: CTCCAGCTTGGCGGCGGCCTCCTTGGCGGCGGCCTCCTTGGCGGCG 
GCCTCGGCCTCCAG 
H4 sense: CTGGAAGCAGAGGCGGCTGCAAAGGAGGCTGCAGCCAAAGAGGCCGC 
TGCTAAAGAAGCCGCCGCCAAGGCCCTCGAA 
H4 antisense: TTCGAGGGCCTTGGCGGCGGCTTCTTTAGCAGCGGCCTCTTTGGCTG 
CAGCCTCCTTTGCAGCCGCCTCTGCTTCCAG 
The sequences for an array of linkers, either natural (hinge region of IgG2) or empirical, with 
different flexibility determined by secondary structure and number of amino acid residues 
were introduced between the C-terminus of the heavy chain and the N-terminus of LL37. The 
codons used to encode the amino acid sequences of the linkers were chosen for optimal 
expression in mammalian cells (optimization GENEius Tool from Eurofin Genomics). For 
PIPE cloning of most linker sequences, we generated two PCR amplicons with 5’-end 
overlapping regions. Briefly, primers specific to the beginning of the LL37 sequence or to the 
end of the heavy chain sequence were designed with 5’ overhangs that included part of the 
linker sequence. The 5’ overhangs encoding the linker sequence, contained at least 7 
nucleotides overlapping with the adjacent primer. Cloning workflow was performed as 
described above. 
The codon sequences for H3 and H4 were too long to include in the 5’-ends of primers and 
were ordered as long oligos (Extremers) from Eurofin Genomics, which we used as templates 
for PCR reactions to generate the H3 or H4 insert. Sense and antisense oligos were mixed at 
molar ratio 1:1 and diluted to 25ng/ml. 1µl of the stock was used as template in PCR reactions. 
Primer pairs were designed to amplify the backbone fragments of the pVITRO-Trastuzumab-
LL37 plasmid (Table 2.7). Full amino-acid and nucleotide sequences for all linkers are shown 
in appendix G. 
PCR reactions were performed as described in section 2.2.1 with conditions mentioned in 
Table 2.7. Fragment purification and bacterial transformation were performed as mentioned 
in section 2.1.1. At least 5 different clones from each construct were verified by Sanger 
sequencing (Eurofin Genomics). Cloning for the (G4S)x3 linker was performed by Dr. Sandra 
S. Diebold. 






































Table 2.7a. Primers designed to clone flexible glycine-serine linkers between the Fc terminus of Trastuzumab heavy chain and LL37. Sequence encoding part of each 
linker is underlined. For all the PCR reactions, pVITRO-Trastuzumab-LL37 plasmid was used as the template. fw - forward; rv – reverse; ext time – extension time; 
GC enh – GC enhancer. 
 



















68°C (GC enh) 150 sec 
ratIgGbb_modif.rv ATCCCTAATACCTGCCACC 
H 
hIgG1_H2. rv TCTCCCTGTCTCCGGGTAAACTGGAAGCTGAGGCAGCGGCCAAGGAAGCTGC 




















68°C (GC enh) 45sec 
H4.rv CCGCCAAGGCCCTCGAACTGCTGGGTGATTTCTTCC 















68°C (GC enh) 150 sec 
IgG2h.rv AGCCTCTCCCTGTCTCCGGGTAAAGAGCGCAAATGTTGTGTCGAGTGCCCACCGTGCCCA 
Table 2.7b. Primers designed to clone rigid alanine-based linkers or natural linkers between the Fc terminus of Trastuzumab heavy chain and LL37. Sequence 
encoding part of each linker is underlined. The following templates were used for the PCRs: * pVITRO-Trastuzumab-LL37; ** H3 Extremer; *** H4 Extremer.  fw- 
forward; rv – reverse.  
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2.2.4    Generation of pVITRO-Trastuzumab THIOMAB 
To use the ThioMAb technology for site-specific conjugation of TLR agonists to Trastuzumab, 
we exchanged the nucleotides encoding valine (codon GTC) at position 205 (Kabat 
numbering) in the constant region of the light chain with nucleotides encoding cysteine (codon 
TGT). The mutation in the sequence is illustrated in appendix F. For this single amino-acid 
mutation (V205C) in the sequence of Trastuzumab we employed PIPE cloning as described 
above, with the following modifications: 
- the exchanged codon (TGT) was introduced in 2 primers (one forward, one reverse) 
with 5’-overlapping ends – highlighted in grey in table 2.8 
- extension time for each PCR reaction was shortened by 10% of the calculated value 
for fragment length to enable incomplete extension 
- the 5 min final extension step at 72ºC (see section 2.2.1) after the 35 PCR cycles was 
dropped. 
PCR fragments were processed, and subsequent steps were performed as described in section 
2.2.1. 

















 68°C 36 sec 
pVITROrvF1 CTTGAGTTTTGAGCGGAGCTAATTCT 
Table 2.8. PCR primers designed to generate the THIOMAB V205C using PIPE cloning. Codon encoding 
cysteine is highlighted in grey. pVITRO-Trastuzumab IgG1/κ was used as template for all PCR reactions.  
fw – forward; rv – reverse.  
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2.2.5 Generation of isotype controls 
Isotype controls of human IgG1 isotype were generated for Trastuzumab (Tr), Trastuzumab-
H3-LL37 (Tr-LL37) and Trastuzumab-ThioMab (Tr(TH)) by exchanging the variable regions 
(both the heavy and light chain) from each of the mentioned antibodies with sequences of 
variable regions of in-house generated isotype control antibodies of mouse or rat isotypes (see 
appendix F for sequence and annotation of variable regions of Trastuzumab IgG1 and 
appendix H for isotype control variable regions). Cloning, protein purification and validation 
of all isotype controls were performed by Dr. Sandra S. Diebold. 
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2.3 Plasmid preparations  
2.3.1 Minipreparations by alkaline lysis 
Materials: 
Rnase A (Sigma R4642) 
Buffer 1 – GET solution: 50mM glucose, 10mM EDTA, 25mM Tris-HCl pH 8.0 
Buffer 2 – NaOH/SDS solution: 0.2N NaOH, 1% SDS 
Buffer 3 – Kac solution: 3M potassium acetate, 11.5% acetic acid (w/w) 
Resuspension buffer: Rnase A diluted 1:3000 in TE buffer (e.g. from Quiagen kits) 
To generate plasmid minipreparations, bacteria was grown overnight in 5ml Luria Broth and 
selection antibiotic. The next day, 1.5-2ml of culture was pelleted by centrifugation for 3 min 
at 10 000x g. Pellets were resuspended in 100μl ice-cold Buffer 1 and incubated on the bench 
for 5 min. 200μl of Buffer 2 (freshly prepared before use) were added, mixed and incubated 
for another 5 min at room temperature (RT). 150μl ice-cold Buffer 3 were added. Samples 
were vortexed and incubated for 5 min on ice. Afterwards, samples were centrifuged for 5 min 
at 14 500x g and 400μl supernatant was carefully transferred into sterile Eppendorf tubes, to 
which 800μl of 96% ethanol were added. Samples were centrifuged for 5 min at 14 500x g. 
Supernatant was removed and pellets were washed with 500μl of 70% ethanol. Samples were 
centrifuged again for 5 min at 14 500x g and pellets were dried. Subsequently, pelleted DNA 
was dissolved in 35-50μl resuspension buffer and stored at -20ºC until further use.  
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2.3.2 Midi- and maxipreparations 
Materials: 
NucleoBond Xtra Midi / Maxi EF kits (Macherey-Nagel) 
Isopropanol ≥ 99.5% (Sigma) 
Ethanol 96% (Hayman Group) 
NanoDrop 1000 spectrophotometer (Thermo Scientific) 
Avanti J-26S, high-speed centrifuge (Beckman Coulter) 
In order to generate large quantities of endotoxin-free, transfection-compatible plasmid 
preparations, we used the NucleoBond Xtra Midi / Maxi EF kits from Macherey-Nagel and 
performed the High-copy plasmid purification protocols (midi or maxi) using the 
manufacturer’s instructions supplied with the kit. Briefly, bacterial cultures were centrifuged 
at 6 000x g, 15 min, 4ºC. Pellets were resuspended in resuspension buffer. Bacteria were lysed 
by adding lysis buffer followed by neutralization with neutralization buffer. Lysates were 
loaded onto columns, washed as recommended and plasmid DNA was eluted using elution 
buffer. Plasmid DNA was precipitated in isopropanol. Pellets were washed in 70% ethanol, 
dried on the bench and resuspended in endotoxin-free water. Plasmid DNA yield was assessed 
by measuring absorption at 260nm, adjusted to 1-2μg/μl and stored at -20ºC until further use.  
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2.4 Lentivirus vector production by three-plasmid transient transfection 
Plasmids: 
pSIN-SFFV-HER2 (transgene plasmid generated as described above) 
p8.91 - 2nd generation HIV-derived packaging plasmid (Plasmid Factory) 
pMD.G - plasmid encoding VSV-G envelope (Plasmid Factory) 
Materials: 
Opti-MEM (Gibco) 
FuGENE transfection reagent (Promega) 
Optima L-90K Ultracentrifuge (Beckman Coulter) 
DNA Easy Blood & Tissue Kit (Qiagen) 
QuantiTect buffer (Quiagen) 
PBS: 1x DPBS [-] CaCl2, [-] MgCl2 (Gibco) 
HEK293T cells were transiently co-transfected with plasmids pSIN-SFFV-HER2, p8.91 and 
pMD.G at 1.5:1:1 ratio. Plasmids were diluted in Opti-MEM (Gibco) and incubated with 
FuGENE (Promega) transfection reagent also pre-diluted in Opti-MEM for 15 min at RT 
before adding dropwise to HEK293T cells. Supernatants containing lentivirus were harvested 
after 48 and 72 h, filtered through a 0.45μm syringe filter and concentrated 200-fold by ultra-
centrifugation at 64 000x g, 2 h,  4°C. Viral pellets were re-suspended in ice-cold DPBS (hence 
called PBS) incubated on ice for 1 h, then aliquoted and stored at -80ºC until use.  
For lentivirus quantification, 2x105 HEK293T cells were transduced with 5µl lentivirus. 
Genomic DNA was extracted using DNA Easy Blood & Tissue Kit (Qiagen), following the 
manufacturer’s instructions. Quantitative PCR was used to quantify integrated lentivirus using 
primers for long terminal repeat regions flanking the transgene: forward primer GT 248 (5’-
TGTGTGCCCGTCTGTTGTGT-3’), reverse primer GT 249 (5’-
GAGTCCTGCGTCGAGAGAGC-3’), TaqMan probe 5’-FAM-
CAGTGGCGCCCGAACAGGGA-TAMRA-3’ in QuantiTect buffer (Qiagen). Untransduced 
cells were used as negative control and values were calculated using a standard curve (the 
genomic DNA for the standard curve was provided by Kam Zaki).  
PCR program used included: 
- denaturation at 95ºC 15 min, 
- 40 cycles of: 
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95ºC 15 sec   
60ºC 30 sec 
72ºC 30 sec 
- followed by cool-down at 4ºC. 
 
2.5  Generation of HER2 positive B16 cell lines  
B16, B14.3 (B16 OVA-GFP) and B14.3 Luciferase (B14.3 Luc) cell lines were harvested and 
seeded in an appropriate volume of R10 at a density equal to the virus titer (IU) in 1 µl. After 
incubating at 37ºC, 5% CO2 for 3 h, cells were transduced with human HER2-ecoding 
lentivirus at increasing multiplicity of infection (MOI). 293T cells were treated in the same 
way and transduced with the same lentivirus batch at MOI 1 only, for positive control. R10 
medium was added the next day to double the original volume. Cells were passaged when 
confluent.  
At day 7 post-transduction, cells were stained for HER2 expression and analysed by flow 
cytometry. For staining protocol and the antibodies used, see section 2.7. Cell samples 
showing a distinct HER2 positive population were subjected to fluorescence activated cell 
sorting (FACS) using BD FACS Aria II (100uM nozzle 4-laser, 13-color). After gating for 
cells and exclusion of doublets, a gate was placed on HER2 expressing cells and single cells 
were sorted into 96-well plates containing 200μl R10. Single-cell clones that grew well in 
plates were further expanded and aliquots of cells were frozen for later use and selection.  
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2.6  In vitro Bioluminescent Assays 
Materials:  
White flat bottom tissue culture treated 96 well plate (3917, Costar) 
XenoLight D-Luciferin, Potassium Salt (PerkinElmer) 
0.22μm syringe filter, 33mm (Merck Millipore) 
MicroBeta 2® Microplate Counter (Perkin Elmer) 
In Vivo Imaging System - IVIS Spectrum® (Perkin Elmer) 
B14.3 Luc HER2 positive monoclonal cell lines were harvested and plated into white flat 
bottom tissue culture-treated 96-well plates at 1x 105, 2x 105 and 4x 105 cells/well in 100μl 
R10. Either duplicates or triplicates were used. To compare among higher numbers of 
monoclonal cell lines, only the 1x 105 cell density was used. The B14.3 Luc parent cell line 
and B14.3 HER2 clone E5 cell line were included in each assay as positive and negative 
controls, respectively. Cells were incubated at 37ºC, 5% CO2 for 2-3 h. Luciferase substrate, 
XenoLight D-Luciferin, was reconstituted in 1x DPBS at 15mg/ml and sterile filtered using a 
0.22μm syringe filter. 100μl of luciferin substrate was added to each well. Cells were incubated 
for 5 min at 37ºC, 5% CO2 and bio-luminescence intensity were measured using a MicroBeta 
2® Microplate Counter for 10 seconds with a 3 minute start delay.  
When the IVIS Spectrum was used instead, substrate was added 10 min prior to imaging and 
the cells were left on the heated (37ºC) platform of the IVIS chamber until imaging. 
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2.7 Flow Cytometry  
Materials: 
FACS tubes (BD) 
96-well U-plates, sterile, non-TC treated (3788, Costar) 
LIVE/DEAD Fixable Violet Dead Cell Stain Kit (Thermo Fisher Scientific)  
Streck Cell Preservative (Alpha Laboratories) 
Paraformaldehyde (PFA) (VWR) 
FACS buffer: PBS, 1% heat-inactivated FCS, 5mM EDTA, 0.02% NaN3  
Intracellular buffer: FACS buffer supplemented with 0.1% saponin  
OneComp eBeads™ Compensation Beads (eBioscience) 
FACS Canto II flow cytometer (BD) – 3-lasers (blue, red and violet) 8-colour (4-2-2) 
LSR Fortessa flow cytometer (BD) - 3-lasers (blue, red and violet) 14-colour (5-3-6) 
FACS Aria II (BD) - 4-lasers (blue, red, violet, yellow) 13-colour (3-2-5-3) 
FlowJo v10 software (FlowJo, LLC) 
2.7.1 Staining for surface markers 
Cultured cells or single cells suspensions were stained with 1-3µl LIVE/DEAD Fixable Violet 
Dead Cell Stain (Thermo Fisher Scientific) diluted in 1ml DPBS for 30 min on ice, protected 
from light, then washed once in PBS and centrifuged at 500x g. Cells were either directly 
stained for surface markers or were fixed in 50% v/v of Streck. Cell Preservative for at least 
30 min. When either fresh or fixed murine cells were used, Fc receptors were blocked with 
1µg anti-mouse CD16/CD32 (BD) for 30 min on ice. To stain for surface markers, cells were 
washed once in FACS buffer, then incubated for 30 min with antibodies diluted in FACS 
buffer, either on ice (live cells) or at 4ºC (fixed cells). Cells were washed 3x times with FACS 
buffer. Subsequently, cells were either stored at 4ºC until acquisition or stained with secondary 
antibodies for another 30 min on ice (live cells) or 4ºC (fixed cells) and then washed 3x times 
in FACS buffer. Cells were resuspended in 200µl of FACS buffer for analysis by flow 
cytometry and were stored at 4ºC until samples were acquired. 
Data was expressed as percent positive cells or geometric mean fluorescence (MFI) or as 
resolution metric (RD), as appropriate for each experiment. RD was calculated by subtracting 
the MFI of isotype control from the MFI of stained cells and dividing the difference by the 
sum of standard deviations. RD= 
𝑀𝐹𝐼 (𝑠𝑡𝑎𝑖𝑛𝑒𝑑)−𝑀𝐹𝐼 (𝑖𝑠𝑜𝑡𝑦𝑝𝑒) 
𝑆𝐷(𝑠𝑡𝑎𝑖𝑛𝑒𝑑)+𝑆𝐷(𝑖𝑠𝑜𝑡𝑦𝑝𝑒)
  




Dilution Fluorophore Isotype Source 
Identifier 
(clone) 











CD3 1:100 APC-eFluor 780 Rat IgG2b, κ eBioscience 17A2 
CD4 1:100 APC, Pacific Blue Rat IgG2a, κ BD RM4-5 





Rat IgG2a, κ BD 53-6.7 
CD44 1:100 PE, PerCP-Cy5.5 Rat IgG2b, κ BD IM7 
CD62L 1:40 FITC Rat IgG2a, κ BD MEL-14 







Rat IgG2a, κ BD RA3-6B2 




CD11b 1:100 V500 Rat IgG2b, κ BD M1/70 
CD24 1:100 FITC Rat IgG2b, κ BD M1/69 
Granzyme 1 1:100 FITC Rat IgG2b, κ BD RB6-8C5 
CD86 1:100 PE Rat IgG2a, κ BD GL1 
MHC II (I-A/I-E) 1:100 PE 
Rat BN x LEW 
IgG2b, κ 
BD M5/114.15-2 
MHC II (I-Ab) 1:100 PE Mouse IgG2a BD AF6-120.1 
MHC II (I-Ab) 1:100 BV786 Mouse IgG2a BD 25-9-17 
IFN-ɣ 1:100 PE, APC Rat IgG1, κ BD XMG1.2 
TNF-α 1:100 PE Rat IgG1, κ BD MP6-XT22 






1:100 FITC Rat LOU IgG1 BD R19-15 








Isotype control 1:100 FITC, PE, APC Rat IgG2a, κ BD R35-95 
Isotype control 1:100 
FITC, APC, APC-
Cy7 
Rat IgG2b, κ BD A95-1 
Isotype control 1:100 PE Rat IgG1, κ BD R3-34 




Isotype control 1:10 PE Mouse IgG1, κ Miltenyi IS5-21F5 
H-2kb-SIINFEKL-
pentamer 
10µl/test  PE - ProImmune 
Pro5 MHC 
Pentamer 
Table 2.9a. List of antibodies used to stain for mouse cell markers for flow cytometry analysis 
throughout the study.  











- Human IgG1, κ 
Either Herceptin 
(Roche) or 






























Mouse IgG2a, κ Invitrogen M5E2 
HLA-DR 1:10 APC-Cy7 Mouse IgG2a, κ BioLegend L243 
CD3 1:100 PerCP-Cy5.5 Mouse IgG1, κ BioLegend SK7 
CD19 1:100 PE-Cy7 Mouse IgG1, κ BD HIB19 
BDCA-1 1:10 PE Mouse IgG2a Miltenyi AD5-8E7 
BDCA-2 1:10 FITC Mouse IgG1, κ Miltenyi AC144 
BDCA-3 1:10 APC Mouse IgG1 Miltenyi 
AD5-
14H12 
Table 2.9b. List of flow cytometry antibodies used throughout the study to stain human cell surface 
markers. Secondary antibodies are specified as such.    
2.7.2 Staining with pentamers  
Splenocytes from mice treated with antibodies or conjugates were first stained in FACS tubes 
with 1µl LIVE/DEAD fixable Violet stain (Thermo Fisher Scientific) in 1ml PBS for 30 min 
on ice, protected from light. Then cells were washed once in PBS and fixed overnight in Streck. 
Cells were subsequently stained with 10µl/test of Pro5 H-2kb-SIINFEKL-pentamer 
(Proimmune) in a total of 60µl FACS buffer volume for 30 min at RT in the dark. Cells were 
washed twice with 1ml FACS buffer, then stained 30 min at 4ºC in the dark in 100µl FACS 
buffer for CD8α with APC-conjugated antibody. Cells were washed 3 times and stored in 
FACS buffer in the fridge until acquisition. 
2.7.3 Staining for intracellular markers 
For intracellular staining, cells were stained for live/dead-cell discrimination as described in 
2.7.1 and the directly stained for surface markers with antibodies diluted in FACS buffer for 
30 min on ice. Cells were washed twice in FACS buffer then fixed in 4% paraformaldehyde 
(PFA) for 15 min. Subsequently, cells were washed twice in intracellular buffer, then 
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incubated with the respective antibodies diluted in intracellular buffer for 30 min on ice, 
protected from light. Cells were washed twice with intracellular buffer, then resuspended in 
200µl FACS buffer and stored at 4ºC until acquisition on the flow cytometer. 
2.7.4 Fluorescence activated cell sorting (FACS) 
When cells were stained for sorting, FACS buffer without NaN3 was used in all steps of the 
protocol. 1-2 million B16 and B16-derived cell lines, either transduced at MOI 10-20 with a 
lentivirus for human HER2 expression or parental controls, were stained in FACS tubes with 
0.5µg Trastuzumab IgG1 in 100µl FACS buffer for 60 min on ice and then washed thrice in 
1ml FACS buffer. Afterwards, cells were stained with 3µl anti-human IgG-PE (BioLegend) 
diluted in 100µl FACS buffer for 30 min on ice, in the dark. Cells were washed thrice and 
resuspended in FACS buffer. SKBr3 (human HER2 overexpressing) cells were harvested and 
stained in parallel with the B16 cells and used as positive controls. Cells were analysed and 
sorted using FACS Aria II (100uM nozzle 4-laser, 13-color (3-2-5-3) 20psi). Human HER2 
positive single cells were sorted immediately in wells of TC-grade 96-well plates containing 
200µl R10. 
2.7.5 Serum cytokine multiplex 
Materials: 
LEGENDplex™ Mouse Th1 panel (5-plex) with V-bottom Plate V02 (740745, BioLegend) 
96-well V plate (740379, BioLegend) 
LEGENDplex™ data Analysis Software v8.0 (BioLegend) 
Blood harvested from tumour-bearing mice was harvested at different time-points after 
treatment. Blood was allowed to clot for 30 min at RT, then centrifuged for 10 min, 4ºC, 1500x 
g. Serum was collected and stored in sterile conditions at -80ºC until assayed.  
To analyse levels of IFN-ɣ, TNF-α, IL-2, IL-6, IL-10 in serum of mice treated with 
Trastuzumab-CpG or controls, the LEGENDplex kit was used according to the manufacturer’s 
protocol. Briefly, samples were thawed on ice, mixed and centrifuged 5min at 10 000x g to 
remove particulates. Samples were diluted 1:2 in assay buffer, then 1:2.5 in Matrix B, to a 
final dilution of 1:5. 25µl diluted sample were plated in duplicates in wells containing 25µl 
assay buffer. The standard curve was diluted 1:4 in assay buffer, then each dilution was plated 
in duplicate in wells containing 25µl matrix B. Beads were diluted 1:13 and mixed together, 
then 25µl/well were added. The plate was incubated for 2 h RT in the dark on a platform 
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shaking at 800x rpm. Afterwards, the plate was washed twice with washing buffer. 
Subsequently, 25µl/well of detection antibodies were added and plate was incubated 1 h RT 
800x rpm in the dark. In a following step, 25µl Streptavidin-PE were added to each well, 
without washing the plate and incubated 30 min RT 800x rpm in the dark. Samples were 
washed twice in washing buffer. Samples were resuspended in 150µl and stored in the fridge 
until acquiring on BD Canto II cytometer. 
Data was analysed using the LEGENDplex™ data Analysis Software. Cytokine levels in 
serum were measured on their respective standard curve. 
2.7.6 Mouse antibody isotyping multiplex 
Materials: 
LEGENDplex™ Mouse Immunoglobulin Isotyping Panel (6-plex) with V-bottom Plate V02 
(740493, BioLegend) 
96-well V plate (740379, BioLegend) 
LEGENDplex™ data Analysis Software v8.0 (BioLegend) 
Blood was harvested before or after treatment from tumour-bearing mice or from tumour-free 
mice. After leaving 30 min at RT to clot, blood was centrifuged at 1500x g, 4ºC for 10 min. 
Serum was collected and stored in sterile conditions at -80ºC until assayed. Samples were 
analysed according to the protocol provided with the kit. Briefly, serum samples were diluted 
1:50 000 in assay buffer. 25µl sample were incubated in duplicates with 25µl beads and 
incubated for 2 hours while rotating at 800 rpm. The plates were washed twice in wash buffer, 
then 25µl/well detection antibody cocktail was added and further incubated for 1 h, RT, 800 
rpm. After 2 subsequent washes, samples were incubated for 30 min with 25µl/well of 
streptavidin-PE. The plates were washed twice before resuspending in 150µl and stored in the 
fridge until acquiring on BD Canto II cytometer. Data was analysed using the LEGENDplex™ 
data Analysis Software. Specific antibody isotype levels in serum were measured on their 
respective standard curve. 
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2.8   Enzyme-linked immunosorbent assay (ELISA) 
2.8.1 ELISA for detection of antibodies or cytokines 
Materials: 
Nunc Maxisorp Immunoplates, 96-well (Nunc 4-39454, Thermo Scientific) 
Flexiplates: Serocluster™ 96-well “U” bottom Plate, non-treated, vinyl (2797, Costar)  
Lid for flexible plate (BD) 
Coating buffer: 0.1M NaHCO3, pH 8.2 
PBS-Tween: PBS containing 0.05% Tween 
Blocking buffer 1: PBS containing 2.5% FCS and 0.02% NaN3  
ExtrAvidin®-AP: Steptavidin-Alkaline phosphatase (Sigma) 
ELISA substrate: SIGMAFAST™ p-Nitrophenyl phosphate tablets (Sigma)  
FreeStyleTM Expression Medium (Invitrogen) 
R10: RPMI 1640, 2mM glutamine, 10% FCS and 100 U/ml penicillin, 100μg/ml 
streptomycin, 50μM 2-ME  
PBS: 1x DPBS [-] CaCl2, [-] MgCl2 (Gibco) 
SpectraMax M5 96 well plate reader (Molecular Devices) 
 
Immunoplates were coated with 50µl per well of the relevant antibody raised against mouse 
or human cytokines or human IgG1, diluted as specified (Table 10a) in coating buffer. Plates 
were incubated overnight at 4ºC in a humid chamber.  
The next day, plates were washed 3 times with 300µl PBS-Tween per well and patted dry on 
paper towels. Next, 150µl of blocking buffer 1 was added per well and incubated for 2 h at 
RT. instead. After 2 h, plates were washed with 300µl PBS-Tween per well, 4x times. Samples 
and standard dilutions were prepared in Flexiplates before adding to the ELISA plates. Cell 
culture supernatant analysed for cytokine detection was diluted in R10. Cell culture 
supernatant from FS 293 cells was diluted in FreeStyleTM Expression Medium. Relevant 
dilutions for standard curves were prepared in the same way. Starting concentrations for 
standards are shown in Table 10. Samples and standard were added in triplicates (or duplicates 
for mouse serum only), 50µl/well and incubated in a humid chamber either 4 h at RT or 
overnight at 4ºC.  
Subsequently, plates were washed with 300µl PBS-Tween per well, 4x times and the specific 
biotinylated secondary antibody for the detected molecule was diluted in blocking buffer 1 
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and 100µl was added to the wells. Plates were incubated 1 hour at RT in a humid chamber, 
then washed again with 300µl PBS-Tween per well, 4x times. When a 3-step detection 
protocol was required, as for mouse IFN-α ELISA, wells were first incubated with the antibody 
detecting the cytokine, washed, then incubated again with the biotinylated secondary antibody 
specific for the detection antibody and washed once more. Streptavidin-Alkaline Phosphatase 
was diluted 1:10 000 in blocking buffer and added 100µl to the wells. After 1h incubation and 
4 washes with 300µl PBS-Tween per well, 100µl ELISA substrate were added per well. To 
prepare the ELISA substrate stock solution, to make stock 1 buffer tablet + 1 substrate tablet 
from the SIGMAFAST kit were diluted in 20ml H2O. Plates were incubated for 30 min to 1 
hour at RT, in a humid chamber, protected from light.  
Absorption at 405nm was measured using the plate reader. The OD405 values of the standard 
dilutions were plotted against the concentrations of the diluted standards to obtain standard 
curves. Sample concentrations were determined using the linear part of the standard curve, for 
which the goodness of fit (R squared was >0.992).  
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Table 2.10a. List of antibodies and recombinant proteins used throughout the study for coating or detection in ELISA.  
Standard Starting concentration Serial dilution Source Identifier 
Human IgG1, recombinant 1µg/ml 1:2 BioLegend QA16A12 
Human IL-12, recombinant 20ng/ml 1:3 BD 554633 
Human IL-6, recombinant 5ng/ml 1:3 BD 550071 
Mouse IL-12, recombinant 16.7 ng/ml 1:3 R&D 419-ML 
Mouse IL-6, recombinant 50ng/ml 1:3 R&D 406-ML 
Mouse IFNα, recombinant 10 000U/ml 1:3 Hycult Biotech HC 1040b 
Table 2.10b. List of standards used in ELISA (antibodies and recombinant proteins) used throughout the study. 
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2.8.2 Antibody binding assay  
Materials: 
ERBB2, Human protein, recombinant, hIgG1-Fc Tag (1004-H02H, Sino Biological) 
EGFR, Human protein, recombinant, hIgG1-Fc Tag (10001-H02H, Sino Biological) 
Blocking buffer 2: PBS containing 3% BSA 
PBS-BSA: PBS containing 0.5% BSA 
Horse-radish peroxidase (HRP) anti-human kappa light chain (A7164, Sigma) 
3,3′,5,5′-Tetramethylbenzidine (TMB) substrate: 1 TMB tablet (T3405, Sigma) to 10ml 0.05 
M phosphate-citrate buffer, 0.006% H2O2 
Stop solution: 2 M H2SO4 
SpectraMax M5 96 well plate reader (Molecular Devices) 
To compare the binding properties of Trastuzumab-based conjugates and complexes with the 
relevant parent antibody, human HER2 (Sino Biological) was immobilised to the ELISA plate 
at 0.5µg/ml, diluted in DPBS, 50µl/well. To analyse binding properties of Cetuximab-CpG 
alongside the parent antibody Cetuximab, plates were coated with 1µg/ml EGFR, diluted in 
DPBS, 50µl/well. All the following steps were performed in the same way. Plates were 
incubated overnight at 4ºC in a humidified chamber.  
The next day, plates were washer 3 times with 300µl PBS-Tween per well then incubated for 
2 h at RT with 150µl ELISA blocking buffer 2. Samples (antibodies and conjugates or 
complexes) were diluted 1:2 in PBS-BSA from a top concentration of 500ng/ml in Flexiplates 
in triplicates before adding 50µl per well to the ELISA plate. These were incubated 4 h at RT 
or overnight at 4ºC in a humid chamber.  
ELISA was developed the next day using either the ExtrAvidin-AP system as described in 
section 2.8.1 for ELISAs, or the HRP system. To achieve the later, plates were washed 4x 
times with 300µl PBS-Tween per well, before being incubated for 1 hour with 100µl of HRP 
anti-human kappa light chain antibody diluted 1:5000 in PBS. Plates were washed again 
(300µl PBS-Tween per well, 4 times) and 100µl freshly prepared TMB substrate were added. 
2-10 min later (when top concentrations on the plate turned a rich blue), 50µl stop solution 
were added per well.  
Plates were measured for absorption at 450nm using the plate reader. The OD405 values were 
plotted against antibody concentration (nM) and data was analysed using nonlinear regression 
function (variable slope) of GraphPad Prism. To describe the similarity of binding curves, the 
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difference in upper and lower asymptotes and the fitted slope factors were compared. The 
goodness of fit of the equation chosen for nonlinear regression was verified by R squared. 
Parameters were extracted for further analysis when R squared was >0.992. 
2.8.3 Determining of serum concentration of Tr and Tr-derived conjugates and 
complexes 
Mice were treated IV with either one dose or three of Trastuzumab and derived conjugates and 
complexes as described in section 2.18.6. To determine serum availability of treatments, blood 
was harvested at different time-point depending on the regimen. Blood was stored at RT for 
30 min to clot. Blood was centrifuged 10 min, 4ºC, 1500x g. Serum was collected and stored 
in sterile conditions at -80ºC until assayed. Serum samples were thawed on ice, diluted in PBS-
BSA and analysed in duplicates by ELISA with immobilized human HER2 and developed 
using anti-human IgG1 biotinylated antibody (clone G18-145) and the ExtrAvidin-AP system. 
ELISA was performed and developed as described for antibody binding assay in section 2.8.2. 
For each antibody, conjugate or complex, the respective standard of known concentrations was 
included in the assay. Serum antibody / conjugate / complexes concentration were calculated 
using the linear part of the respective standard curve.  
2.8.4 Determining tumour-specific antibody responses in mouse serum 
Materials: 
ERBB2, Human protein, recombinant, hIgG1-Fc Tag (1004-H02H, Sino Biological) 
Ovalbumin, endotoxin-free (321000, Hyglos) 
Anti-OVA antibody, mouse IgG1 (clone 14, Sigma-Aldrich)  
Anti-mouse IgG1, biotinylated (clone A85-1, BD) 
Anti-mouse IgG2a/IgG2c, biotinylated (clone R19-15, BD) 
Anti-mouse IgM, biotinylated (clone R6-60.2, BD) 
PBS-BSA: PBS containing 0.5% BSA 
Blocking buffer 2: PBS containing 3% BSA 
ExtrAvidin®-AP: Steptavidin-Alkaline phosphatase (Sigma) 
ELISA substrate: SIGMAFAST™ p-Nitrophenyl phosphate tablets (Sigma) 
SpectraMax M5 96 well plate reader (Molecular Devices) 
Serum from mice was harvested as described above and stored at -80°C until use. Serum 
samples from 2-5 mice were pooled together and analysed as one sample. The assay was 
performed using the method described for antibody binding assay in section 2.8.2. Briefly, 
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serum was diluted in PBS-BSA and then incubated with ELISA plates pre-coated overnight 
with either 0.5µg/ml human HER2 or 10µg/ml OVA. The next day, mouse IgG1, IgG2c and 
IgM were detected by incubating individual plates with the specific biotinylated antibody, 
streptavidin and substrate. Plates were measured for absorption at 450nm using the plate 
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2.9   In vitro cell proliferation assays 
2.9.1 Trypan Blue exclusion method 
Materials: 
Trypan Blue 0.4% (Gibco)  
Neubauer counting chamber (Fisher Scientific) 
TC treated 6-well plates (353046, Costar) 
B16, B16 HER2, B14.3 Luc and B14.3 Luc HER2 cells were detached using PBS-EDTA and 
seeded 50 000 cells per well in 3ml R10 in 6-well TC-treated plates in duplicates. At days 1-
3 after seeding, cells were harvested, and an aliquot was mixed with Trypan Blue pre-diluted 
1:5 in PBS. Live cells excluding Trypan Blue were counted under the microscope.  
2.9.2 MTS assay 
Materials: 
96 Well Tissue culture treated, round bottom plates (3799 Costar) 
CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega) 
SpectraMax M5 96 well plate reader (Molecular Devices) 
Human HER2 positive or negative cell lines and B16 or B16-derived cell lines were used in 
this assay. Cells were harvested and seeded 10 000 cells per well in 50μl R10 in TC treated 
96-well plates. Cells were incubated at 37ºC, 5% CO2 for 3-4 h. Serial dilutions of vehicle 
(PBS), isotype control, derived conjugates or complexes, Herceptin, Trastuzumab or 
Trastuzumab-derived conjugates and complexes were performed in R10 and 50μl were added 
per well. Cells were incubated at 37ºC, 5% CO2 for 48 h in a TC incubator. Subsequently, 20μl 
of the CellTiter 96® AQueous One Solution Reagent containing the MTS (3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner 
salt) compound were added per well. Plates were left at 37ºC, 5% CO2 for 30 min for the MTS 
substrate to be converted by metabolically active cells into a coloured product detected using 
a 96-well plate reader to measure absorption at 490nm. OD490 of vehicle-treated cells was 
considered 100% proliferation in the conditions of the assay. Proliferation of treated cells was 
expressed as percent of vehicle-treated cells.   
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2.10 Recombinant antibody production 
2.10.1 Expression of antibodies in mammalian cell lines 
Expression using the FreeStyleTM MAX 293 Expression System 
Materials: 
FreeStyleTM 293-F cells (Invitrogen) 
FreeStyleTM Expression Medium (Invitrogen) 
FreeStyleTM MAX reagent (Invitrogen) 
OptiPROTM serum-free medium (SFM) (Invitrogen) 
Midi- or maxipreparations of pVITRO plasmids 
Erlenmeyer flask, flat bottom, vented cap either 125ml, 250ml or 500ml (Costar) 
Stericup® 0.45μm PVDF membrane (Millipore)  
FreeStyleTM 293-F cells were maintained according to the manufacturer’s instructions 
(described in section 2.1) and used for transfections starting with passage 5 and not exceeding 
passage 30. Cells were harvested, counted and seeded 0.5x 106 cells/ml of FreeStyleTM 
Expression Medium the day before transfection (day -1). On transfection day (day 0), cells 
were diluted if necessary, to 1x 106 cells/ml. OptiPROTM SFM (1/25 of cell culture volume) 
was used to form complexes of plasmid/MAX Reagent. Both FreeStyleTM MAX reagent and 
plasmid were used at 0.8μg/ml of cell culture volume) and diluted separately in OptiPROTM 
SFM. Diluted plasmid and MAX reagent were mixed together and incubated for 10 min at RT. 
Complexes were added dropwise to the cells while swirling the flask. Cells were incubated at 
37ºC, 8% CO2. On day 7 post-transfection, cells were centrifuged at 500x g, 10 min, RT. 
Supernatant was filtered through a 0.45μm Polyvinylidene difluoride (PVDF) membrane and 
stored at 4ºC until further use. To evaluate relative antibody expression levels to Trastuzumab 
in cell supernatant, a human IgG1 ELISA was performed as described in section 2.8. 
Expression using the ExpiCHOTM Expression System 
Materials: 
ExpiCHO-STM cells (Gibco) 
ExpiCHOTM Expression Medium (Gibco) 
ExpiFectamineTM CHO Transfection Kit (Gibco) 
OptiPROTM serum-free medium (SFM) (Invitrogen) 
Midi- or maxipreparations of pVITRO plasmids 
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Erlenmeyer flask, flat bottom, vented cap either 125ml, 250ml or 500ml (Costar) 
Stericup® 0.22 μm and 0.45 μm PVDF membrane (Millipore)  
ExpiCHO-STM cells cells were maintained according to the manufacturer’s instructions (as 
described in section 2.1) and only used for transfections experiments starting with passage 3 
and only up to 30 passages. One the day before transfection (day -1) cells were seeded 3.5x 
106 cells/ml ExpiCHOTM Expression Medium. On transfection day (day 0), cells were diluted, 
if necessary, to 7-10x 106 cells/ml. Complexes of plasmid/ExpiFectamineTM CHO were 
formed in OptiPROTM SFM (1/25 of cell culture volume). Plasmid DNA was used at 1μg per 
ml of culture volume and diluted in OptiPROTM SFM. ExpiFectamineTM CHO was used at 2μg 
per ml of culture volume and diluted in OptiPROTM SFM. Plasmid and ExpiFectamineTM CHO 
were mixed together and incubated for 4 min at RT. Complexes were added dropwise to the 
cells while swirling the flask. Cells were incubated at 37ºC, 8% CO2. On day 1 post-
transfection, ExpiCHOTM Enhancer (1/6000 of culture volume) and ExpiCHOTM Feed (1/4 of 
culture volume), corresponding to the standard protocol in the product instruction manual. 
Supernatant was harvested on day 8 post-transfection by centrifugation at 500xg, 10 min, RT. 
Supernatant was filtered through a 0.45μm (PVDF) membrane and stored at -20ºC until further 
use. When thawed, supernatant was clarified by passing through a 0.22μm PVDF membrane. 
To evaluate antibody expression levels, human IgG1 ELISA was performed as described in 
section 2.8. 
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2.10.2 Purification of recombinant antibodies 
Materials: 
AKTA Start 29022094 and Unicorn Start 1.0 software (GE Healthcare) 
HiTrap MabSelect SuRe (protein A) column, 5ml (GE Healthcare) 
HiTrap Protein G column, 5ml (GE Healthcare) 
Stericup® 0.22 μm and 0.45 μm PVDF membrane (Millipore) 
Fractionation tubes 3 ml (300500, DeltaLab) 
Amicon Ultra centrifugal filter units 2-15ml with either 10kDa or 100kDa cut-off (Merck-
Millipore) 
Spin-X centrifuge tube filter 0.22μm (8160 Costar) 
NanoDrop 1000 spectrophotometer (Thermo Scientific) 
Cleaning solution: 1M NaOH 
10x DPBS [-] CaCl2, [-] MgCl2 (Gibco) 
Sterile non-pyrogenic water (Baxter) 
Column storage solution: 70% ethanol 
Neutralisation buffer: 1M Tris-HCl, pH 9.0 
Buffers for protein A column only: 
Binding buffer A: 20mM sodium phosphate, 0.15M NaCl, pH 7.2 
Elution buffer A: 0.1M sodium citrate, pH=3.2, 50mM NaCl 
Column cleaning in place (CIP) solution: 0.2M NaOH 
Buffers for protein G column only: 
Binding buffer G: 20mM sodium phosphate, pH 7.2 
Elution buffer G: 0.1M glycine-HCl, pH2.7 
1x DPBS [-] CaCl2, [-] MgCl2 (Gibco) 
All antibodies, weather Trastuzumab, Isotype control, ThioMab or fusion antibodies with 
LL37, were purified by affinity chromatography using either a protein A or a protein G 
column. All buffers were made up with sterile endotoxin-free water and sterile filtered through 
a 0.22μm membrane prior to use. Throughout the purification process, only pyrogen-free 
materials were used. During the run, the Unicorn software was used to monitor pressure in the 
system (which was always kept under 0.22MPa), absorbance at 280nm and conductivity.  
The AKTA start system was cleaned, first with 1M NaOH, followed by 1x PBS and 70% 
ethanol using a flow rate of 5ml/min. All tubing used in the purification process (line A, line 
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B, sample line, waste tube, fractionation tube) were cleaned for at least 8 min with each 
solution.    
After cleaning the machine, a flow rate of 1ml/min was set up while running 70% ethanol and 
the column was inserted. 5-7ml ethanol were run through the column at 1ml/min before 
equilibrating the column with minimum 5x column volumes of binding buffer (A for the 
protein A column and G for the protein G column) at 3ml/min flow rate. AutoZero of the UV 
detector was performed while running binding buffer. Cell supernatant was loaded onto the 
column through the sample line at 3ml/min. Unbound material was washed with 6 column 
volumes of binding buffer. Flow-through was collected into a sterile plastic flask, sterile 
filtered through a 0.22μm membrane and stored at 4ºC. Elution was performed with the 
respective buffer at 3ml/min with fractionation of 2ml in tubes pre-filled with 200μl 
neutralization buffer. The fractions containing eluted antibody (according to the UV trace) and 
a few adjacent fractions were analysed by NanoDrop for absorbance at 280nm. Fractions 
containing antibody were pooled. Buffer exchange and sample concentration were performed 
simultaneously using Amicon Ultra centrifugation filters with either 10kDa or 100kDa cut-
off. Filters were spun at maximum speed of the centrifuge (800xg) for 20-25 min, topping up 
the filter 5x times with cold PBS. Concentrated antibody preparation was sterile filtered 
through a 0.22μm membrane and stored at 4ºC until further use.  
While performing buffer exchange of the antibody, the column was regenerated with 30ml 
elution buffer at 3ml/min, followed by 6x column volumes of binding buffer. Only when the 
MabSelect Sure protein A column was used, cleaning in place (CIP) was performed with 0.2M 
NaOH run at 3ml/min for 15 min. Column was re-equilibrated with 6x column volumes of 
binding buffer and then used to purify another batch of antibody or stored. For storage, either 
of the columns were washed at 2ml/min with 5 column volumes of 70% ethanol. Columns 
were stored at 4ºC between runs.   
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2.10.3 Quantification of antibody yield 
BCA assay 
Materials: 
Polypropylene tubes of plates 
BCA assay kit (Pierce) 
Bovine gamma globulin (BGG) standard (Thermo Scientific) 
Assay plate, non-treated, round bottom, 96 well (Costar)  
SpectraMax M5 96 well plate reader (Molecular Devices) 
BCA assays were performed according to the manufacturer’s instructions. A standard curve 
was prepared using the BGG standard and used to determine antibody concentration of all 
purified antibodies or fusion antibodies, but also of antibody conjugates. Standard curve 
(triplicates) and samples (duplicates) were diluted in PBS to 25μl per well, to which 200μl 
substrate was added. The plate was incubated for 10 min at RT in the dark, then absorption at 
595nm was measured with a plate reader. 
Spectrophotometry  
Materials:  
NanoDrop 1000 spectrophotometer (Thermo Scientific) 
PBS: 1x DPBS [-] CaCl2, [-] MgCl2 (Gibco) 
2μl of antibody suspension in PBS was used to measure absorption at 280nm against the blank 
(PBS). For measurements, we have used the reported extinction of Herceptin, ε280nm = 
225,000 M−1 cm-1.   
Calculating total antibody yield from transfection experiments 
To calculate the total antibody yield generated via transient transfection, purified antibody c% 
was measured by BCA. The following formulas were applied: 
Mass of purified antibody (mg) = c% of purified batch (mg/ml) * volume (ml) 
Total antibody yield (mg/L) = mass of purified antibody (mg) / volume of supernatant it was 
purified from (L). 
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2.11 Organ isolation and cell cultures 
2.11.1 Generation of GM-CSF-derived bone marrow dendritic cells (BMDC) 
Materials: 
R10: RPMI 1640, 2mM glutamine, 10% FCS and 100 U/ml penicillin, 100μg/ml 
streptomycin, 50μM 2-ME  
GM-CSF, recombinant, murine (Peprotech) 
1ml syringe, 23G needle 
70μm strainer (BD) 
Femur and tibia of C57BL/6 mouse hind legs were removed using sterile instruments. The 
bone marrow cells were flushed out with R10 using a 23 G needle and syringe. Cells were 
placed in a 10 cm TC dish and incubated for 30 min at 37ºC, 5% CO2. Afterwards, non-
adherent cells were harvested and passed through a 70μm strainer, then centrifuged 5 min at 
300xg, RT. Cells were cultured at 1.3x 106 cells/ml in 10cm TC dishes in 12ml R10 
supplemented with 20ng/ml GM-CSF, as described previously (Inaba et al. 1992). The day 
cells are placed in culture was counted as day 0. On day 2, 10ml of the culture medium were 
carefully removed without disturbing the cells and replaced with 12ml of fresh R10 
supplemented with 20ng/ml GM-CSF. On day 3, medium and non-adherent cells were 
discarded. Adherent cells were gently washed with R10 and further cultured in 12ml R10 
containing 20ng/ml GM-CSF. Non-adherent and loosely adherent cells were harvested in R10 
and used in assays on day 5 or 6. Differentiation of bone marrow cells into dendritic cells was 
verified by flow cytometry, specifically through analysis of surface markers CD11c, Gr-1 
(common epitope on Ly-6G and Ly-6C), CD86 and MHC class II.  
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2.11.2 Generation of Flt3L-derived bone marrow dendritic cells (BMDC) 
Materials: 
R10: RPMI 1640, 2mM glutamine, 10% FCS and 100U/ml penicillin, 100μg/ml streptomycin, 
50μM 2-ME  
Flt3-ligand, recombinant, murine (Flt3L) (R&D Systems) 
1ml syringe, 23G needle 
70μm strainer (BD) 
C56BL/6 mice were culled and using sterile instrument, the femur and tibia of hind legs were 
removed. Bone marrow cells were flushed out with R10 using a needle and syringe and 
differentiated into dendritic cells following previously published protocols (Gilliet et al. 2002; 
Brawand et al. 2002). Cells were passed through a 70μm strainer and cultured in 5ml per well 
of R10 supplemented with 50ng/ml Flt3L in 6-well TC treated plates at a density of 1.5x106 
cell/ml. On day 5, 4.5ml medium were exchanged for 5ml of R10 + 50ng/ml Flt3L. similarly, 
on day 7, 4.7ml medium were exchanged for 5ml of R10 + 50ng/ml Flt3L. Only non-adherent 
and loosely adherent cells were used for in vitro assays on day 10 of culture. Differentiation 
into dendritic cells was verified by staining the cells for surface cell markers CD11c, B220, 
CD24 and CD11b. 
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2.11.3 Generating single cell suspensions from mouse lung 
Materials: 
R0: RPMI 1640 (no supplementation)  
R10: RPMI 1640, 2mM glutamine, 10% FCS and 100 U/ml penicillin, 100μg/ml streptomycin, 
50μM 2-ME  
Cell-wash buffer: 1x DPBS [-] CaCl2, [-] MgCl2 (Gibco) + 1% FCS + 5mM EDTA 
gentleMACS Dissociator (Miltenyi Biotec) 
gentleMACS (TM) C tubes (Miltenyi Biotec) 
Collagenase D solution (Roche #11 088 866 001) 
DNase I solution (Roche #1 284 932) 
100μm cell strainer (Thermo Fisher) 
Red blood cell (RBC) lysis buffer (10x): 1.5M NH4Cl, 100mM NaHCO3, 5mM EDTA  
Mouse lungs were harvested in sterile conditions, for some samples after in situ lung 
perfusion with 20ml DPBS. Lung tissue was carefully dissected from adjacent organs 
and connective tissue and rinsed in R0. Each mouse lung was injected with 2.5ml R0 
containing 1mg/ml collagenase D and 0.1mg/ml DNase I. The lung and media placed 
into gentleMACS C tubes were processed with the gentleMACS Dissociator using the 
program m_impTumor_02. Subsequently lungs were incubated for 40 min at 37°C, 
gently inverting the tubes every 5-10 min. Tissue was processed again by running the 
m_impTumour_03 program of the gentleMACS Dissociator. Samples were passed 
through 100μm cell strainer and washed with cell-wash buffer. Cells were centrifuged 5 min, 
RT at 500x g. Red blood cell lysis was performed for 7 min at RT, then cells were washed, 
centrifuged and strained again, then resuspended either in R10 or PBS, depending on 
application. 
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2.11.4 Preparation of splenocytes 
Materials: 
R0: RPMI 1640 (no supplementation)  
PBS-EDTA: PBS-EDTA: 1x DPBS [-] CaCl2, [-] MgCl2 (Gibco) + 5mM EDTA 
R10: RPMI 1640, 2mM glutamine, 10% FCS and 100 U/ml penicillin, 100μg/ml 
streptomycin, 50μM 2-ME  
Collagenase D solution (11 088 866 001, Roche) 
DNase I solution (1 284 932, Roche) 
70μm strainer (BD) 
Red blood cell (RBC) lysis buffer 10x: 1.5M NH4Cl, 100mM NaHCO3, 5mM EDTA  
Spleens were harvested from C57BL/6 mice using sterile instruments and aseptic technique. 
Enzymes were diluted in R0 to 1mg/ml collagenase and 200μg/ml DNase I. Each spleen was 
injected with 1ml of diluted enzymatic cocktail and incubated for 30 min at 37ºC. Spleens 
were filtered through a 70μm strainer and washed in PBS-EDTA. Cells were centrifuged 5 
min at 300x g, 4ºC. Subsequently, cells were either filtered one more time, centrifuged and 
resuspended in R10 for in vitro activation assays, or subjected to RBC lysis. 
To lyse RBC, the 10x buffer was diluted 1:10 in TC grade sterile water and 1ml was used per 
spleen, incubated 7 min on the bench. Afterwards, 20ml PBS-EDTA were added to the tube. 
Cells were centrifuged and filtered again through a 70μm strainer. Cells were either 
resuspended in FACS buffer and stained or resuspended in R10 and incubated ex vivo 37ºC, 
5% CO2 with either tumour-specific peptides for 72 h, or with 5μg/ml Brefeldin A (3 h) for 
intracellular staining. Incubated cells were filtered again after harvesting to prevent clogging 
of the cytometer, stained with their respective antibody panels and analysed by flow-
cytometry.  
2.11.5 Ex vivo restimulation of splenocytes 
Materials: 
R10: RPMI 1640, 2mM glutamine, 10% FCS and 100 U/ml penicillin, 100μg/ml streptomycin, 
50μM 2-ME  
24-well plates, TC treated (353047, Corning Incorporated)  
SIINFEKL peptide (CRUK, London) 
TRP-1 and TRP-2 peptides (Thermo Fisher Scientific) 
Recombinant human HER2 (10004-H08H, SinoBiological)  
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SIINFEKL OVA 257-264 I SIINFEKL 
TRP-1 a TRP-1 I TWHRYHLLC 
TRP-1 b TRP-1 I TAYRYHLLC 
TRP-1 IIa TRP-1 II LFLMLFYQVWAQFPREC 
TRP-1 IIb TRP-1 II TCRPGWRGAACNQKILT 
TRP-1 IIc TRP-1 II RRLEDILGPDGNTPQFE 
TRP-2 TRP-2 180-188 I SVYDFFVWLC 
TRP-2 IIa TRP-2 II GCKFGWTGPDCNRKKPA 
TRP-2 IIb TRP-2 II VLNKECCPPLGPEATNI 
TRP-2 IIb TRP-2 II KCTGNFAGYNCGGCKFG 
Table 2.11. Peptides, either MHC class I of class II-restricted, used for ex vivo stimulation of treated 
tumour bearing mice.  
Splenocytes isolated from tumour-bearing mice on day 7 post-treatment with either vehicle, 
antibodies or conjugates were stained with 2µM CFSE. For CFSE labelling, cells were taken 
up in PBS containing diluted CFSE and incubated 10 min at 37ºC. Afterwards, 50% v/v FCS 
was added and cells were incubated for 1 min at RT. Cells were washed twice before 
incubating 1-2x 106 splenocytes in R10 with 2-4x 105 GM-CSF derived BMDC (harvested on 
day 4 of culture) and 0.03µM of the following: recombinant human HER2, SIINFEKL (OVA 
class I-restricted peptide), TRP-1 and TRP-2 peptides shown in Table 2.11. The bulk of cells 
were harvested after 72 h, stained for live/dead-cell discrimination (see section 2.7.1) and fixed 
in Streck. Subsequently, cells were stained for CD3, CD4, CD8 and the number of proliferating 
cells diluting CFSE was analysed by flow cytometry.  
Alternatively, 1-2x106 splenocytes were stimulated with SIINFEKL only (final concentration 
0.66µM) in the presence of 2-4x105 GM-CSF derived BMDC for 72 h. Cells were harvested, 
stained for live/dead-cell discrimination and then fixed with Streck. Cells were stained with 
H-2Kb-SIINFEKL pentamers (PE-labelled) and anti-CD8α antibodies and analysed by flow 
cytometry (for staining details see section 2.7.2).    
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2.12 Cell culture with human primary cells 
2.12.1 Isolation of peripheral blood mononuclear cells (PBMCs) 
Materials: 
PBS: 1x DPBS [-] CaCl2, [-] MgCl2 (Gibco) 
Heparin Sodium (5000 IU/ml, Wockhardt) 
Lymphocyte separation medium (LSM 1077, GE Healthcare) 
50ml centrifuge tubes (Greiner) 
Leukocyte cones (product NC24) were ordered from NHS Blood and Transplant (HTA 
Research Licence 12321, NIBSC HuMAC ethical approval 18/02/AN). Blood from 1 cone 
was diluted 1:2 with PBS. 10IU heparin/ml were added to the tubes to prevent coagulation. 
50ml tubes were pre-filled with 15ml lymphocyte separation medium. 30ml diluted blood was 
carefully overlaid on top of the separation medium, without mixing the two. Cells were 
centrifuged at 1200 rpm for 20 min RT without brake. The interphase of white blood cells 
(buffy coat) containing PBMCs was harvested. Cells were washed twice in PBS with 
centrifugation at 1200rpm, 10 min, with brake. Cells were either processed in assays or 
resuspended 5-10x 107 cells in 900µl FCS, to which 100µl DMSO were added dropwise and 
cells were frozen at -80ºC until further use. Stored PBMCs were logged under HTA Research 
Licence no.12321 at NIBSC. 
2.12.2 Enrichment of pan dendritic cells from PBMC 
Materials: 
Enrichment buffer: 1x DPBS [-] CaCl2, [-] MgCl2, 2% FCS, 1mM EDTA 
EasySep® Human panDC Enrichment Kit (StemCell Technologies) 
EasySep® “The Big Easy” Silver Magnet (StemCell Technologies) 
15ml centrifuge tubes (Starstedt) 
Dendritic cells (DC) were enriched from freshly isolated PBMCs using the human panDC 
enrichment kit (StemCell) following the manufacturer’s protocol. Cells were stained in 
enrichment buffer at a density of 5x 107 cells/ml with reagents from the kit. First, cells were 
incubated with 30µl/ml of sample Fc Blocker for 10 min RT. Then 50 µl/ml of sample 
Enrichment cocktail were added, and cells were incubated 30mi RT. Next, magnetic particles 
were added 100µl/ml of sample and incubated 10 min RT. If necessary, enrichment buffer was 
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added to a reach a total volume of 3.5 ml when starting with < 1x 108 cells, or 6.5ml when 
starting with > 1x 108 cells. The tube was placed in the EasySep Silver Magnet for 5 min. 
Subsequently, the tube was inverted while placed in the magnet to collect the enriched 
panDCs. To characterise the DC populations in the enriched PBMCs, cells were stained either 
with the myeloid DC (mDC) panel or the plasmacytoid DC (pDC) panel. The mDC panel 
contained antibodies against the following human markers: CD14 (FITC / Pacific Blue), HLA-
DR (APC-CY7), CD3 (PerCP-Cy5.5), CD19 (PE-Cy7), BDCA-1 (PE) and BDCA-3 (APC). 
The pDC panel contained antibodies against BDCA-2 (FITC), HLA-DR (APC-CY7), CD3 
(PerCP-Cy5.5), CD19 (PE-Cy7). 
2.12.3 Generation of monocyte-derived dendritic cells from human PBMCs 
Materials: 
R10: RPMI 1640 containing 10% heat-inactivated FCS, glutamine, 100 U/ml 
penicillin/streptomycin and 50µM β-Mercaptoethanol 
Human GM-CSF (200-04, Peprotech) 
Human IL-4 (300-03, Peprotech) 
Enrichment buffer: 1x DPBS [-] CaCl2, [-] MgCl2, 2% FCS, 1mM EDTA 
EasySep Negative Selection, Human Monocyte Enrichment Kit (19059, StemCell) 
EasySep® “The Big Easy” Silver Magnet (StemCell Technologies) 
15ml centrifuge tubes (Starstedt) 
For this protocol we used PBMCs isolated from cones as per protocol 2.12.1. Monocytes were 
enriched by negative selection using “The big easy” Silver EasySep Magnet and the EasySep 
Negative Selection, Human Monocyte Enrichment Kit as per manufacturer instructions. 
Enriched monocytes were washed once and resuspended in R10 at 3x 106cells/ml. Cells were 
seeded in TC treated 6-well plates, 3ml per well and cultured in the presence of 20ng/ml human 
GM-CSF and IL-4. At day 2 and day 5, 0.5ml R10 containing sufficient GM-CSF and IL-4 to 
achieve a concentration of 20ng/ml in the entire volume were added to each well. Cells were 
used on day 6 or 7 from the start of culture.  
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2.13 In vitro immune activation assays 
Materials: 
R10: RPMI 1640, 2mM glutamine, 10% FCS and 100 U/ml penicillin, 100μg/ml streptomycin, 
50μM 2-ME  
96-well plates, TC-treated, flat bottom (353072, Corning) 
DOTAP (Roche Diagnostics) 
LL37 (Invivogen) 
CpG various types (synthesised by Eurofin Genomics) 
HEPES buffer: 20mM HEPES, 150mM NaCl, pH=7.1-7.3 
The immune activation profile of nucleic acid endosomal TLR agonists used in this study 
(listed in Table 2.12), either soluble, conjugated or in the form of complexes were evaluated 
in vitro using either human PBMCs, enriched human panDCs, mouse splenocytes, mouse GM-
CSF derived BMDCs or Flt3L-derived BMDCs. 1-5x 105 cells were cultured in 100µl 
complete R10 in flat bottomed TC-treated 96-well plates. For GM-CSF differentiated BMDCs, 
R10 was also supplemented with 40ng/ml GM-CSF. Similarly, when Flt3L derived BMDCs 
were stimulated in vitro, R10 was supplemented with 100ng/ml Flt3L. TLR agonists or 
controls were diluted to 100µl /replicate with R10 before adding to the wells. The final volume 
in each well was kept constant at 200µl. Each dilution of TLR agonist, control or vehicle was 
performed in triplicate. When complexes were formed with either DOTAP (20µl/sample), 
LL37 synthetic peptide or fusion antibodies, these were added to CpG or polyUs21 in HEPES 
buffer, in a final volume of 80µl. The wells containing 100µl cells were topped up with 75µl 
R10 and 25µl of complexes were added per well. Plates were incubated overnight at 37ºC, 5% 
CO2 in the tissue culture incubator. The following day, plates were frozen at -20ºC or -80ºC. 
The read-out of the assay was cytokine production (typically IL-6 and IL-12p40) measured by 
ELISA, as described in section 2.8.
Chapter 2 Materials and methods 
91 




CpG 1668 - 
PTO Mouse  B TCC ATG ACG TTC CTG ATG CT 
CpG 1668-SH 3’-C3-thiol 
CpG 1668-C6-NH3 3’-C6-NH3 
CpG 1668-FITC 3’-FITC 
TAMRA CpG 1668-SH 3’-C3-thiol, 5’-TAMRA 
TAMRA CpG 1668-SH 3’- C6-NH3, 5’-TAMRA 
GpC 1668 - 
PTO Negative control - TCC ATG AGC TTC CTG ATG CT 
GpC 1668-SH 3’-C3-thiol 
CpG 2006 - 
PTO Human B TCGTCGTTTTGTCGTTTTGTCGTT 
CpG 2006-C6-NH3 3’-C6-NH3 
CpG 2216 - PTO / pde Human A GGgggacga:tcgtcGGGGGG 
CpG M362 - PTO Human/murine C TCGTCGTCGTTC:GAACGACGTTGAT 
CpG C274 - 
PTO Human C TCGTCGAACGTTCGAGATGAT 
CpG C274-SH 3’-C3-thiol 
polyUs21 - PTO Human/mouse TLR7 N/A UUUUUUUUUUUUUUUUUUUUU 
Table 2.12. List of oligonucleotides, either endosomal TLR agonists. PTO – phosphorothioate backbone of bases are shown in capital letters; pde – phosphodiester 
backbone of bases shown in lower case; CpG or GpC motifs are highlighted in grey; CpG oligos are TLR9 agonists, while polyUs21 is a TLR7 agonist. 
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2.14 Calcein-release antibody-dependent cytotoxicity (ADCC) assays  
Materials: 
Targets: BT474 cells 
Effectors: PBMC – isolated and frozen at -80 
R0, R5, R10, no beta-mercaptoethanol 
Assay plate: 96-well plates, TC-treated, flat bottom (353072, Corning) 
Read-out plate: 96-well, sterile white bottomed plate (3917, Corning) 
Flexiplates: Serocluster™ 96-well “U” bottom Plate, non-treated, vinyl (2797, Costar)  
Calcein (65-0853-39, eBioscience) 
10x Lysis buffer: Triton-X-100 9% 
SpectraMax M5 96 well plate reader (Molecular Devices) 
BT474 cells were used as targets cells. BT474 cells were labelled with 11.2µM calcein in R5 
for 30 min at 37°C, then washed twice, resuspended at 1.6x 105 cells/ml of R10 and 50µl were 
plated per well in the assay plate. Trastuzumab, conjugates or controls were diluted in R10 
and added on top of BT474 cells in 50µl per well, in triplicates. Target cells were incubated 
with antibody, conjugate or control for 30 min at 37°C.  
PBMCs were used for effector cells. Frozen PBMCs were rapidly thawed the day before the 
assay and rested overnight in R10. On the day of the assay, cells were washed twice in RPMI 
1640 and resuspended in R10 and diluted to 2x 106 cells/ml. 100µl PBMCs were plated per 
well to achieve an effector to target ratio of 25. For the spontaneous release controls, R10 was 
added to targets pre-incubated with Trastuzumab or conjugate. The plate was centrifuged for 
1 min at 100x g and incubated at 37°C overnight. Each assay contained the following controls: 
no antibody control, antibody / conjugate induced spontaneous release, spontaneous release 
control (no antibody), maximum release control.  
After 14-16 hours incubation of targets with effectors, 10ul of 10x lysis buffer were added to 
the wells containing the maximum release control. The plate was incubated for 30 min before 
centrifuging 5 min at 300x g. Cell supernatant was carefully collected and added to the read-
out white bottomed plate. Fluorescence was read using excitation at 494nm and emission at 
517nm in a spectrophotometer. 
A dose response corrected for spontaneous calcein release from target cells was calculated: 
% cytotoxicity = (experimental value – target cell spontaneous control) / (target cell maximal 
release – target cell spontaneous control). 
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2.15 Conjugate preparation 
2.15.1 Stochastic conjugation using SMCC 
Materials:  
Trastuzumab or Herceptin (Roche)  
UltraLeaf Human IgG1, κ isotype control (QA16A12, BioLegend) 
CpG 1668-SH (CpG 1668-thiol) (synthesised by Eurofin Genomics) 
CpG C274-SH (CpG C274-thiol) (synthesised by Eurofin Genomics) 
Succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) (Thermo 
Scientific) 
Dimethylsulfoxide, anhydrous (DMSO) (Life technologies) 
Dithiothreitol (DTT) (Sigma) 
Endotoxin Free (EF) water (Macherey Nagel) 
Borate buffer 0.05M, 150mM NaCl, pH=8.9-9.1 
Conjugation buffer: PBS + 2mM EDTA, pH=7.1-7.3 
0.5ml Amicon Ultra centrifugal filter units with 100kDa cut-off (Merck-Millipore) 
Micro Bio-Spin™ 6 Chromatography Columns (Bio-Rad) 
ThermoMixer (Eppendorf) 
Firstly, antibodies were concentrated when necessary to 9mg/ml in PBS, or for some samples 
in borate buffer using 0.5ml Amicon Ultra filters. A range of 250-1000µg were used per 
conjugation batch. SMCC was purchased as 1mg one-use tubes. One vial was reconstituted in 
150µl DMSO. Then, SMCC was added to the antibody, 5-30 molar excess. Most experiments 
were performed with 10x molar excess of SMCC. The mixture was incubated at 22ºC for 1 h 
on the Thermoblock rotating at 300 rpm. Then, the samples were purified from excess 
unreacted SMCC by ultracentrifugation using 0.5ml Amicon Ultra filters. Samples were 
topped up to 500µl PBS and centrifuged at 14 000x g RT. The same was repeated 3x times but 
using conjugation buffer instead. Samples were recovered in a small volume (30-50µl) by 
inverting the column and centrifuging 2 min, 1000x g, RT. 
While activating the antibody with SMCC, CpG-thiol was reduced in 50mM DTT (freshly 
reconstituted in EF water), for 1 h at 22ºC on the Thermoblock rotating at 300 rpm. Afterwards, 
CpG was purified from DTT using Micro Bio-Spin™ 6 Chromatography Columns. Just before 
use, columns were washed 3x times with 500µl conjugation buffer (centrifugation at 1000x g, 
2 min, RT) follower by an additional centrifugation step to empty the column from excess 
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fluid. Then the column was moved into a clean tube and the CpG was purified and buffer 
exchanged by centrifuging 4 min at 1000x g, RT.  
Reduced and purified CpG was added 3-10 molar excess to SMCC-activated antibody 
(depending on the experiment) and incubated for 2 h at 22ºC on the Thermoblock rotating at 
300 rpm. Antibody-conjugates were purified from unreacted CpG by ultrafiltration using 
Amicon filters with 100kDa cut-off, by washing 5x times with PBS (10 min centrifugation at 
14000x g, RT). Samples were recovered in a small volume, then the volume was topped with 
DPBS to 50µl if necessary. Finally, the conjugates were sterile filtered through a 0.22µm 
membrane and stored at 4ºC until further use. 
2.15.2 Stochastic conjugation using CC 
Materials:  
Trastuzumab or Herceptin (Roche) 
CpG 1668-SH (CpG 1668-thiol) (synthesised by Eurofin Genomics) 
polyUs21 
Cyanuric chloride (CC) (from Ram Abuknesha) 
Borate buffer 0.05M, pH=9-9.5 
Acetone (VWR) 
Diethyl ether (Sigma) 
Glass vials, 0.5ml (JG Finneran) 
0.5ml Amicon Ultra centrifugal filter units with 100kDa cut-off (Merck-Millipore) 
Spin-X centrifuge tube filter 0.22μm (8160 Costar) 
Cyanuric chloride (CC) was weighed and dissolved at 2mg/ml in ice-cold acetone. 150µl of 
the solution was transferred into a glass vial and the acetone was evaporated by fumigating 
with N2.  
Either CpG or polyUs21 were diluted in borate buffer to 1mg/ml and added 300µg (300µl) to 
the glass vial with the dried CC. A tint magnetic flea was added to the glass tube and the 
solution was stirred at RT for 90 min. Afterwards, excess unreacted CC was removed using 
Diethyl ether. 2ml were added to the glass vial and mixed thoroughly. After 1-2 min the two 
phases separate and the upper one was removed. This was repeated 2x more times. 
In a subsequent step, Trastuzumab was diluted to 2mg/ml in borate buffer and 150µl were 
added to the CC-activated CpG or polyUs21.  This mixture was incubated at 37ºC overnight. 
The next day, samples were purified from unreacted oligo and buffered exchanged in DPBS 
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by ultrafiltration using 0.5ml Amicon Ultra filters. Samples were topped up to 500µl DPBS 
and centrifuged at 14000x g RT. This was repeated 5 times, then samples were recovered in a 
small volume in an Eppendorf by inverting the column and centrifuging for 2 min at 1000x g 
RT. Finally, samples were diluted to 50µl if necessary and sterile filtered through an 0.22µm 
membrane. CC conjugates were stored in the fridge until further use.  
2.15.3 Site-specific conjugation of THIOMABs 
Materials: 
Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) (C4706-10G, Sigma)   
(L)-Dehydroascorbic acid (dhAA) (Sigma)  
PBS-TH: 12mM sodium phosphates, 140mM sodium chloride, pH = 7.4 
PBS: 1x DPBS [-] CaCl2, [-] MgCl2 (Gibco) 
CpG 1668-C6-NH3 (amino-CpG) (synthesised by Eurofin Genomics) 
DyLight488™-maleimide (Thermo Scientific) 
Succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) (Thermo 
Scientific) 
Dimethylsulfoxide, anhydrous (DMSO) (Life technologies) 
0.5ml Amicon Ultra centrifugal filter units with 100kDa cut-off (Merck-Millipore) 
VIVACON 500, 10kDA MWCO / 50kDA MWCO (Sartorius) 
Spin-X centrifuge tube filter 0.22μm (8160 Costar) 
Micro Bio-Spin™ 6 Chromatography Columns (Bio-Rad) 
ThermoMixer (Eppendorf) 
Trastuzumab-ThioMab (Tr-TH) with engineered cysteines (LC-V205C) as described in 
section 2.2.4 was further expressed in FS293 cells and purified on a protein A column (see 
section 2.10). Tr-TH was conjugated to CpG 1668 synthesised with a 3’-terminal amino (-C6-
NH3+) group (amino-CpG) using a modified version of the original ThioMab conjugation 
protocol (Junutula et al. 2008). Tr-TH (25µM) was reduced in 1mM TCEP for 1 h at 23ºC on 
the ThermoMixer rotating at 300 rpm. Next, the reduced antibody was purified from TCEP by 
ultrafiltration on VIVACON 10kDA columns (5x washes, 15 min centrifugation at 14 000x 
g). Reduced Tr-TH was recovered in a small volume (minimum concentration 6.73µM) by 
placing the column upside-down in a sterile Eppendorf and further subjected to accelerated re-
oxidation with 400x molar excess of dhAA (freshly reconstituted in DMSO), for 3 h at 23ºC 
and mild agitation (300 rpm). Tr-TH was once more purified from dhAA by ultracentrifugation 
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using either VIVACON 50kDA columns or Amicon Ultra 100kDa columns (2x washes with 
PBS-TH, 10 min centrifugation at 14 000x g).  
To generate CpG conjugates, amino-CpG was activated with SMCC. This conjugation was 
timed to the end of the antibody re-oxidation process. CpG was buffer exchanged in PBS-TH 
(150µM) and conjugated for 30 min at 23ºC with 20x molar excess of SMCC (1mg freshly 
reconstituted in 150µL DMSO), then purified from excess cross-linker using Micro Bio-Spin 
columns in PBS-TH. Then, the antibody was incubated with either 10x molar excess SMCC-
activated amino-CpG or DyLight-488-maleimide overnight at 4ºC. The next morning, the 
conjugate was purified, and buffer exchanged into 1x PBS by ultracentrifugation using either 
VIVACON 50kDA cut-off or 0.5ml Amicon 100kDA cut-off. Conjugates were sterile filtered 
through a 0.22µm membrane and stored in the fridge until further use. 
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2.16 Conjugate characterization 
2.16.1 Quantification of nucleic acid content of biochemical conjugates 
Materials: 
NanoDrop 1000 spectrophotometer (Thermo Scientific) 
PBS: 1x DPBS [-] CaCl2, [-] MgCl2 (Gibco) 
Trastuzumab  
UltraLeaf Human IgG1, κ isotype control (QA16A12, BioLegend) 
CpG various types (synthesised by Eurofin Genomics) 
GpC 1668 (synthesised by Eurofin Genomics) 
polyUs21 (synthesised by ThermoFisher Scientific) 
A standard curve was generated containing 0.5µg/µl of human IgG1 antibody (either 
Trastuzumab or isotype control) in all samples and 1:5 dilution of the conjugated 
oligonucleotide (either CpG, GpC or polyUs21) from a starting concentration of 200ng/µl in 
PBS. Using the NanoDrop blanked with PBS absorbance at 260nm was measured in the 
SSDNA-33 channel for the standard curve in triplicates. Conjugate samples were first 
measured in a BCA assay to determine the antibody concentration, then were diluted to 
0.5µg/µl antibody. Absorption at 260nm was measured for conjugates in duplicates. The 
concentration of nucleic acid was calculated against the standard curve. 
2.16.2 Ellman’s test 
Materials: 
Reaction buffer: DPBS (Ca and Mg free, Gibco) + 2mM EDTA, pH=7.1 
Cysteine (44889, Thermo Scientific) 
Ellman’s reagent solution (DTNB) (22582, Thermo Fisher) 
Assay plate: 96-well, round bottom plates (3799 Costar) 
SpectraMax M5 96 well plate reader (Molecular Devices) 
Cysteine was reconstituted in reaction buffer. A standard curve was built using 1:2 dilutions 
in reaction buffer starting from a top concentration of 1.5mM cysteine. In the assay plate, 
125µl/well reaction buffer were added. Then, 25µL standard or appropriate diluted sample 
were added in triplicates. 1mM DTNB solution was added 50µL/well. The plate was incubated 
for 3-5 min at RT, then absorption at 412nm was measured using the plate reader. Cysteine 
concentration in the sample was measured against the standard curve. 
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2.16.3 SDS-PAGE analysis 
Materials: 
Gel electrophoresis chamber (Thermo Fischer Scientific) 
Novex Wedge 4-20% Electrophoresis Gels, 1.5mm (Life Technologies) 
BoltTM 4-12% Bis-Tris Plus Gels, 10-well (Invitrogen) 
Running buffer (10x): 250mM Tris base, 2.5 M glycine, 1%SDS (pH 8.3) 
Non-Reducing Sample buffer (2x): 100nM Tris base, 4% SDS, 20% glycerol, spatula tip of 
bromophenol blue  
β-Mercaptoethanol 50mM (2-ME) (Gibco)  
ThermoMixer (Eppendorf) 
ColorPlus prestained Protein Standard 10-230 kDa (NEB BioLabs)  
Mark12 Unstained Standard 2.5–200 kDa (Invitrogen) 
Ethidium Bromide (Fisher Scientific) 
SYBR Gold Nucleic acid gel stain, 10 000x concentrate (Invitrogen) 
SymplyBlue SafeStain (Invitrogen) 
20% NaCl solution 
Syngene PXi image analysis system (Syngene) 
GeneTools software (Syngene) 
Samples were normalized for antibody concentration and prepared in 2x non-reducing sample 
buffer. When sample were reduced prior to analysis, 20% 2-ME was added in the final volume 
and the sample was boiled for 5 min at 96ºC on the Thermoblock. To help with gel orientation, 
5μl of ColorPlus pre-stained Protein Standard were consistently loaded on the first lane, 
followed by 7µl of Mark12 Unstained Standard and antibody samples. The gel was run at 25 
min at 230V (constant voltage) in 1x running buffer diluted in ultrapure water.  
To analyse oligonucleotide-containing biochemical conjugates, the gel was first stained for 
nucleic acid with 2µg/ml Ethidium Bromide in 50ml ultrapure water for 30 min. The gel was 
destained in 100ml ultrapure water for 2h, changing the water every 30 min. A subset of gels 
was stained instead with SYBR Gold diluted 1:10 000 in 50ml ultrapure water for 20 min and 
imaged without destaining. 
When the gel contained fluorescently labelled antibodies or was stained for nucleic acid with 
either SYBR Gold or Ethidium bromide, the gel was imaged using the appropriate 
excitation/emission settings of the fluorophore on the Syngene PXi System. Subsequently, the 
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gel was washed for 10min in 100ml water and stained for protein for 1 h in 20ml of 
SymplyBlue SafeStain. The gel was either destained for 1 h in water or overnight in 2% NaCl 
and imaged using the Coomasie Blue channel with the Syngene PXi System. Images were 
analysed with GeneTools from Syngene software. 
2.16.4 Size exclusion chromatography (HPLC) 
Materials: 
TSK G4000SWXL (7.8 x 300 mm, 8µm pores) column (TOSOH, code 808542) 
Guard column TSK gel Guard SW XL (TOSOH, product code 808543) 
Mobile Phase:   0.2 M Sodium Phosphate, 0.1 M Sodium Sulphate pH 6.0, filtered (0.22 µm), 
degassed 
Tr and Tr-MCC-GpC conjugate 
Dionex Ultimate 3000 (Thermo Fisher) controlled by Chromeleon 7.2 
10µg of either Tr or Tr-MCC-GpC were diluted in mobile phase and left at 6°C for 30 min to 
allow equilibration between monomeric and dimeric material. The column was equilibrated 
in mobile phase and maintained at 25ºC and constant pressure (14 bar). 10µl water were run 
to establish baseline. Then, prediluted analytes were injected. Flow rate was 0.4ml/min and 
run time was 60 min. 
2.16.5 Limulus Amoebocyte Lysate (LAL) assay 
To test for bacterial endotoxins in our antibody/conjugate preparations, the gel-clot method of 
the LAL assay was performed using Endosafe lysate from Charles River Laboratories and the 
3rd WHO International Standard (10/178). The semi-quantitative assay was performed 
following the protocol described as Method B in the European Pharmacopoeia Section 2.6.14. 
Concentrated samples were diluted to either 0.4mg/ml or 1:20 prior to testing. LAL assays 
were performed by Janet Sutherland, Trusha Desai or Sophie Myhill NIBSC.   
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2.17 Complex formation and visualisation 
2.17.1 Complex formation 
Materials: 
1x DPBS [-] CaCl2, [-] MgCl2 (Gibco) 
HEPES buffer: 20mM HEPES, 150mM NaCl, pH=7.1-7.3 
LL37 (Invivogen) 
CpG 1668 (synthesised by Eurofin Genomics) 
polyUs21 - (synthesised by ThermoFisher Scientific) 
Trastuzumab-linker-LL37, Isotype-H3-LL37 
For complex formation, Trastuzumab-LL37 or Isotype-LL37 were diluted in PBS or HEPES 
buffer for some experiments at 0.6-1mg/ml. Endosomal TLR agonist (CpG or polyUs21), was 
also diluted in either PBS or HEPES buffer at 0.2-0.5mg/ml. The two dilutions were mixed 
together to achieve 1:1 oligo to LL37 molar ratio and incubated for 2-10 min RT. For some 
experiments, the molar ratio of oligo to LL37 moiety varied from 1:2 to 1:20. When further 
dilutions were required, complexes were subsequently diluted in HEPES, DPBS or R10.   
2.17.2   Visualising complexes 
Materials: 
1x DPBS [-] CaCl2, [-] MgCl2 (Gibco) 
CpG 1668 (synthesised by Eurofin Genomics) 
polyUs21 - (synthesised by ThermoFisher Scientific) 
Trastuzumab-H3-LL37 
96-well U-plates, sterile, non-TC treated (3788, Costar) 
SpectraMax M5 96 well plate reader (Molecular Devices) 
Complex formation was visualised with the naked eye as clouding of the solution upon 
addition of CpG or polyUs21 to Tr-H3-LL37 or Iso-H3-LL37.  
Complexes were formed as described in 2.17.1 and plated in triplicates in 96-well clear plates. 
Tr-H3-LL37, CpG and PBS were plated as well. Absorbance at 405nm and 600nm was 
measured at 1, 5, 10 and 30 min after complex formation.  
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2.18 B16 HER2 pseudo-metastasis mouse model 
2.18.1 Mice 
Seven-eight weeks old female C57BL/6 mice weighing a minimum 18g were obtained from 
Envigo and were acclimated in the Mouse Facility at NIBSC for at least 5 days before 
commencing experiments. All experiments were conducted in accordance to the Animal 
Scientific Procedures Act 1986 under the project license 70/8831. Animals were randomly 
allocated into treatment groups. NIBSC personnel administering the treatment were blinded to 
allocation during experiments or tissue harvest. 
2.18.2 Preparation of tumour cells 
Materials: 
PBS: 1x DPBS [-] CaCl2, [-] MgCl2 (Gibco) 
PBS-EDTA: 1x DPBS [-] CaCl2, [-] MgCl2 (Gibco) + 5mM EDTA 
R10: RPMI 1640, 2mM glutamine, 10% FCS and 100U/ml penicillin, 100μg/ml streptomycin, 
50μM 2-ME 
B16 and B16-derived tumour cell lines were seeded the day before in vivo experiments at 1.5-
2x 106 cells per 145cm2 TC dishes in complete R10. The next day, cells were detached using 
PBS-EDTA and centrifuged 300x g, 5 min, 4ºC. Cells were resuspended in ice-cold PBS, 
counted using Tripan Blue exclusion, adjusted to the concentration required for the respective 
cell line and experiment and injected intravenously (IV) in mice within 40 min from 
harvesting. 
2.18.3 Tumour growth profiles 
Materials: 
PBS: 1x DPBS [-] CaCl2, [-] MgCl2 (Gibco) 
Fekete solution: 70% EtOH, 3.7% PFA, 0.75M glacial acetic acid 
Mice received on day 0 intravenous injections (IV) in the tail vein with 0.5-0.9x 105 B16 and 
B16-derived cell lines in 150μl PBS. IV injections were performed by Alan Haynes, NIBSC. 
To asses tumour burden, in vivo imaging was performed at different time-points (see below in 
section 2.18.5). 15-18 days after tumour inoculation, mice were euthanized with 200mg/kg 
Pentobarbital by intraperitoneal (IP) route; for tumour growth profile, the lungs were 
harvested, washed in PBS and imaged using the IVIS Spectrum. Then, lungs placed in Fekete 
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solution and fixed for at least 24 h. Subsequently, lungs were weighed, and pulmonary nodules 
were counted under Olympus S2X10 microscope (DF PLAPO 1x-4 lens) at zoom 
magnification setting 0.63. Representative images of the lungs were acquired using Olympus 
SC30 camera connected to an Olympus S2X10 microscope (DF PLAPO 1x-4 lens) at zoom 
magnification setting 0.63 and processed with CellSens Entry 1.5 software.  
2.18.4 In vivo imaging 
Materials: 
In Vivo Imaging System - IVIS Spectrum® (Perkin Elmer) 
Living Image® 4.7.2 (Caliper Life Sciences) 
XenoLight D-Luciferin, Potassium Salt (PerkinElmer) 
Mice were weighed and subsequently injected IP with 150mg/kg XenoLight D-Luciferin 
substrate by NIBSC animal technicians. After 10 min, mice were imaged under anaesthesia 
with 2% isoflurane using IVIS Spectrum® (Perkin Elmer) and the Living Image® 4.7.2 (Caliper 
Life Sciences) software. Acquisition was performed using a 22.5cm field of view (FOV) and 
excitation and emission filters open. A group of mice with expected high signal was imaged 
first to optimize additional acquisition settings (time, lens aperture (F), binning). Acquisition 
parameters were optimized for at the beginning of each imaging timepoint and kept constant 
among groups of mice. A minimum of two luciferase-free mice (injected with B16 tumours) 
were included in each experiment. In some experiments, mice were dissected, major organs 
harvested and imaged ex vivo to verify the source of the bioluminescent signal. Data were 
analysed using Living Image software. Regions of interest (ROI) of 2.647cm diameter were 
placed to measure luminesce signal in the thorax area. Data were expressed as luminescence 
intensity in the ROI area (photons/sec). To compare the growth profiles, the CGGC 
permutation test (http://bioinf.wehi.edu.au/software/compareCurves) with 10 000 
permutations was used (Elso et al. 2004).  
2.18.5 Treatment with conjugates and complexes 
One-dose regimen 
Mice were injected IV, on day -11, with 0.6x 105 B14.3 Luc HER2 bright cells in 100μl PBS. 
Ten days later (day -1), mice were injected IP with 150mg/kg XenoLight D-Luciferin and 
imaged 10 min later using the IVIS System to confirm tumour burden. Tumour-bearing mice 
were treated IV on day 0 with Trastuzumab or Trastuzumab-derived conjugates and 
complexes. Each treatment sample contained 270pmoles of antibody per mouse in 100μl PBS. 
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Pyrogen-free materials were used for all dilutions. Blood samples were harvested at day 1, 4 
and 7 post-treatment. Blood was allowed to clot for 30 min at RT, then centrifuged for 10 min, 
4ºC, 1500x g. Serum was collected and stored in sterile conditions at -80ºC until assayed.  
Three-dose regimen 
Mice received either 0.5-0.6x 105 B16 cells or 0-9x 105 B14.3 Luc HER2 bright cells (clone 
H2) IV in 150μl PBS (day 0). Mice were treated with 270pmoles of either isotype control, 
Trastuzumab, conjugates or complexes on days 4, 8 and 11.  Blood samples were harvested 
on day 1 (pre-treatment), day 14 (day 3 post-treatment) and day 18 (day 7 post-treatment). In 
vivo imaging was performed on days 3, 7, 10, 15 and 18 post-tumour inoculation.  Mice were 
culled on day 18, or earlier if starting to develop symptoms. Lungs were harvested and imaged 
ex vivo using IVIS. Subsequently, lungs were fixed in Fekete solution for minimum 24 h, then 
weighed and tumour nodules counted.  
2.19 Statistical analysis 
GraphPad Prism was used to depict data and for statistical analyses. Data are shown as mean 
± standard deviation (SD) or as mean ± standard error of mean (SEM) in the case of tumour 
growth profiles. Luminescence intensity data from in vivo imaging experiments was analysed 
using the CGGC test (Elso et al. 2004) online platform at 10 000 permutations: 
http://bioinf.wehi.edu.au/software/compareCurves/.  The rest of data was analysed in 
GraphPad Prism 8.1 (GraphPad; La Jolla, CA, USA), using appropriate statistical tests for 
each data set, as described separately for each figure. All t tests were two-tailed. Differences 
were considered significant when p ≤ 0.05. Stars of significance are: *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001.  
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Chapter 3: Developing a tumour model using human HER2-transgenic cell lines 
in immunocompetent mice 
Introduction 
For our proof-of-concept study, a relevant mouse model is required. We work with the 
clinically available anti-human HER2 antibody Trastuzumab and investigate whether it is 
suitable for delivery of nucleic acid adjuvants such as CpG to the tumour tissue. Trastuzumab 
is a recombinant antibody recognising human HER2 and does not bind to the mouse homolog 
(Massicano, Marquez-Nostra, and Lapi 2018; Park et al. 2017). Our aim was to investigate 
Trastuzumab-mediated delivery of adjuvants to the tumour tissue in a HER2-expressing 
tumour mouse model. Since endosomal TLR agonists such as CpG promote T cell and B cell 
responses, we required an immunocompetent mouse model.  
Transplantable tumour mouse models have been extensively employed in testing novel 
immunotherapies and demonstrated their use, especially in proof-of-principle studies (Dranoff 
2011). Since transplantable tumour models allow for fast experimental turn-over and cell 
modifications with reporters such as luciferase or model antigens such as ovalbumin (OVA) 
(Dranoff 2011), we decided to use a transplantable mouse model for our initial experiments.   
Our lab has experience in working with the B16 pseudo-metastasis mouse model. This model 
involves injecting B16 melanoma cells IV in syngeneic C57/BL6 mice to generate pulmonary 
(pseudo-metastatic) nodules. Moreover, a B16-OVA cell line was developed in our lab as well 
and has previously proven useful when investigating OVA antigen-specific T cell responses 
(Kreutz et al. 2012; Rajagopal et al. 2010). An important characteristic of B16 tumours is that 
they are poorly immunogenic. These tumours are void of T cell infiltration and only partially 
responsive to immune checkpoint blockade therapy, rendering them a relevant model for 
evaluating novel immunotherapeutic approaches (Dranoff 2011; Lechner et al. 2013). 
Moreover, our lab has shown that B16 cells do no express TLR7 or TLR9 themselves 
(Appendix I), making them useful for testing TLR7 or TLR9 agonist-based immunotherapies. 
Considering the advantages of the model and our experience with it, we used the B16 
melanoma cells as a starting point in developing a human-HER2 tumour model in 
immunocompetent mice.  
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3.1 Overview of workflow 
Human HER2 transgenic B16 cells have been previously described and used to test 
immunotherapies (Wang et al. 2012). However, these cells were generated by transfection, as 
we wished to work with transduced cells and avoid the use of antibiotics to maintain transgene 
expression. 
We established a pipeline to generate and characterise human HER2-transgenic B16 
melanoma monoclonal cell lines (Fig. 3.1). We began with the production of a lentivirus 
encoding the sequence of human HER2. Then, 3 different cell lines were transduced for human 
HER2 expression: B16 melanoma cell line, B14.3 cells which are B16 cells expressing OVA-
GFP and B14.3 luciferase (Luc) cells which express both OVA-GFP and Firefly luciferase in 
an independent manner. Transduced cells were stained with Trastuzumab to evaluate human 
HER2 expression. HER2 positive single cells were isolated by fluorescence activated cellular 
sorting (FACS) and expanded. 7-14 monoclonal cell lines were derived from each of the three 
parental cell lines, and human HER2 expression was confirmed by flow cytometry. Then, 
specific clones were chosen for further tests based on their human HER2 expression levels. 
Human HER2 positive daughter cell lines derived from B14.3 Luc cells were also evaluated 
for luciferase expression using an in vitro bioluminescence assay. B16 HER2 and B14.3 Luc 
HER2 monoclonal cell lines with suitable in vitro profiles were further assessed for their 
ability to generate pulmonary tumours upon IV administration in C57/BL6 mice (Fig. 3.1).  




Figure 3.1. Overview of workflow for the generation and characterisation of immunocompetent 
mouse model using a human HER2-transgenic murine melanoma cell line. B14.3 – B16 OVA-GFP 
transgenic cells; Luc – Firefly luciferase. 
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3.2 Lentivirus production 
To generate a lentivirus encoding human HER2, we began by cloning the sequence of human 
HER2 from the pcDNA3 plasmid from Addgene into the pSIN-SFFV-transgene plasmid 
(sequences in appendices A and B, respectively). The pSIN-SFFV lentiviral vector had no 
restriction sites suitable for the insertion of the human HER2 transgene. Therefore, we used 
the restriction enzyme independent Polymerase Incomplete Primer Extension (PIPE) cloning 
technique. Primers were designed with overlapping 5’-overhangs for amplification of HER2 
sequence and 2 backbone fragments of pSIN-SFFV fragment. PCR amplified fragments were 
purified and transformed in competent E. coli cells (Fig. 3.2). Then single bacterial colonies 
were expanded, and plasmid minipreparations were generated. The introduced sequence of 
human HER2 contained 2 EcoRI and 2 KpnI restriction enzyme sites, which are not present in 
the pSIN-SFFV vector. Plasmid preparations were digested separately with each of these 
enzymes and run on a 1% agarose gel to identify plasmid containing the HER2 insert (Fig. 
3.3). These were sequenced (Eurofin Genomics) to confirm the correct position of human 
HER2 in the plasmid and identify base pair mutations. One plasmid preparation was stored as 
glycerol stock and used in all subsequent experiments.  
The lentivirus encoding human HER2 was produced by transient co-transfection of HEK293T 
cells with plasmids pSIN-SFFV-HER2, p8.91 (2nd generation HIV-derived packaging 
plasmid, Plasmid Factory) and pMD.G (encoding VSV-G envelope, Plasmid Factory). Virus 
was purified from cell supernatant by ultracentrifugation, then lentivirus titre was determined. 
For lentivirus quantification, HEK293T cells were transduced with the purified lentivirus, and 
the number of integrated lentiviral copies in extracted genomic DNA was determined by 
qPCR. The titre of our lentivirus preparation was 2.79 x 107 IU/ml, and this batch was 
sufficient to transduce all three cell lines. 
 
  




Figure 3.2 PIPE cloning to introduce human HER2 sequence in the pSIN-SFFV plasmid for lentiviral 
vector production. A. Schematic representation of PIPE cloning strategy to introduce the sequence of 
human HER2 in the pSIN-SFFV plasmid. B. 1% agarose gel electrophoresis of purified PCR amplified 
fragments transformed in XL-1 blue competent bacteria for the generation of pSIN-SFFV-HER2WT 
plasmid. WT – wild type. 
 
 
Figure 3.3. Representative 1% agarose gel electrophoresis of single bacterial colony plasmid 
minipreparations of pSIN-SFFV-HER2WT. Plasmid preparations were separately digested with EcoRI or 
KpnI and run on a gel. Highlighted in red boxes are plasmids with bands of the expected size (9266bp, 
1816bp and 1622bp for EcoRI; 11321bp and 1383bp for KpnI), signifying the HER2 insert. 
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3.3 Generation of HER2 positive B16 cell lines 
B16, B14.3 and B14.3 Luc melanoma cell lines were transduced with the produced lentivirus 
encoding human HER2 at MOI 1, MOI 10 and MOI 20. At day 7 post-transduction, cells were 
stained with Trastuzumab to detect HER2 expression and analysed by flow cytometry. 
Transduction efficiency curves showed an approximate proportional relation between number 
of lentivirus particles per cell and human HER2 florescent signal for all transduced cell lines. 
Transduction at MOI 1 only resulted in less than 1% of HER2 positive cells, while transduction 
at MOI 10, generated 6.5-8.3% HER2 positive cells. Increasing the MOI to 20 achieved even 
higher percentages (11.2-13.4%) of HER2 positive cells for all three B16 cell lines (Fig. 3.4). 
 
Figure 3.4. Evaluating HER2 expression on transduced cells. Cells were transduced with lentivirus 
encoding human HER2 at different MOI and then stained for human HER2 expression and analysed by 
flow cytometry. A Representative flow cytometry data of B16 cells transduced at different MOI and 
stained either for HER2 expression with Trastuzumab (blue) or with isotype control (solid grey 
histograms). Data is representative of three independent acquisitions by flow cytometry. B-D Percent 
of HER2 positive cells is shown as mean ±SD in relation to MOI for B16 cells (B), B14.3 cells (C), and 
B14.3 Luc cells(D). Data was pooled from 2 independent experiments and shown as mean ± SD. WT = 
wild type. 
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As illustrated in Figure 3.1, B16 cells transduced at MOI 10, B14.3 cells MOI 20 and B14.3 
Luc cells MOI 20 were used for sorting of single human HER2 positive cells by FACS. These 
single cell clones were expanded and human HER2 expression was confirmed by flow 
cytometry. Fluorescence intensity data was converted to resolution metric (R) to describe the 
degree of separation between Trastuzumab-stained and isotype control-stained cells. The 
metric corrects for the spread of each population and allows pooling of data from experiments 
acquired on separate days (Erdbrugger et al. 2014; Yoo et al. 2015). Evaluated cells lines 
showed highly variable human HER2 expression levels, as exemplified for B14.3 Luc HER2 
cells (Fig. 3.5 A). Hence, cells with higher HER2 expression, with RD around 2 were named 
HER2 bright, while the ones with lower expression levels were labelled HER2 dim (Fig. 3.5 
B).  
 
Figure 3.5. Evaluating surface expression of human HER2 of generated monoclonal cell lines. Cells 
were stained with either Trastuzumab or Isotype control, followed by an APC-conjugated secondary 
antibody and analysis by flow cytometry. A. Resolution metric (RD) of B14.3 Luc HER2 monoclonal cell 
lines. Resolution metric (RD) is calculated as the MFI of Trastuzumab minus the MFI of the isotype 
control corrected by the sum of standard deviations of the analysed populations in the APC channel. 
Data is shown as mean±SD of 2 independent experiments. B. Representative flow cytometry 
histograms and MFI of cell lines considered HER2 dim or HER2 bright. Cells were stained with either 
isotype control (white) or Trastuzumab (grey). Data is representative of 2 independent experiments 
for B14.3 cells and minimum 3 independent experiments for B16 and B14.3 Luc cells. 
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For the purposes of the project, we preferred HER2 bright cells for in vivo work, to enable 
efficient concentration of Tr and Tr-derived conjugates and complexes at the tumour tissue. 
Therefore, we focused our efforts in characterising HER2 bright monoclonal cell lines and 
only included one HER2 dim cell line for comparison in selected downstream assays.  
Next, we verified that human HER2 transduced B14.3 and B14.3 Luc cells maintain OVA-
GFP expression of the parent cell lines by flow cytometry (Fig. 3.6 A, B, respectively). We 
also verified luciferase activity of human HER2 bright B14.3 Luc monoclonal cell lines in 
vitro (Fig. 3.6 C). Members of the retroviral family have distinct patterns of preferred 
integration sites (Gabriel, Schmidt, and von Kalle 2012). These preferred integration sites 
might be reused upon subsequent transduction with the same or even similar virus encoding 
other transgenes, changing expression levels of the previously introduced transgenes. The 
OVA-GFP transgene was introduced using a retrovirus into B16 cells by Dr. Sandra S. 
Diebold, to generate the B14.3 monoclonal cell line. Upon subsequent transduction with the 
HER2 encoding lentivirus, most B14.3 HER2 single cell clones showed comparable OVA-
GFP signal relative to parental cells (Fig. 3.6 A). The same was observed for B14.3 Luc HER2 
cells, with one out of 10 cell lines showing a clear drop in OVA-GFP signal (Fig. 3.6 B). In 
terms of Firefly luciferase, this transgene was introduced via lentiviral transduction. Relative 
to the parental cell line, some of the B14.3 Luc HER2 single cell clones with unaltered GFP 
signal, such as F10 and G10 showed reduced (F10) or even abolished (G10) luciferase activity, 
as measured by luminescence intensity in an in vitro assay (Fig. 3.6 C). Together, these data 
confirm that upon subsequent transduction, previously introduced transgenes may dampen or 
lose expression and monoclonal cell lines must be verified in this respect to identify suitable 
clones. 
To establish how human HER2 expression by lentivirus integration changes the tumour growth 
profile of B16 cells, we went on to evaluate B16 HER2 bright (clone E5) and B16 HER2 dim 
(clone H5) in vivo. As we wished to make use of the luciferase reporter as well as the OVA-
GFP antigen, we chose to further evaluate B14.3 Luc HER2 bright cells and not B14.3 HER2 
cells in mice. In terms of B14.3 Luc HER2 cells, monoclonal cell lines A4, H2 and H4 
expressed high levels of human HER2 and OVA-GFP, as well as similar levels of 
luminescence activity to their parental cell line and were chosen for further evaluation in mice.  
 





Figure 3.6. Evaluating maintenance of OVA-GFP and luciferase transgenes in B14.3 and B14.3 Luc 
human HER2 expressing monoclonal cell lines. For OVA-GFP expression, cells were analysed by flow 
cytometry. A. OVA-GFP MFI of daughter HER2 cell lines was expressed as percent of OVA-GFP MFI of 
the B14.3 parental cell line. Data representative of one experiment, except for B14.3 and derived 
clones D7, E5 and G4, which were tested twice (mean ± SD). B. OVA-GFP MFI of daughter HER2 cell 
lines was expressed as percentage of the OVA-GFP MFI of parental B14.3 Luc cells. Data is shown as 
mean±SD of 2 independent experiments. C. Evaluating luciferase activity of B14.3 Luc HER2 
monoclonal cell lines. Cells were plated in triplicates and incubated with an equal volume of luciferase 
substrate. Luminescence intensity was measured as corrected counts per second and expressed 
relative to the luminescence levels of the parental B14.3 Luc cells, which was set to 100%. Mean ± SD 
of 3 technical replicates. Data for B16, B14.3 Luc and daughter cell lines H2 and H4 were pooled from 
2 independent experiments. 
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3.4 In vivo profile of tumours generated with B16 HER2 cells 
3.4.1. Growth kinetics of B16 HER2 tumours compared to B16 tumours 
To establish the growth profile of B16 HER2 cells in the pseudo-metastasis model, mice were 
injected IV with 5x 105 of either B16, B16 HER2 dim (clone H5) or B16 HER2 bright (clone 
E5) cells. Mice were culled 15 days later, and lung tissue was collected and weighed (Fig. 3.7 
A). Afterwards, lungs were fixed for minimum 12 h in Fekete solution, transferred to PBS and 
lung nodules were counted. Mice injected with B16 cells showed over 200 lung tumour 
nodules at day 15 endpoint (Fig. 3.7 C). This significant tumour burden almost doubled the 
weight of lungs as compared to tumour free lungs of age-matched mice (Fig. 3.7 D). In 
comparison, B16 HER2 bright cells generated fewer tumour numbers with high variability 
between animals. Lungs with B16 HER2 bright tumours still weighed significantly more 
(p<0.05) than tumour free lungs, although the difference was not as striking. Notably, 2 mice 
that received B16 HER2 dim cells only developed 2-3 tumour nodules (Fig. 3.7 C), and this 
minimal tumour burden did not increase the weight of the lungs over tumour free control (Fig. 
3.7 C). In terms of morphology, B16 HER2 bright tumours were of lighter colour, indicative 
of less melanin content, than B16 tumours, but were similar to these in terms of nodules size 
and distribution. B16 HER2 dim tumour nodules, however, were both paler and larger (Fig. 
3.7 B). Together, these data show that different human HER2 expressing monoclonal cell lines 
generate tumours with distinct profiles. 
Although lower than for B16 cells, B16 HER2 bright cells also generated relatively high 
tumour burden in mice. The growth profile was much more favourable than for B16 HER2 
dim cells. Therefore, we continued to use B16 HER2 cells for future experiments.  
  




Figure 3.7. Tumour growth profiles of B16 HER2 cells. A. Mice were injected with 5x 105 tumour cells. 
Tumour burden was measured 15 days later. B. Representative images of lungs with B16 and B16 HER2 
bright and dim tumours after fixation in Fekete solution. Images of B16 and B16 HER2 bright are 
representative of three independent experiments. Tumour burden measured as weight of lungs (B) or 
as number of tumour nodules (C) counted after fixing the lungs in Fekete solution. Data from one 
experiment with minimum n=3. Each symbol represents a mouse, with mean ± SEM depicted by lines 
in C and D. Data for the B16 group in D was collected in two independent experiments. D. Data was 
analysed using Welch’s t test.  
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3.4.2 Response of B16 HER2 bright tumours to treatment with Trastuzumab 
To investigate the proliferation of B16 HER2 bright cells (clone E5) treated with Trastuzumab 
(Tr) in vitro, MTS assays were performed as previously described (Zhang et al. 2011). 
Multiple studies illustrated that HER2 signalling drives tumour growth and proliferation of 
HER2 overexpressing human tumour cell lines, which can be stunted by treatment with 
Trastuzumab (Mittendorf et al. 2010; Yu and Hung 2000; Milano et al. 2010). This, however, 
is unknown for ectopic expression of the human HER2 transgene in mouse tumour cell lines.  
In line with the publications mentioned above, we replicated in vitro proliferation assays 
showing that HER2 overexpressing human tumour cell lines such as BT474 and OE19 show 
a dose-dependent decrease in proliferation upon treatment with Trastuzumab, but not with 
isotype control (Fig. 3.8 A, B). Impairment of tumour growth was observed for recombinant 
Trastuzumab produced in our laboratory and the clinical-grade Herceptin®. No change in 
proliferation was observed for the MDA-MB-231 cell line, which expresses HER2 at minimal 
levels (Fig. 3.8 C) or with B16 cells, which are of mouse origin (Figure 3.8 D). The 
proliferation of B16 HER2 bright cells was not influenced by treatment with Trastuzumab, 
either the recombinant antibody produced in our laboratory or in the form of commercially 
available Herceptin (Fig. 3.8 E). The results are not surprising since B16 cells grow robustly 
in cell culture in the absence of human HER2. Moreover, B16 cells are also mouse HER2 
negative (Ueno et al. 2008; Yan et al. 2012) and do not require HER2 signalling for growth.  
Mice with B16 HER2 bright (clone E5) pulmonary nodules were treated 3 days after tumour 
inoculation (6x105 cells IV) with either vehicle or different doses of Tr (5µg, 10µg or 30µg) 
and tumour burden was measured after culling the mice on day 15 by weighing the lungs (Fig. 
3.9 A). The weight of lungs from mice treated with vehicle had a mean of 260.2±57.62 mg, 
which was significantly higher than the weight of tumour free lungs. Mice treated with either 
5µg, 10µg or 30µg Trastuzumab had lower lung weights (means of 212.4±30.53 mg, 
308.6±151.2 mg and 201.8±21.95 mg respectively). Comparing treatment groups among 
themselves and with vehicle did not reach statistical difference. Importantly, there was no 
statistically significant difference between the weights of Tr treated tumour-bearing and 
tumour free lungs for the doses of 5µg and 30µg. When tumour nodules were counted (Fig. 
3.9 C), we observed that the method is inaccurate, since many nodules are very pale. In this 
data set, the variability was high, and we do not have sufficient numbers for statistical analyses. 
Crucially, tumour burden was very low for most mice in the Tr treated groups (Fig. 3.9 C). 
This has substantial implications when it comes to testing novel Tr-derived immunotherapies 
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in this model. The B16 HER2 bright E5 cell line is not suitable for such experiments, as there 
is no difference between the weight of Tr-treated groups and tumour-free lungs. 
 
Figure 3.8. In vitro proliferation of HER2 positive and negative cell lines upon treatment with 
Trastuzumab measured using the MTS assay. Cells were plated in triplicates and treated with 
Trastuzumab or isotype 4 h later. MTS reagent was added after 48 h. BT474 (A) and OE-19 (B) are 
Trastuzumab sensitive HER2 overexpressing human cancer cell lines. MDA-MB-231 shows minimal 
HER2 expression (C). B16 cells are of mouse origin (D). B16 HER2 bright (E) cells do not respond to 
treatment with Trastuzumab in vitro. Data were normalised against non-treated cells and is shown as 
mean ± SEM of technical triplicates. Dose-response curves generated with the non-linear fit equation 
in GraphPad. Data is representative of 2 independent experiments.   
Together, the data so far illustrate the following important observations. For one, individual 
HER2 expressing monoclonal cell lines generated different growth profiles. This implies that 
more monoclonal cell lines should be evaluated in vivo. We observed high variability among 
groups. This indicates that high numbers of mice will be required for experiments and power 
calculations would be valuable. It also became apparent that using lung weight alone as a 
measure of tumour burden may or may not be accurate, and different methods of assessing 
tumour burden should be employed. 
 




Figure 3.9. In vivo response of B16 HER2 bright tumours to treatment with Trastuzumab (Tr). A. Mice 
were injected with 6x 105 tumour cells or left tumour free. 16 days later, lungs were extracted and 
then weighed (B). Data points from 2 independent experiments are shown as mean ± SEM. Number 
of mice per group: tumour free lung – 4; vehicle – 9; Tr 5µg – 4; Tr 10µg – 8; Tr 30µg-4. Kruskal-Wallis 
test with Dunn post-hoc test, **p<0.005, *p<0.05, ns – not significant. C. In one of the 2 experiments, 
lungs were fixed in Fekete solution and lung tumours were counted. Number of mice was 3 for all 
groups, except vehicle group, where n=4. Each symbol represents a mouse with a line showing mean.   
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3.5 In vivo profile of tumours generated with B14.3 Luc HER2 cells 
3.5.1 Evaluating B14.3 Luc HER2 H2 tumour burden 
To better understand the kinetics of tumour growth in immunocompetent mice, we decided to 
evaluate 3 monoclonal B14.3 Luc HER2 bright cell lines (A4, H2 and H4) in vivo and employ 
in vivo imaging to monitor tumour burden at multiple time-points post-tumour inoculation by 
measuring bioluminescence intensity (Fig. 3.10 A). Pulmonary tumour growth of B14.3 Luc 
HER2 tumours was compared to B16 cells tumours. Since we observed that HER2-transgenic 
cells generate lesser tumour burden in mice, we increased the dose of B14.3 Luc HER bright 
cells for IV injections to 9x 105 cells. This dose was chosen, as it was successfully used before 
with B14.3 cells in our lab (Rajagopal et al. 2010). The dose of B16 cells was kept to 6x 105 
cells per mouse.  
At day 18 post tumour-inoculation, all 3 tested B14.3 Luc HER2 bright cell lines generated 
dark, melanin-rich pulmonary tumours with identic morphology to B16 pulmonary nodules 
(Fig. 3.10 B). We assessed tumour burden at day 18 by weighing lungs (Fig. 3.10 C) and 
counting tumour nodules (Fig. 3.10 D). B16 cells generated substantial lung tumour burden, 
with more than 250 pulmonary tumour nodules (Fig. 3.10 D), which significantly increased 
the weight of the lungs within the tested 18-day period (Fig. 3.10 C). In contrast, none of the 
three tested clones of B14.3 Luc HER2 bright cells (clones A4, H2 and H4) increased the 
weight of the lungs significantly over lungs of tumour-free mice (Fig. 3.10 C). Numbers of 
tumour nodules were lower than in mice with B16 tumours, despite injecting more B14.3 Luc 
HER2 bright cells (Fig. 3.10 D). Among tested cell lines, B14.3 Luc HER2 bright H2 
generated the highest number of tumour nodules. Clone A4 yielded much lower numbers of 
tumour nodules than H2 and H4 (Fig. 3.10 D). Since B14.3 Luc HER2 cells did not 
significantly increase the weight of the lungs, we stopped using this measurement in future 
experiments. 
In vivo luminescence intensity of mouse lungs measured at day 18 reflected the number of 
tumour nodules for B14.3 Luc HER2 bright H2 and H4 tumours. Lungs with low numbers of 
tumours showed lower luminescence intensity and vice versa. In contrast, luminescence 
intensity of A4 tumours did not relate to the number of lung nodules (Fig. 3.10 E). Here, the 
luminescence levels are comparable with other cell lines, but the number of nodules was much 
lower. We observed that some of the lung nodules were larger in volume, and others lost 
melanin pigmentation and were more difficult to count accurately, which might contribute to 
the discrepancy.  
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In vivo imaging enabled us to assess tumour growth of these mice at multiple time-points (Fig. 
3.10 F-J). Mice inoculated with B16 cells developed luciferase-free lung tumours and were 
used to establish the background levels. For all tested B14.3 Luc HER2 cell lines, 
luminescence intensity increased progressively after tumour inoculation to reach maximum 
values at day 18. Among the tested cell lines, clone B14.3 Luc HER2 H2 generated tumours 
with highest levels of luciferase activity (Fig. 3.10 I). When plotting the luminescent data for 
individual mice with H2 tumours (Fig. 3.10 E), it became evident that after day 7, some mice 
control tumour growth without any further increase in luminesce signal after this time-point. 
The same was observed for mice bearing B14.3 Luc HER2 tumours generated with clone H4 
(data not shown). We cannot rely on results for A4 tumours, as luminescence activity did not 
relate to tumour burden for these tumours. 
Together, these data illustrate that in vivo imaging showed an appropriate representation of 
tumour burden for 2 out of 3 tested luciferase-expressing cell lines and enabled us to visualise 
that tumour growth was stunted in some mice after day 7 from tumour inoculation. Among the 
tested cell lines, B14.3 Luc HER2 bright H2 showed the most favourable in vivo profile, and 
we proceeded to characterise these tumours further.  
 





Figure 3.10. Tumour growth profiles of B14.3 Luc HER2 bright tumours. A. Time-line for monitoring 
tumour burden. Mice (n=5 per group) were injected IP with 150mg/kg XenoLight D-Luciferin substrate 
and imaged (☼) 10 minutes later. Regions of interest (ROI) with 2.647cm diameter were placed over 
the anterior thorax of each mouse to capture luminescence signal of pulmonary tumours (photons/s). 
B. Representative images of lung tumours generated B16 cells (top) and B14.3 Luc HER2 bright H2 cells 
(bottom). C. Weight of tumour-bearing lungs compared to tumour-free lungs. Mean ± SD. Student’s t 
test, ***p<0.001. D. Number of tumour nodules counted on the surface of lungs fixed in Fekete 
solution. Mean ± SD.  E. In vivo luminescence intensity of luciferase-expressing tumours at day 18. 
Each data point represents one mouse with mean ± SEM depicted by lines for each group. F. 
Representative images of luminescence signal measured in vivo. G-I. Luminescence intensity of lung 
tumours over time. Data from one experiment shown as mean ± SEM of total flux (photons/s) of n=5 
mice bearing either B16 tumours (open) or B14.3 Luc HER2 tumours clone A4 (green), H2 (red) or H4 
(blue).  J. Luminesce signal of each mouse bearing B14.3 Luc HER2 clone H2 tumours.  
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3.6 Characterising the B14.3 Luc HER2 bright clone H2 
The human HER2-transgenic B14.3 Luc cell clone H2 showed high expression levels of 
human HER2 and expresses the GFP-OVA and the Firefly luciferase transgenes at comparable 
levels to the parental B14.3 Luc cell line (see section 3.3). Importantly, this cell line generated 
a significant amount of tumour burden in vivo, higher than the other tested monoclonal cell 
lines, including the luciferase-negative HER2 transgenic lines. We were able to assess tumour 
burden both at endpoint, by counting tumour lung nodules and additionally by measuring 
luciferase activity using in vivo imaging at different time points throughout the experiment. 
As H2 was the cell line generating the most promising in vivo profile, we have further 
characterised it in vitro and in vivo. 
3.6.1 In vitro growth kinetics 
B14.3 Luc HER2 bright H2 cells generated lesser tumour burden in mice compared to the 
parent B16 cells (Fig. 3.10). We verified whether this difference in tumour growth was due to 
changes in cell proliferation generated through repeated transduction and multiple transgene 
expression. To test this, we compared the growth kinetics of B14.3 Luc HER2 bright H2 cells 
with B16 cells in vitro (Fig. 3.11). Both cell lines proliferated in vitro with comparable kinetics 
(Fig. 3.11).  
Together with data from tumour growth profiles, these results suggest that the control in 
growth of B14.3 Luc HER2 H2 tumours we have observed in some mice is mediated by the 
host immune responses and not by changes in the growth rate of tumour cells themselves. 
 
Figure 3.11. In vitro growth kinetics of B14.3 Luc HER2 bright H2 cells. 50 000 cells were plated in 
duplicates in 6-well plates. Each day, duplicate cell samples were harvested, and live cells were 























B14.3 Luc HER2 bright H2
Chapter 3 Results 
 
123 
3.6.2 HER2 expression analysis of cultured cells  
To evaluate expression of human HER2 on B14.3 Luc HER2 bright cell line H2 in comparison 
with cell lines derived from patient tumours often used for cancer research, cells were stained 
with Trastuzumab and analysed by flow cytometry (Fig. 3.12). For our analysis, we used the 
resolution metric (RD), which accounts for separation between HER2 signal and control as 
well as the spread of data, to rank cell lines based on intensity of HER2-staining signal. As 
negative controls, we included HER2 negative MDA-MB-468 and the mouse B16 cells in the 
analysis. Reportedly, the Trastuzumab resistant JIMT-1 cells express human HER2 at robust, 
but moderate levels, lower than other human HER2 positive cell lines such as BT474 (Tanner 
et al. 2004) and OE-19 which are HER2-high (Wainberg et al. 2010). Corresponding to 
previous reports, JIMT-1 cells showed lower HER2 relative expression than BT474 or OE-19 
cells, but higher levels than the low HER2 expressing cell line MDA-MB-231. B14.3 Luc 
HER2 bright H2 cell line showed similar resolution metric (1.75 ± 0.03) to JIMT-1 cells (1.77 
± 0.08) (Fig. 3.12).  
 
Figure 3.12. Evaluating human HER2 expression on cancer cell lines by flow cytometry. Comparing 
human HER2 expression of B14.3 Luc HER2 bright H2 cells with other cancer lines by flow cytometry. 
Cells were stained with Trastuzumab or isotype control. The resolution metric was calculated by 
subtracting the MFI of the isotype antibody control from the MFI of Trastuzumab and dividing the 
difference by the sum of standard deviations. Data were pooled from two independent experiments 
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3.6.3    B14.3 Luc HER2 H2 lung tumours express human HER2 in vivo  
Using flow cytometry, we evaluated HER2 expression of tumours generated with either B16 
or B14.3 Luc HER2 clone H2 cells in C57BL/6 mice. Mice were injected IV with 9x 105 B14.3 
Luc HER2 H2 tumour cells or 6x 105 B16 lung cells and lung tissue was harvested 15 days 
later. Single cell suspensions were generated from lung tissue. Cells were stained for live/dead 
discrimination, then fixed in Streck. Cells were stained after fixation and then analysed by 
flow cytometry alongside the cultured tumour cells. The tyrosinase related protein-1 (TRP-1) 
is a crucial component of the melanosome’s membrane involved in melanin production and 
therefore specific melanocyte marker (Rosenberg 1997). In our lung single cell suspensions, 
only B16 or -derived tumours cells contain melanosomes and TRP-1. Both B16 and B14.3 Luc 
HER2 H2 tumours are black, melanin-containing tumours (Fig. 3.10 B). Hence, tumour cells 
were defined as CD45 negative and TRP-1 positive cells (Fig. 3.13 A). HER2 expression was 
analysed on gated tumour cells using a commercial anti-human HER2 antibody that binds a 
different epitope than Trastuzumab (data not shown). B16 cells were negative for HER2 
staining. Compared to cultured cells used for tumour inoculation (Fig. 3.13 B), B14.3 Luc 
HER2 H2 tumours showed dimmer HER2 staining (Fig. 3.13 C). The MFI of HER2 positive 
cells was variable among animals inoculated with B14.3 Luc HER2 H2 cells, ranging from 
1225 to 1514. Interestingly, tumour cells showed heterogeneous HER2 expression, as 
demonstrated by the width of the histograms. Whether HER2 expression differs among tumour 
lung nodules or among tumour cells of the same nodule remains to be established by future 
immunohistochemical studies. 
Data indicate that HER2 expression of H2 cells is dimmed in vivo to a variable extent among 
individual mice. Further experiments including more mice are required to confirm the 
reproducibility of our results and better define the extent of this variability. 




Figure 3.13. Evaluating human HER2 expression of B14.3 Luc HER2 H2 pulmonary tumours. Mice 
were injected with 6x 105 cells and culled 15 days later. Single cell suspensions were generated from 
lung tissue and cells were stained for surface markers and analysed by flow cytometry. A. Gating 
strategy. B. HER2 expression on B16 (grey open histogram) and B14.3 Luc HER2 bright H2 (blue) 
cultured cells. C. Human HER2 expression on B16 (filled grey) and B14.3 Luc HER2 bright H2 (orange) 
tumour cells. Data collected in one experiment. 
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3.6.4 B14.3 Luc HER2 H2 tumours do not respond to treatment with Trastuzumab 
To investigate the direct response of B14.3 Luc HER2 bright cells to treatment with 
Trastuzumab, we performed MTS assays. The controls for this assay, showing that 
Trastuzumab inhibits in vitro proliferation of HER2 over-expressing human cancer cell lines, 
but not of HER2 negative or low-expressing cells are shown in Fig. 3.8. As expected, similarly 
to B16 HER2 cells (Fig. 3.8), the proliferation of B14.3 Luc HER2 bright cells clone H2 is not 
influenced by treatment with Trastuzumab (Tr), either produced in our lab or the clinical grade 
Herceptin® (Fig. 3.14).  
Next, we investigated the response of B14.3 Luc HER2 bright H2 tumours to treatment with 
Tr in vivo (Fig. 3.15). Mice inoculated IV with 9x105 B14.3 Luc HER2 bright cells were treated 
4, 8 and 11 days later with either vehicle or 40µg Trastuzumab equalling a dose of approx. 
2mg/kg body weight. Tumour burden was monitored using in vivo imaging by quantifying 
luminesce intensity of the bioreporter luciferase, and additionally on day 18, by enumeration 
of lung nodules (Fig. 3.15 A). Luminescence intensity of Trastuzumab treated mice was only 
slightly higher than for the vehicle treated group at days 10 and 15, but there was no difference 
in luminescence intensity at earlier time points (Fig. 3.15 B). At day 18, vehicle treated mice 
had 173.0 ± 73.79 tumour nodules, while Tr treated mice showed 186.0 ± 53.87 tumour 
nodules, with no statistically significant difference between the groups (Figure 3.13 C). 
Together, these results show that B14.3 Luc HER2 bright H2 pulmonary tumours are resistant 
to treatment with Trastuzumab. While the in vitro assay investigated a wide range of doses 
and excludes a direct growth inhibiting effect of the therapeutic antibody on the tumour cells, 
we did not titrate Tr in vivo. Therefore, it cannot be entirely excluded that higher doses of 
Trastuzumab may influence tumour burden. Future experiments are required to investigate 
human HER2 expression on tumours treated with Tr. So far, the model shows significant 
tumour burden despite repeated treatment with robust doses of Trastuzumab and was deemed 
suitable for investigating the effects of Trastuzumab-based conjugates and complexes. 
Consequently, all subsequent animal experiments performed for this study used the B14.3 Luc 









Figure 3.14. Treatment with Trastuzumab does not impact proliferation of B14.3 Luc HER2 bright H2 
cells in vitro. Cells were treated for 48 hours with increasing concentrations of Tr or Herceptin or 
isotype control and MTS assay was performed. Controls for this assay are shown in Figure 3.7. Data 





Figure 3.15. Response of B14.3 Luc HER2 bright H2 lung tumours to in vivo treatment with 
Trastuzumab. A. Mice were injected with tumour cells at day 0. At days 4, 8 and 11, mice were treated 
with 2mg/kg Trastuzumab IV. N=14 for vehicle group and n=10 for Tr group. B. Tumour burden was 
monitored using in vivo imaging. Data are mean ± SEM of values pooled from 3 independent 
experiments. Groups were compared using CGGC permutation test with 10 000 permutations. C. At 
day 18 mice were culled, lung tissue was fixed in Fekete solution, and pulmonary nodules were 
enumerated. Each symbol represents an individual mouse, and the mean is shown by a bar. Mann-
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3.7 Generating subcutaneous tumours with B14.3 Luc HER2 H2 cells 
3.7.1 Tumour growth profile of subcutaneous B14.3 Luc HER2 H2 tumours 
Upon intravenous administration of any drug, the first reached capillary bed is in the lung 
(Chao et al. 2010; Kutscher et al. 2010). We were interested in comparing treatment efficacy 
between Tr-CpG conjugates, for targeted delivery of CpG to the lung tumours and free, 
unconjugated Tr + CpG. In our mouse model of lung tumours, it is likely that upon IV 
administration, both treatments would distribute to the lung first and this effect could 
potentially skew our results. To expand our options in terms of mouse models, we investigated 
the tumour growth profile of subcutaneous B14.3 Luc HER2 bright H2 tumours.  
Mice were injected subcutaneously with B16 cells in the left flank and B14.3 Luc HER2 bright 
H2 in the right flank (Fig. 3.16). Since we knew from the IV inoculation model that larger 
numbers of B14.3 Luc HER2 bright H2 cells are required to increase tumour burden, we 
increased the numbers relative to B16 cells in this experiment as well. Tumour burden was 
measured regularly, and mice were culled when the cumulative tumour volume from both 
flanks reached 1000 mm3. Tumours generated with 1x 105 B16 cells (Fig. 3.16 A) reached 
maximum volume at day 18, later than tumours generated with 2x 105 B16 cells (Fig. 3.16 C). 
B14.3 Luc HER2 bright H2 tumours, however, grew much less, with very little tumour burden 
achieved with either cell numbers. When growth of B14.3 Luc HER2 bright H2 tumours was 
visualised separately for each mouse, independently of dose (Fig. 3.16 B and Fig 3.16 D), it 
became apparent that all mice developed tumours and many of them rejected them, with drops 
in tumour burden at days 8-11. Tumour control was not observed with B16 cells, suggesting 
that expression of human HER2 and/or luciferase acts as a novel antigen in these 
immunocompetent mice and enables immune recognition and control of the tumour. These 
data show that B14.3 Luc HER2 bright H2 cells generated subcutaneous tumours and some of 
the mice rejected these tumours.  
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Figure 3.16. Tumour growth profile of subcutaneous B14.3 Luc HER2 bright H2 tumours. Mice were 
inoculated subcutaneously with B16 cells in the left flank and B14.3 Luc HER2 bright H2 cells in the 
right flank in 0.05ml PBS. Tumour growth was followed over time and mice were culled when 
cumulative volume of both tumours reached 1000 mm3. A. Growth profile of subcutaneous tumours 
generated using 1x 105 B16 cells and 3x 105 B14.3 Luc HER2 bright H2 cells. Mean ± SEM of data from 
3 mice. B. Growth profile of tumours generated with 3x 105 B14.3 Luc HER2 bright H2 cells. Data from 
A is shown separately for individual mice. C. Growth profile of subcutaneous tumours generated using 
2x 105 B16 cells and 5x 105 B14.3 Luc HER2 bright H2 cells. Mean ± SEM of data from 3 mice. D. Growth 
profile of tumours generated with 3x 105 B14.3 Luc HER2 bright H2 cells. Data from C is shown 
separately for individual mice. Data was collected in one experiment.      
3.7.2 Human HER2 expression of subcutaneous B14.3 Luc HER2 H2 tumours 
Human HER2 expression of subcutaneous B14.3 Luc HER2 bright H2 cells was analysed by 
flow cytometry (Fig. 3.17). Single cell suspensions were generated from excised tumours. 
Cells were stained for live dead discrimination and immediately fixed in Streck. Fixed cells 
were stained for CD45, TRP-1 and human HER2 expression. Gating was performed as shown 
in Fig. 3.13. Tumour cells were defined as CD45 negative and TRP-1 positive cells. Human 
HER2 expression was analysed on gated tumour cells (Fig. 3.17 A). As expected, B16 tumour 
cells were negative for human HER2. B14.3 Luc HER2 bright H2 subcutaneous tumour cells 
maintained a degree of HER2 expression, which was lower than on cultured cells used for 
tumour inoculation and varied between animals. 
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Together, data in section 3.7 illustrate that B14.3 Luc HER2 bright H2 cells generate variable 
tumour burden and that some mice completely eliminate the tumour cells within 11 days. 
Human HER2 expression of tumours persisting beyond day 11 was diminished and variable 
between animals. Overall, tumour rejection seemed more pronounced for the subcutaneous 
model than for the IV model, where none of the mice rejected tumours completely. Hence, 
experiments using the subcutaneous model would require very large numbers of mice and 
careful selection of mice that do not reject these tumours. Therefore, we only used IV 
inoculation in subsequent experiments.   
 
Figure 3.17. Human HER2 expression of subcutaneous B14.3 Luc HER2 bright H2 tumours. A. 
Representative plot showing gating on subcutaneous tumour cells. B. Histograms depicting human 
HER2 staining of tumours harvested from 2 individual mice. C. Human HER2 expression of cells used 
to generate the above analysed tumours. Data obtained in one experiment. 
  




Our aim was to generate a transplantable mouse model using human HER2-transgenic cells in 
immunocompetent mice. Human HER2 expression was achieved via lentiviral transduction of 
B16 melanoma cells (Fig. 3.5). Upon IV administration, compared to B16 cells, all B16 HER2-
expressing cell lines tested induced fewer lung tumour nodules. In vivo evaluation of several 
monoclonal cell lines was required to identify one that reliably generated sufficient tumour 
burden. In order to achieve this, increasing cell numbers for IV inoculation were necessary 
compared to the parental cell line.  
Among tested cell lines, we identified B14.3 Luc HER2 bright H2 cells to reproducibly 
generate pulmonary tumours (Fig. 3.10), which maintained heterogeneous levels of human 
HER2 expression (Fig. 3.13). The mechanisms responsible for diminished human HER2 
expression are yet unknown. Cleavage of the extracellular domain of human HER2 by 
metalloproteinases has been demonstrated in patients (Codony-Servat et al. 1999) and might 
be a possible explanation. Anti-human HER2 mouse immune responses driving immune 
evasion might be implicated as well. B14.3 Luc HER2 H2 tumours did not respond to 
treatment with 3 doses of 2 mg/kg body weight Trastuzumab, doses which are in the clinical 
range (Fig. 3.15). In patients, intratumoral HER2 heterogeneity correlates with poor responses 
to Trastuzumab therapy and poor prognosis (Hosonaga et al. 2018; Muller, Marotti, and Tafe 
2019; Motoshima et al. 2018; Kaito et al. 2019). Our mouse model reflects several tumour 
characteristics of this group of patients with a great need for novel therapies.  
B14.3 Luc HER2 bright H2 cells proliferated in vitro at the same rate with B16 cell (Fig. 3.11) 
but generated lesser tumour burden in vivo (Fig. 3.10). These cells express Firefly luciferase 
independently of human HER2 and luciferase activity measured by in vivo imaging related 
well to the number of lung tumour nodules (Fig. 3.10). This imaging technique enabled us to 
observe that starting 7 days after tumour inoculation, some of the mice controlled tumour 
growth and this resulted in decreased and variable tumour burden. The timing corresponds to 
the generation of adaptive immune responses in mice. Previous studies have demonstrated that 
dying cells are intrinsically immunogenic, releasing damage-associated molecular patterns 
(DAMPs) as well as exposing antigens (Hou et al. 2013; Krysko et al. 2012). Considering that 
each preparation of cells for inoculum may contain a few dying cells and injections themselves 
can damage cells, the generation of immune responses cannot be excluded. It is, therefore, 
possible that in some mice, B14.3 Luc HER2 H2 tumour growth is controlled by immune 
responses. The impact of such immune responses on immunotherapy experiments as planned 
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for this study is unknown. Multiple assays investigating anti-tumour immune responses were 
performed for untreated, but also treated mice and are discussed together in Chapter 5. 
In summary, we generated a Trastuzumab-resistant, human HER2-expressing transplantable 
tumour mouse model which facilitates rapid immunotherapy studies, with a turn-over of 18 
days. The B14.3 Luc HER2 bright H2 cells used for inoculum express luciferase, which 
enables monitoring of lung tumour burden via in vivo imaging. Among limitations of the 
model, diminished and heterogeneous human HER2 expression implies limited access of 
Trastuzumab-derived therapy to the tumour tissue. Moreover, tumour burden is controlled in 
some mice, possibly by the immune system, resulting in variability within groups of mice. 
While incomplete, data so far justify further evaluation of the model and its potential 
usefulness for in vivo evaluation of our Trastuzumab-based targeted delivery approaches of 
endosomal TLR agonists. However, other in vivo models, for instance, xenograft tumours in 
humanised mice may ultimately be required to evaluate the targeted delivery of Trastuzumab-








Trastuzumab-LL37 fusion antibodies  
for targeted delivery of endosomal TLR agonists  
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Chapter 4: Trastuzumab-LL37 fusion antibodies  




This work investigates the use of monoclonal antibodies against tumour associated antigens in 
generating vehicles for targeted delivery of endosomal TLR agonists to the tumour tissue. As 
a model antibody, we use Trastuzumab, which is a clinically approved anti-human HER2 IgG1 
antibody for the treatment of HER2 overexpressing breast (Hudis 2007) and gastric cancer 
(Palle et al. 2020). Since the encoding sequence of Trastuzumab is available to us in a pVITRO 
plasmid (Dodev et al. 2014), we can express the recombinant antibody and even further modify 
the sequence to facilitate linking to endosomal TLR agonists. 
In this chapter we explore fusion of Trastuzumab with LL37. As described in section 1.4, LL37 
is a cationic peptide that has been shown to bind various nucleic acids, including synthetic 
endosomal TLR agonists due to their intrinsic opposite polarity (Ganguly et al. 2009; Singh, 
Vaughan, and Kao 2014). Here we describe the generation of Trastuzumab-LL37 fusion 
antibodies and investigate their capacity to enhance local anti-tumour immune responses 
through delivery of endosomal TLR agonists to the HER2-expressing tumour tissue.  
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4.1 Expression and purification of antibodies  
4.1.1 Description of workflow 
For this study it is crucial to express and purify recombinant Trastuzumab (Tr), with or without 
modifications to the antibody structure in our lab. An overview of the workflow used to 
generate antibodies is shown in Figure 4.1. Briefly, the PCR-based cloning technique PIPE 
(Polymerase Incomplete Primer Extension) was used to modify the antibody sequence and to 
generate recombinant antibodies with additional heavy chain C-terminal moieties resulting in 
so called “fusion antibodies”. This technique involves generating fragments of plasmid DNA 
by PCR with 5’-overlapping overhangs, which are transformed into competent bacteria, which 
assemble the fragments into the intended plasmid. This method does not require the use of a 
ligation step prior to transformation.  
For the expression of unmodified and modified Trastuzumab, we used the pVITRO-
Trastuzumab IgG1/κ from Addgene (Dodev et al. 2014). Hygromycin-resistant single bacterial 
colonies were screened for the presence of plasmid with the desired modifications. Screening 
methods included PCR, digesting the plasmid with restriction enzymes and evaluating the 
generated bands or Sanger sequencing (by Eurofin Genomics) and are described separately for 
each cloning strategy. Bacteria containing plasmid with the correct sequence were expanded, 
plasmid was isolated and sequenced (by Eurofin Genomics) to verify for point mutations. 
Between two and five clones were compared for recombinant antibody expression using the 
FreeStyleTM 293 (FS 293) expression system. Supernatants from transiently transfected 
cultures were harvested day 5-7 post transfection. Expression levels were determined by 
human IgG1 ELISA. To develop this ELISA, we used a detection antibody recognising the Fc 
of human IgG1. In select instances, we performed a second ELISA, using the same capture 
antibody and a different detection antibody, recognising the light κ chain. The clone generating 
the highest expression levels was used in subsequent experiments.  
Antibodies were purified on Protein G or Protein A columns using FPLC. Human IgG1 was 
detected in the flow-through by human IgG1 ELISA, to verify efficiency of purification. 
Eluted antibody was desalted using Amicon Ultra centrifugal units with various MW cut-off 
and further characterised appropriately for their purpose.  
 




Figure 4.1. Schematic representation of workflow used to express and purify recombinant antibodies 
or fusion antibodies, starting with either plasmid or PIPE cloning fragments. 
4.1.2 Validation of recombinant Trastuzumab 
For validation of our antibody preparations, Trastuzumab (Tr) expressed and purified with our 
workflow (Figure 4.1) was compared to the clinical grade Trastuzumab produced by Roche, 
Herceptin® (Herc) in several in vitro assays.  
First, antibodies were analysed by SDS-PAGE under non-reducing conditions (Figure 4.2 A). 
Both antibodies migrated on the gel corresponding to their expected molecular weight of 
approx. 150kDa. Additionally, very faint bands of higher molecular weight corresponding to 
multimers and very faint bands migrating faster, representing antibody fragments (blue 
arrows) were observed. These bands were slightly more visible for some preparations of Tr 
than for Herc and not present in every batch of purified antibody.  
Binding of Tr to human HER2 was investigated using two methods, namely by ELISA with 
immobilised human HER2 and by staining of human HER2-expressing cells and analysis by 
flow cytometry. Both Herc and Tr bound immobilised human HER2, generating comparable 
curves (Figure 4.2 B). Furthermore, flow cytometry assays confirmed specific binding of both 
antibodies to cell-associated membrane-bound human HER2 (Figure 4.2 C). Additionally, 
both Tr and Herc inhibit in vitro proliferation of human HER2 overexpressing cell lines, but 
not HER2 minimal cell line MDA-MB-231, as shown in Figure 3.7.  





Figure 4.2. Validation of Trastuzumab IgG1 expressed and purified in our laboratory. A. SDS-PAGE 
analysis under non-reducing conditions Trastuzumab produced with our workflow and clinical grade 
Herceptin. B. ELISA with immobilised human HER2 was performed to compare binding properties of 
Trastuzumab (closed black) with Herceptin (open black) and isotype control (grey). The data was fitted 
with a four-parameter logistic model in GraphPad Prism C. Cell lines with different expression levels 
of human HER2 were stained with either isotype control (grey histogram), Herceptin (open black 
dotted histogram) or Trastuzumab (open black histogram) and an anti-human IgG secondary antibody 
(APC) before analysis by flow cytometry. Data are representative of minimum three independent 
experiments.  
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4.2 Generation of Trastuzumab-LL37 fusion antibody 
4.2.1. Fusion of LL37 at the C-terminus of Trastuzumab heavy chain hinders 
expression of the resulting fusion antibody 
Trastuzumab-LL37 (Tr-LL37) fusion antibody contains two LL37 domains per Trastuzumab 
IgG1 (Tr) molecule, which are fused at the C-terminus of Tr heavy chain (Figure 4.3A). We 
have opted for this fusion antibody architecture, as we wanted to maintain the original 
properties of the full-length Tr and orient the cationic peptide LL37 away from the antigen 
binding site. The role of fused LL37 is to form complexes with nucleic acid (NA) TLR agonists 
and deliver them to human HER2 overexpressing tumour tissue targeted by Tr. 
To generate Tr-LL37 fusion antibody, we started with the dual cassette pVITRO plasmid 
encoding the heavy and light chain of Tr. The pVITRO vector map is shown in Appendix E, 
while the full sequence with annotations are shown in Appendix F. The sequence for LL37 
(Appendix G), cloned by Dr. Sandra S. Diebold from human neutrophils, was introduced in 
the pVITRO vector immediately after the sequence for the heavy chain of Tr (Figure 4.3B) 
using Polymerase Incomplete Primer Extension (PIPE) cloning technique. The sequence for 
LL37 was amplified by PCR from the pVITRO-397-LL37 plasmid to generate the LL37 insert 
with 5’ overlapping regions with the pVITRO vector. Two PCR fragments were amplified that 
covered the pVITRO vector backbone including the Trastuzumab antibody heavy and light 
chain sequences and transformed together with the LL37 insert into competent bacteria (Figure 
4.3C). Plasmid preparations containing Tr-LL37 from single bacterial colonies were analysed 
for the LL37 insert by PCR using LL37 specific primers. Out of 10 analysed plasmid 
minipreparations, 9 contained the LL37 insert (Figure 4.3 D). We sequenced 5 
midipreparations to confirm LL37 presence and verify for point mutations at the cloning site, 
then used the plasmids to transiently transfect FS 293 cells.  




Figure 4.3. Generation of Trastuzumab-LL37 fusion antibody. A. Schematic representation of 
Trastuzumab-LL37 (Tr-LL37) fusion antibody and complex formation with nucleic acid TLR agonists. NA 
- nucleic acid. B. Schematic representation of pVITRO vector highlighting LL37 in relation with the 
sequence for Tr heavy chain. C. PIPE cloning strategy for introducing the sequence of LL37 into the 
pVITRO-Trastuzumab IgG1 mammalian expression vector. LL37 insert and pVITRO backbone fragments 
were generated with single stranded 5’-ends, containing overlapping sequences. When mixed, the 
sequences anneal, while nicks and gaps in the sequence are repaired in vivo by competent bacteria. 
D. 1.5% agarose gel analysis of PCR amplification of LL37 sequence in plasmid minipreparations (#1-
#10) of pVITRO-Trastuzumab-LL37 IgG1/κ generated by PIPE cloning. pVITRO-397-LL37 was used for 
positive control, pVITRO-Trastuzumab IgG1/κ was used for negative control.  
Expression levels of Tr-LL37 fusion antibody were approx. 10-fold lower than for the parent 
antibody Tr when measured using either an anti-Fc monoclonal detection antibody (Figure 4.4 
A) or an anti-κ light chain polyclonal antibody (Figure 4.4 B). When we upscaled the 
transfection and purified Tr-LL37 on a protein G from 300ml supernatant, only 27.8µg Tr-
LL37 were obtained. This was approx. 15x times lower than the yield we obtained from 300ml 
unmodified Tr (312µg). For both Tr and Tr-LL37, purification was efficient, as verified by 
measuring antibody levels in the flow-through by human IgG1 ELISA (data not shown).  
Upon analysis by SDS-PAGE (Figure 4.4 D), only a fraction of the purified Tr-LL37 migrated 
corresponding to the expected MW of ~ 160kDa. In terms of purity, multiple bands of various 
molecular weights were observed, which was in contrast with integrity and purity of Tr. This 
suggests that folding and assembly of Tr-LL37 is probably suboptimal, leading to antibody 
fragments and aggregation. However, the nature of the additional bands observed on SDS-
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PAGE was not further investigated by Western blot to confirm the presence of heavy chain 
and/or light chain fragments. The minute expression levels of Tr-LL37 in this system rendered 
a more extensive evaluation of the fusion antibody unfeasible within manageable laboratory 
costs. 
 
Figure 4.4. Expression levels of Trastuzumab-LL37 (Tr-LL37) compared to the parent antibody Tr. 
Human IgG1 ELISA using a recombinant anti-Fc detection antibody (A and C) or a polyclonal anti-kappa 
chain detection antibody (B) to assess antibody levels in supernatant of transiently transfected FS-293 
cells (A and B) or ExpiCHO cells (C). Data is representative of 4 (A and B), or 2 (C) independent 
transfection experiments and ELISAs. Mean values ± SD of technical triplicates. Commercial human 
IgG1 (Ultra-LEAF from BioLegend) was used as standard in all assays. D. SDS-PAGE analysis of purified 
Tr and Tr-LL37 with Simply Blue staining. Both antibodies were expressed in FS-293 cells. 2µg of each 
sample were loaded.   
In order to boost expression levels of the fusion antibody, the ExpiCHO™ expression system 
(Life Technologies) was tested. At day 4 post-transfection, expression levels of the parent 
antibody Tr were 10-fold higher for the ExpiCHO™ expression system compared to the FS 
293 expression system. However, expression levels of Tr-LL37 were also reduced by 
approximately 10-fold as compared to Tr when ExpiCHO cells were used (Figure 4.4 C). 
Viability of both FS 293 cells and ExpiCHO cells was comparable when transiently transfected 
with pVITRO-Tr or pVITRO-Tr-LL37 (data not shown). 
Taken together, expression levels of Tr-LL37 were drastically reduced across expression 
systems. Low purity and poor integrity of the Tr-LL37 indicates that LL37 might interfere 
with antibody folding and assembly, resulting in a drastic dip in expression levels.  
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4.2.2 Rigid alpha-helical linkers separating LL37 and the C-terminus of Tr heavy chain 
facilitate expression of Tr-LL37 fusion antibody 
In order to evaluate the potential use of Trastuzumab-LL37 for targeted delivery of TLR 
agonists, it is essential to generate sufficient amounts of fusion antibody for both in vitro and 
in vivo characterisation.  
It has been demonstrated that folding and assembly of IgG isotype antibodies consisting of 
light and heavy chains is a complex post-translational process. Assembly of most IgG 
antibodies, including human IgG1, is guided by obligate homo-dimerization of the CH3 
domains, an interaction mediated by non-covalent bonds (Feige, Hendershot, and Buchner 
2010). While LL37 is a cationic peptide with strong polarity, we hypothesised that its direct 
proximity to the CH3 domain of the antibody interferes with CH3 homo-dimerization and 
thereby disturbs antibody assembly, hindering expression. Hence, we decided to investigate 
whether the introduction of a linker which spatially separates LL37 from the CH3 domain of 
Tr would improve or even restore expression levels.  
To identify linkers suitable for our purposes, we decided to compare the effect of various 
linkers used in fusion protein engineering (Table 4.1) for their ability to rescue expression 
levels of Trastuzumab-LL37. The sequence for each linker was introduced between the C-
terminus of the CH3 domain and LL37 (Figure 4.5A), using PIPE cloning. Using PCR 
reactions, we generated PIPE fragments with single stranded 5’-ends, overlapping by 
minimum 7 nucleotides, containing the sequence of shorter linkers (Figure 4.5B). Nucleotide 
sequences of linkers H3 and H4, were too long for this strategy and were ordered as long oligos 
from Eurofin Genomics instead. The H3 and H4 long oligos were used as PCR templates to 
generate the H3 and H4 inserts. These were introduced into the pVITRO vector using the PIPE 
cloning strategy we employed for cloning of LL37 (see Figure 4.3 C above). For protein 
expression experiments, at least two clones with confirmed sequence were compared and one 











No. of amino acid 
residues 
Amino acid sequence 
(single letter code) 
Hinge 
human IgG2 
Natural, rigid Rod-like 19 ERKCCVECPPCPAPPVAGP 
G4S Empirical, flexible Coil 5 GGGGS 
(G4S)x2 Empirical, flexible Coil 10 (GGGGS)x2 
(G4S)x3 Empirical, flexible Coil 15 (GGGGS)x3 
H1 Empirical, rigid α-helix 11 LEA(EAAAK)ALE 
H2 Empirical, rigid α-helix 16 LEA(EAAAK)2ALE 
H3 Empirical, rigid α-helix 21 LEA(EAAAK)3ALE 
H4 Empirical, rigid α-helix 26 LEA(EAAAK)4ALE 
Table 4.1. List of linkers used to generate Trastuzumab-liker-LL37 IgG1 fusion proteins. Amino acids 
determining the α-helix secondary structure are shown in bold. 
Expression levels of Tr-liker-LL37 fusion antibodies generated with several linkers were 
analysed by human IgG1 ELISA. Hinge regions of human IgG isotype function as linkers 
between the Fab and Fc regions of antibodies. The hinge from human IgG2 is the shortest and 
is more rigid than other hinges due to the proline content (Table 4.1), which causes the 
restricted flexibility of the IgG2 isotype (Vidarsson, Dekkers, and Rispens 2014). We 
considered it reasonable to assume that this sequence might be suitable to spatially separate 
LL37 from the CH3 domain. However, using the hinge region of human IgG2 as a linker did 
not improve expression levels of Tr-LL37 (Figure 4.6).  
Several studies report improved function of fusion proteins built with glycine-serine (G4S) 
linkers, with linkers containing fewer G4S repeats providing better separation between 
domains (Gillies et al. 2002; Zhao et al. 2008; Chen, Zaro, and Shen 2013; Silacci et al. 2014). 
In our hands, the introduction of flexible G4S linkers did not impact expression levels of Tr-










Figure 4.5. Generation of Trastuzumab-linker-LL37. A. Schematic depiction of Trastuzumab-linker-
LL37 fusion antibodies. B. Schematic depiction of PIPE cloning strategy for cloning different linkers into 
the pVITRO-Trastuzumab-LL37 vector. Annealing of overlapping single stranded 5’-ends is exemplified 
for the H2 linker. For introduction of longer linkers such as H3 and H4, a separate insert fragment 
enclosing the linker region was generated and introduced into the plasmid by PIPE cloning as 
described. 
 
Figure 4.6. Impact of linker engineering on expression levels of Trastuzumab-linker-LL37 in FS 293 cell 
supernatant. Plasmids encoding Tr, Tr-LL37 or Tr-linker-LL37 were transiently transfected in FS 293 
cells. At day 5 post-transfection human IgG1 levels were measured in supernatant by ELISA against a 
standard curve of purified commercial human IgG1. Representative data from 2 independent 
transfection experiments are shown. Mean ± SD of three technical replicates are shown. Sequence 
and properties of linkers are described in Table 4.1.  
Linkers with the sequence (EAAAK)n have been shown to form rigid alpha helix-structures. 
Independent studies demonstrated that these linkers can provide efficient spacing between 
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protein domains and thereby increase expression yields and improve the function of various 
fusion proteins (Arai et al. 2001; Bai and Shen 2006; Amet, Lee, and Shen 2009). We 
evaluated the impact of α-helical linkers with 1-4 repeats of the EAAAK domain on expression 
of Tr-LL37 fusion antibodies (see Table 4.1). The helical linker with one EAAAK repeat, H1, 
minimally improved expression levels compared with Tr-LL37 (no linker). Introducing H2 in 
the structure of Tr-LL37 rescued the expression to comparable levels with the parent antibody 
Tr. Expression levels of Tr-H3-LL37 and Tr-H4-LL37 exceeded those of Tr by approx. 1.8-
fold and 1.4-fold, respectively (Figure 4.6). These data confirm our hypothesis that efficient 
spatial separation of LL37 from the CH3 domain of the antibody heavy chain, facilitates 
expression of Tr-LL37 fusion antibody.  
Since expression levels were satisfying for Tr-linker-LL37 fusion antibodies generated with 
linkers H2, H3 and H4, we expressed and purified all three for further comparison. Expression 
levels in day 7 supernatant showed the same pattern with day 5 supernatant (Figure 4.7 A). 
Antibodies in day 7 supernatants were purified by affinity chromatography on a protein A 
column (MabSelect Sure, GE Healthcare). Antibody concentration was measured by ELISA 
in the FS 293 cell supernatant before and after purification. Post-purification, the supernatant 
flow-through was consistently depleted of antibody, suggesting that purification efficiency 
was similar for Tr and fusion antibodies (Figure 4.7 A).  
An isotype control antibody was built by exchanging the variable regions in Trastuzumab with 
isotype control variable regions. The cloning and the validation of the isotype control antibody 
was performed by Dr. Sandra S. Diebold. The heavy chain variable region is from the rat IgG1 
antibody 1F6, which was generated to bind mouse DNGR1, but when tested did not bind any 
mouse antigens. The light chain variable region is from the rat IgG1 antibody Mac49 
recognising a plant protein. Full sequences of the isotype control variable regions are shown 
in Appendix H. The isotype control 1F6/Mac was validated by flow cytometry (see Appendix 
J). Subsequently, an isotype control-H3-LL37 (Iso-H3-LL37) fusion antibody was generated 
by Dr. Sandra S. Diebold, by introducing the H3-LL37 sequence of Tr-H3-LL37 after the 
heavy chain sequence of the 1F6/Mac isotype control (Iso) plasmid. Fusion of H3-LL37 at the 
C-terminus of the isotype control increased expression levels of the fusion antibody in FS 293 
cell supernatant by approx. 2x fold over the parent antibody (Figure 4.7 B), showing the same 
trend as observed for Tr-H3-LL37 (Figure 4.7 A). Expression of Tr and Iso was always 
evaluated in separate ELISA assays and, therefore, cannot be directly compared. Further 
transfection experiments would be required to compare expression of Iso to Tr and Iso-H3-
LL37 to Tr-H3-LL37. 




Figure 4.7. Efficiency of purification by affinity chromatography of Tr, Iso and derived fusion 
antibodies. Human IgG1 was detected by ELISA on day 7 FS 293 cell supernatant measured before and 
after purification of antibodies by affinity chromatography. A. Tr and Tr-linker-LL37 day 7 supernatant 
pre- and post-purification. B. Direct comparison of Iso and Iso-H3-LL37 levels in day 7 supernatant pre- 
and post-purification.  Mean ± SD of three technical replicates. Data representative of at least two 
independent transfections.    
SDS-PAGE analysis was used to investigate the composition of purified antibodies. Purified 
Tr and Tr-linker-LL37 antibodies were desalted and concentrated using Amicon Ultra 
centrifugal units with MW cut-off of 10kDa (Figure 4.8 A). While eluted Tr (control) showed 
a main band under native electrophoresis conditions, which migrated corresponding to an 
approx. 150kDa antibody, eluted Tr-linker-LL37, where the linker was either H2, H3 or H4, 
contained multiple additional bands migrating faster. This suggests that fusion antibody 
fragments are also present in tissue culture supernatant and are purified alongside the fully 
assembled form. It is possible that the fusion antibody fragments were also detected in the 
ELISA set-up we used to measure expression levels in FS 293 cell supernatant (Figure 4.6), 
falsely increasing levels for Tr-H2-LL37, Tr-H3-LL37 and Tr-H4-LL37. When we desalted 
all antibodies using filters with 100kDa MW cut-off, we were able to purify the fully 
assembled fusion antibodies almost completely from the fragments (Figure 4.8 B). When 
analysed in reduced conditions, the heavy chains (red arrow) of all three Tr-linker-LL37 (H2, 
H3 and H4) migrated slower than Tr heavy chain (MW of 50kDa), corresponding to increased 
MW of 62-66kDa, due to fusion of linker and LL37. Light chains of all antibodies had the 
expected mobility and apparent MW of 25kDa (grey arrow) (Figure 4.8 A, B).  
Purified 1F6/Mac (Iso) and 1F6/Mac-H3-LL37 (Iso-H3-LL37), which had been desalted using 
100kDa MW cut-off filters, migrated on gels corresponding to their expected MW under native 
or reduced conditions (Figure 4.8 C). SDS-PAGE analysis shows increased MW of the Tr-
linker-LL37 and Iso-H3-LL37 heavy chains, and indicates successful purification using 
100kDa cut-off filters. 




Figure 4.8. SDS-PAGE analysis of purified antibody and antibody-linker-LL37 desalted using filters with 
MW cut-off of 10kDa (A) or 100kDa (B, C). 4µg (A, C) or 3µg (B) of each antibody were analysed in 
native (N) or reduced (R) conditions on 4-20% gradient polyacrylamide gels stained with Simply Blue 
(Life Technologies). Tr-linker-LL37 (A, B) and Iso-H3-LL37 were analysed alongside the parent antibody. 
Arrows highlight the heavy (red) and light chain (grey). Data representative of one (A) or two (B and 
C) independent experiments. 
To assess the purified antibody yield, we started by measuring protein concentration using 
BCA assay against a bovine gamma globulin (BGG) standard and additionally by 
spectrophotometric determination, using absorbance at 280nm (A280) and the reported 
extinction coefficient for Trastuzumab. Antibody concentration and the volume of purified 
antibody were used to calculate the mass (mg) of purified antibody obtained per L of tissue 
culture supernatant. Purified antibody yields were comparable when concentration was 
determined using either the BCA assay (Figure 4.9 A) or A280 spectrophotometry (Figure 4.9 
B). The purified antibody yield was higher for Tr (1.69±0.33 mg/L) than for Tr-H2-LL37 
(0.70±0.19 mg/L), Tr-H3-LL37 (1.13±0.15 mg/L) or Tr-H4-LL37 (0.96±0.10 mg/L). Among 
fusion antibodies, Tr-H3-LL37 consistently showed the highest yield, which only amounted 
for approx. 2/3 of the Tr levels (Figure 4.9). While the expression levels of Tr-H3-LL37 were 
2x fold higher than for Tr in supernatant, the total purified yield was lower, despite successful 
purification (Figure 4.7 A). This discrepancy may be attributable to Tr-H3-LL37 fragments in 
present in cell supernatant (Figure 4.8A) but purified in downstream processing by 
ultracentrifugation (Figure 4.8 B). 
 




Figure 4.9. Purified antibody yield (mg) per L of cell culture supernatant of FS 293 cells. Purified 
antibody preparations were measured for protein concentration using BCA assay (A) or absorbance at 
280nm (B). Total mass of antibody generated from the preparation was normalised against the volume 
of supernatant it was purified from. Mean ± SD of minimum three independent experiments are 
shown. Data representative of at least two independent experiments. 
The antibody yields of fusion antibodies expressed using the FS 293 cells, while acceptable 
for the needs of the project, leave room for improvement. To explore this, we used the 
ExpiCHOTM expression system (Life Technologies), with reportedly superior performance. Tr 
and Tr-H2-LL37 were expressed in ExpiCHO cells and further purified by affinity 
chromatography on a protein A column, as described in section 2.1. At day 7, the supernatant 
from ExpiCHO cells contained approx. 7.6-fold higher levels of Tr compared to supernatant 
from FS 293 cells. Expression levels of Tr-H2-LL37 were higher using ExpiCHO cells as well, 
but only approx. 4-fold compared to FS 293 (Figure 4.10 A).  
When analysed by SDS-PAGE, we observed that purified Tr expressed in ExpiCHO cells has 
increased mobility compared to Tr expressed in FS 293 cells. When analysed in reducing 
conditions, the band corresponding to the light chain (blue arrow) was absent in the ExpiCHO-
expressed antibody, but not in the FS 293 antibody, accounting for the faster migration pattern 
of the antibody analysed in native conditions. Similar results were obtained with Tr-H2-LL37 
as well (data not shown), suggesting that while the heavy chain is expressed by ExpiCHO cells 
(of mouse origin) at high levels, expression of the light chain is suboptimal. This discrepancy 
has not been observed in FS 293 cells, of human origin, when using the same bicistronic 
pVITRO plasmid (Figure 4.8). This suggests that differences in either promoters, enhancers 
or promoter-enhancer combination (see Appendix E) for the two transcription units in the 
pVITRO plasmid determine differential expression of heavy and light chains in the two host 
cells. 
Despite the lower expression levels, we continued to use the FS 293 cells. In order to make 
use of the ExpiCHO expression system, cloning the light and heavy chain in two individual 
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plasmids would have been required, followed by experiments identifying the appropriate 
plasmid ratio to be used for ExpiCHO cell transfection.  
 
Figure 4.10. Expression of Tr and Tr-H2-LL37 in FS 293 and ExpiCHO cells. A. Expression levels in day 7 
cell supernatant measured using human IgG1 ELISA with anti-Fc region monoclonal detection 
antibody. B. Purity and composition of Tr expressed in the two cell lines assessed by SDS-PAGE in 
native and reduced form. The data is representative of two independent experiments. 
The main goal of the project is to evaluate the efficiency of treatment with Tr-linker-LL37 
complexed with NA TLR agonists in vivo. It is thus important for the project to ensure that the 
immune activation which we might observe is triggered by NA TLR agonists and not by 
possible endotoxin contamination in the antibody preparations. The protein A column we used 
(MabSelect Sure, GE Healthcare) is resistant to alkaline treatment, which we employed 
between purification runs to maintain the column and purified material endotoxin-free. 
Purified antibody batches consistently showed minimum levels of endotoxin, as measured by 
the limulus amoebocyte lysate (LAL) gel-clot assay (Table 4.2). For the assay, antibodies were 
diluted to 0.5mg/ml in PBS. We have tested the purified antibodies at this dilution, as 
preliminary in vivo experiments with Tr (see Chapter 3) suggested that the final concentration 
of injected antibody will likely be smaller or equal to 0.5mg/ml. Most batches of antibody 
tested only had minute amounts of endotoxin, below 0.05 IU/ml, many of them under the 
detection limit of the assay of 0.025-0.03. Notably, exceptions were noticed with Tr 
preparations purified on a protein G column (data not shown), which we have not used since. 
The threshold levels of endotoxin of IV administered products, as defined by the European 
Pharmacopoeia 10.0 (Council of Europe 2019) is 5.0 IU per kilogram body weight. As there 
are no recommendations for preparations used in preclinical research, we used this value from 
the European Pharmacopoeia 10.0 as endotoxin limit for our experiments. We intend to 
evaluate recombinant antibodies in mice of approx. 20g body weight, for which the appropriate 
volume for IV injections is 0.1 ml. Hence, we limited the maximal endotoxin level of 
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antibodies to less than 0.1 IU (5.0 IU/kg) in 0.1 ml, or 1 IU/ml. Since the results we obtained 
from the gel-clot LAL assay were well below threshold values, we considered our expression 
and purification workflow endotoxin-free and suitable for in vivo experiments.  
Antibody 
Endotoxin level (IU/ml) in diluted sample 
Batch 1 Batch 2 Batch 3 
Tr <0.05 0.03-0.3 <0.3 
Tr-H3-LL37 0.03-0.3 <0.3 <0.03 
Table 4.2. Endotoxin levels of purified antibodies diluted to 0.5mg/ml.  LAL gel-clot assays were 
performed by Janet Sutherland or Sophie Myhill. 
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4.3 Trastuzumab-linker-LL37 form complexes with nucleic acid TLR agonists  
For this project, we were interested in targeting TLR3, TLR7 and TLR9 agonists to the tumour 
microenvironment and comparing them for their anti-tumour potential. We are therefore 
interested in forming complexes with various nucleic acid agonists: poly(I:C) (TLR3 agonist), 
polyUs21 (TLR7 agonist) and CpG (TLR9 agonist). Poly(I:C) is a polymer of large (1.5-8 
kilobases), undefined molecular weight (Kato et al. 2008), and may cause issues with steric 
hindrance. In our experiments, depending on assay requirements and question to be answered, 
we used either polyUs21 or CpG 1668, which are oligonucleotides of 21 and 20 bases, 
respectively, of defined MW of approx. 6.5kDa.  
Tr-H3-LL37 (theoretical MW=161.4 kDa) has two molecules of LL37 (MW=4.5kDa) per 
molecule of Tr. Complexes were formed with either CpG 1668 or polyUs21 to achieve LL37 
to oligonucleotide molar ratio of 1:1. Importantly, in our hands, complexes adhered to filters 
of ultracentrifugation devices. Therefore, we could not establish if all added oligonucleotide 
was complexed by LL37 or purify the unbound fraction. 
4.3.1 Detecting complex formation 
Previous publications demonstrated that synthetic LL37 peptide condenses and aggregates 
both self-DNA (Lande et al. 2007) and self-RNA (Ganguly et al. 2009), forming complexes. 
When polyUs21 was added to concentrated LL37 peptide or Tr-LL37, complex formation was 
visible with the naked eye as clouding of the suspension, or even presence of particulates, 
which sedimented at the bottom of the tube. This was observed for complex formation with 
CpG 1668 as well (data not shown).  
UV-visible spectrophotometry is typically used to detect aggregates or other particulates with 
a hydrodynamic radius of more than 200nm in protein preparations by measuring absorption 
at wavelengths 320nm (Raynal et al. 2014). Here, we measured absorption at 405nm (A405) 
and 600nm (A600) of Tr-H3-LL37, CpG, Tr-H3-LL37+CpG complexes and their buffer 
(PBS) (Fig. 4.15). Spectrophotometry showed increased 405nm absorbance for Tr-H3-
LL37+CpG complexes compared to Tr-H3-LL37, CpG or PBS alone. This was observed as 
soon as the components were mixed and decreased slightly with time (Fig. 4.11 A). In this 
experiment we formed complexes at 1:1 molar ratio, and it is presently unclear if other molar 
ratios would influence absorbance levels. A similar trend, with lower values was obtained for 
A600 readings (Fig. 4.11 B). Together, these data demonstrate immediate complex formation 
of CpG with Tr-H3-LL37, with generation of particulates visible with the naked eye and likely 
larger than 200nm.  
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This assay, however, is limited in terms of sensitivity and does not give information relating 
to the size of the complexes. To establish this and investigate how different complex formation 
conditions (e.g. concentration, molar ratio) influence the hydrodynamic radius of complexes, 
additional experiments are required in the future, such as dynamic light scattering 
measurements or imaging by scanning electron microscopy. 
 
Figure 4.11. Visualising complex formation of Tr-H3-LL37 with CpG using UV-visible 
spectrophotometry. Complexes (orange) were formed by mixing Tr-H3-LL37 (0.6mg/ml) with CpG 
(0.5mg/ml) in PBS to achieve CpG to LL37 molar ratio of 1:1. Absorbance at 405nm (A) and 600nm (B) 
were read immediately, and different time-points. Each component of complexes, Tr-H3-LL37, CpG 
and PBS were measured as well. Mean ± SD of three technical replicates. Data representative of 2 
independent experiments.  
4.3.2 Trastuzumab-linker-LL37 complexes activate dendritic cells 
Literature reports that the synthetic peptide LL37 complexes self-RNA, protects it from 
degradation by RNases and mediates TLR7 triggering and DC activation (Ganguly et al. 
2009). In our lab we work with polyUs21, a synthetic single stranded RNA (ssRNA) 
oligonucleotide, synthesised to mimic self-RNA activation of DCs through TLR7 (Diebold et 
al. 2006). Flt3L-derived BMDCs (Flt3L-DCs) contain mouse pDCs (Appendix L), which 
express TLR7 and hence we used these cells for in vitro activation assays. However, cytokine 
production (IL-12p40) by Flt3L-DCs in response to polyUs21 can still be observed when 
polyUs21 is added to the cells in non-complexed form (Fig. 4.12 B). IL-12p40 secretion in 
response to polyUs21 was boosted by complex formation with either LL37, or the cationic 
lipid DOTAP. A typical bell-shaped dose response was observed. Notably, Flt3L-DC 
stimulated with only 3µg polyUs21 complexed with LL37 (1:1 molar ratio) produced similar 
levels of IL-12p40 as 30µg of polyUs21 alone and increasing the LL37 to polyUs21 molar 
ratio to 5:1 did not significantly (p=0.2811) increase cytokine production over the 1:1 molar 
ratio (Figure 4.12 C). Interestingly, polyUs21-DOTAP complexes induce higher cytokine 
levels by Flt3L-DCs than polyUs21-LL37 complexes (Fig. 4.12 B). At the highest 
concentration used for complex formation, LL37 peptide in the absence of TLR7 agonists only 
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induces minimal amounts of IL-12p40. Similarly, for the liposome-forming cationic lipid 
DOTAP low level of cytokine production was observed in the absence of polyUs21. 
When GM-CSF derived BMDCs, which do not express TLR7 were used for the in vitro DC 
activation assay, no cytokine production was observed in response to polyUs21 complexes 
(data not shown). Taken together these data illustrate that the LL37 synthetic peptide enhanced 
polyUs21activation of Flt3L-DCs via TLR7, but with lower activity than DOTAP. 
 
Figure 4.12. In vitro activation of Flt3L-DC by polyUS21 is mediated by complex formation. A. 10µg 
polyUs21 was incubated for 1h at 37°C in PBS or 50µg/ml RNase, then analysed on a 2% agarose gel 
stained with SYBR Safe.  B. 2x 103 Flt3L-DCs were incubated overnight with increasing concentrations 
of polyUs21, alone or complexed with either LL37 (1:1 molar ratio) or 20µg DOTAP. Cytokine levels 
were measured in the supernatant by ELISA. C. 1x 103 Flt3L-DCs were incubated overnight with 
increasing concentrations of polyUs21, alone or complexed at either 1:1 or 1:5 molar ratio with LL37. 
Data are mean ± SD of three technical replicates (B, C). To compare between polyUs21 to LL37 molar 
ratios, data was analysed by linear regression (C). All data representative of 2 independent 
experiments. 
Having established that complex formation with synthetic LL37 enhanced immunostimulatory 
activity of polyUs21 when complex at 1:1 molar ratio, we went on to evaluate weather LL37 
fused to Trastuzumab showed similar activity. Since pDCs in the composition of Flt3L derived 
BMDCs also produce IFN-α in response to TLR7 agonists (Swiecki and Colonna 2015), we 
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investigated this cytokine as well. Conversely, conventional DCs do not produce IFN-α. When 
complexed with polyUs21, but not alone, Tr-linker-LL37, where the linker is H2, H3 or H4 
and Iso-H3-LL37 induced activation of Flt3L-DCs, measured as production of cytokines IL-
12p40 (Fig. 4.13 A), IL-6 (Fig. 4.13 B) and IFN-α (Fig. 4.13 C). Production of all three 
cytokines was similar for all mentioned antibody-LL37 fusion antibodies and was comparable 
to synthetic LL37 peptide activity.  
 
Figure 4.13. Impact of LL37 fusion to antibodies on mediating polyUs21 activation of Flt3L-DC. 
Complexes were formed at 1:1 molar ratio polyUs21 to LL37. Fused LL37 moiety of Tr-H2-LL37, Tr-H3-
LL37, Tr-H4-LL37 and Iso-H3-LL37 were compared to the synthetic LL37 peptide. 1x 105 Flt3L-DC were 
stimulated overnight with 3µg/ml polyUs21, alone or in complex with LL37 or fusion antibodies. Plates 
were frozen and thawed, then IL-12p40 (A), IL-6 (B) and IFN-α (C) was measured by respective ELISA. 
Data is representative of minimum 2 independent experiments, apart from Iso-H3-LL37, which was 
added only in one of the experiments. 
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Taken together, these data show that complex formation with LL37 boosted activity of 
polyUs21 and there was no difference between synthetic LL37 and antibody-LL37 fusion 
antibodies.  
Since Tr-H3-LL37 showed better expression levels and was as efficient in activation assays as 
the LL37 peptide, we primarily used this antibody in most downstream experiments. 
One of the objectives of this study is to compare, if possible, the effects of targeted delivery 
of CpG, a TLR9 agonist with the effects of polyUs21, a TLR7 agonist. CpG 1668 is a robust 
NA TLR9 agonist which does not require complex formation for immunostimulatory activity. 
However, to verify that complex formation with LL37 peptide or fusion antibody moiety does 
not influence CpG activity, we stimulated GM-CSF derived BMDCs overnight with either free 
CpG or complexes and detected cytokine production by ELISA as a measure of activation. 
Neither vehicle, Tr, Tr-H3-LL37 or Iso-H3-LL37 induce IL-12p40 (Fig. 4.14. A) or IL-6 (Fig. 
4.14 B) production. CpG activated DC with comparable activity alone, with Tr or complexed 
with Tr-H3-LL37 or Iso-H3-LL37 (Fig. 4.14).  
 
Figure 4.14. Tr-H3-LL37-CpG and Iso-H3-LL37-CpG complexes are as efficient in activating GM-CSF 
BMDCs as CpG alone. 1x 105 GM-CSF BMDCs were incubated overnight with 500ng/ml of CpG, alone 
(white), with Tr (blue) or complexed with Tr-H3-LL37 (orange) or Iso-H3-LL37 (grey). The next day, 
plates were frozen and thawed and IL-12p40 (A) and IL-6 (B) were detected in supernatant as a 
measure of DC activation. Mean ± SD of three replicates. Data representative of 2 independent 
experiments.  
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4.4 Trastuzumab-linker-LL37 fusion antibodies, alone or complexed with NA TLR 
agonists maintain binding to human HER2 
To verify that Trastuzumab-linker-LL37 (H2, H3 or H4 linkers) fusion antibodies and 
complexes maintain human HER2 binding properties of the parent antibody, we performed 
ELISA with immobilised human HER2 and an anti-human IgG detection antibody. Iso-H3-
LL37, alone (Fig. 4.15 A) or complexed with CpG 1668 (Fig. 4.15 B) did not show non-
specific binding. Compared to Tr, the fusion antibodies Tr-H2-LL37, Tr-H3-LL37 and Tr-H4-
LL37 showed similar binding to human HER2, with only subtle differences noticeable in the 
linear part of the binding curve (Fig. 4.15 A). Complex formation at 1:1 CpG to LL37 molar 
ratio only minimally decreased binding to HER2 with mild differences noted in the linear 
range of the binding curve, but not upper asymptote (Fig. 4.15 B). No important differences 
were noticed among fusion antibodies, either alone, or complexed with CpG. Similar results 
were obtained when the NA TLR7 agonist polyUs21 was used for complex formation instead 
of CpG (data not shown). 
Figure 4.15. Human HER2 binding of fusion antibody and complexes. LL37 fusion antibodies alone (A) 
or complexed with CpG 1668 (B) were analysed on ELISA with immobilised human HER2. Detection 
was performed with anti-human IgG biotinylated antibody. Data are mean ± SD of three technical 
replicates and is representative of 3 experiments with Tr-linker-LL37 antibodies and complexes, 2 of 
them including Iso-H3-LL37 antibody and complexes.  
Collectively, in vitro analysis of Tr-H3-LL37 showed that this fusion antibody binds human 
HER2 in a similar fashion with the parent antibody and forms complexes with NA TLR 
agonists CpG and polyUs21.  
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4.5 In vivo evaluation of Tr-H3-LL37 + CpG complexes 
4.5.1 Efficiency of treatment with Tr-H3-LL37 + CpG on B14.3 Luc HER2 pulmonary 
tumour growth 
To evaluate the impact of treatment with Tr-H3-LL37 on tumour growth, we used the pseudo-
metastasis mouse model we established with B14.3 Luc HER2 cells, clone H2 (see Chapter 
3). In this model, treatment with Tr does not significantly impact tumour growth, with a subtly 
higher tumour burden measurements in the Tr treated mice (Figure 3.13).  
For the current experiment, mice were treated trice as indicated by arrows in Figure 4.16 A 
with vehicle (PBS), Tr or Tr-H3-LL37 + CpG in PBS and were imaged in vivo at 10 min after 
injecting luciferase substrate at the indicated time points (☼). Doses for treatment were 270 
picomoles of antibody (2mg/kg body weight, 40µg per mouse), as described for figure 3.15. 
Previous studies showed that this dose of 2mg/kg is optimal for marked accumulation to the 
tumour tissue (McLarty et al. 2009). CpG was complexed at 1:1 molar ratio with LL37. For 
the fusion antibody dose, CpG was 3µg. The dose of CpG and sequence of repeated treatment 
are in range of previously published data showing immune mediated anti-tumour efficacy 
(Kunikata et al. 2004; Kawarada, Ganss, Garbi, Sacher, Arnold, and Hämmerling 2001; 
Chavez et al. 2018). To assess tumour burden, luminescence intensity (photons/s) was 
measured in regions of interest (ROI) of 2.647cm diameter encompassing the lung area on the 
mouse anterior thorax (Fig. 4.16 B). Mice bearing B16 tumours were used to establish 
background. Luminescence intensity increased steadily in B14.3 Luc HER2 mice with time to 
reach a maximum at day 18 (Fig. 4.16 C). When comparing the vehicle group with either Tr 
group or CpG group using the CGGC permutation test (Elso et al. 2004), global luminescence 
intensity profile was not significantly different (data not shown). Luminescence intensity was 
strikingly similar between the Tr and the Tr-H3-LL37 groups across time-points, with p=0.756 
(Fig. 4.16 C).  
At day 18 post tumour inoculation, mice were culled, lung tissue was harvested, bleached in 
Fekete solution and lung nodules were counted. There was no significant difference in the total 
number of lung tumours between either of the groups, with p=0.7289 determined by Kruskal-
Wallis test (Fig. 4.16 D). A repeat experiment with Tr-H3-LL37 + CpG treatment is needed to 
boost n numbers for more robust statistical analysis and confirm our current results. These 
data, however, illustrate that treatment with 3 doses of Tr-H3-LL37 + CpG does not impact 
pulmonary B14.3 Luc HER2 (clone H2) tumour growth.   




Figure 4.16. Treatment with Tr-H3-LL37+CpG does not influence tumour growth. A. Treatment 
regimen and timing for in vivo imaging. B. Representative image showing position of region of interest 
(ROI) for in vivo imaging of tumour burden. C. Luminescence intensity (photons/s) of mouse lungs with 
B16 tumours (background) or B14.3 Luc HER2 tumours, treated with Tr (n=5) or Tr-H3-LL37 (n=5). Data 
are mean ± SEM. Groups were compared using CGGC permutation test with 10 000 permutations. D. 
Number of pulmonary tumour nodules on day 18 post tumour inoculation of mice treated with vehicle 
(n=4), Tr (n=5), and Tr-H3-LL37 (n=5). Data from1 experiment for Tr-H3-LL37 group. Kruskal-Wallis one-
way analysis of variance. 
4.5.2 Serum concentration of Tr-H3-LL37, alone or complexed with CpG 
Previously published data demonstrates that LL37 can be internalised in mammalian cells and 
access intracellular compartments and receptors, either alone, or complexed with nucleic acids 
or other anionic molecules. It was proposed that internalisation is not receptor mediated 
(Sandgren et al. 2004; Xhindoli et al. 2016). A previous study showed that LL37-RNA 
complexes uptake was higher in monocytes and reached not only the endosomal compartment, 
but also the cytosole (Ganguly et al. 2009). Soluble proteins are taken up by cells via 
pinocytosis and used as a source of energy. The long half-life of IgG antibodies is determined 
by interactions with neonatal Fc receptor in the endosomes, which mediate their return into 
circulation (Kuo and Aveson 2011). We consider that LL37, when fused with Tr, might 
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interfere with antibody recycling processes, changing the serum concentration of Tr-H3-LL37, 
relative to Tr.  
To investigate this, mice were treated IV with one dose of 40µg Tr, Tr-H3-LL37 or Tr-H3-
LL37 + CpG (Fig. 4.17 A). Serum samples were harvested at the indicated dates, and 
concentration of antibody was determined using ELISA. Tr, Tr-H3-LL37 or Tr-H3-LL37 + 
CpG were captured with immobilised human HER2 and detected with anti-human IgG Fc 
monoclonal antibody. Standard curves were prepared with Tr, Tr-H3-LL37 and Tr-H3-LL37 
+ CpG. Serum concentrations were obtained by interpolation from the linear range of the 
curve. Serum harvested before treatment was used as negative control and gave a value of 
0.0067±. Among the time-points measured, serum Tr was highest at day 1 post-treatment at 
23.52±3.18 µg/ml and decreased progressively to 6.78±0.45 µg/ml on day 7 post-treatment 
(Fig. 4.17 B). This is in line with previous publications, reporting a similar downwards trend 
of serum Tr upon IV administration in tumour bearing mice (Milenic et al. 2010; Borrok et al. 
2015). In contrast with the profile of Tr, both Tr-H3-LL37 and Tr-H3-LL37 + CpG were 
rapidly depleted from circulation, with day 1 serum concentrations of only 1.82±0.56 µg/ml 
and 1.24±0.17 µg/ml, respectively (Fig. 4.17 B).  
To confirm the rapid depletion of Tr-H3-LL37 + CpG, serum samples were harvested from 
tumour bearing mice which received 3 doses of treatment, as shown in Fig. 4.17 C. In mice 
treated with three 40µg doses of Tr, serum Tr levels reached 33.05±0.43 µg/ml on day 3 post 
the last treatment dose (Fig. 4.17 D), which is an approximate 1.5x fold higher than the values 
measured for mice treated with just one dose of Tr (Fig. 4.17 B). This is consistent with the 
reported half-life of Trastuzumab in (tumour-free) mice which is 12-16 days (Hurst et al. 
2014). Repeated treatment with Tr-H3-LL37 + CpG however, did not improve its persistence 
in serum (Fig. 4.17 D). 
Together, our results demonstrate that serum concentrations of Tr-H3-LL37, alone or 
complexed with CpG are dropping rapidly, within one day or less, which is not consistent with 
the parent antibody Tr or the expected behaviour of a human IgG1 in mice.  
The result is especially important, as it has been shown that antibodies targeting tumour 
associated antigens, such as Trastuzumab, gradually concentrate into the tumour tissue over 
days (Mortimer et al. 2014). Since Tr-H3-LL37 (with or without CpG) is cleared rapidly from 
serum it cannot concentrate into the tumour tissue and activate local immune cells. Hence, IV 
administration of Tr-H3-LL37 complexed with CpG is not a feasible approach for targeted 
deposition of CpG in the tumour tissue.   





Figure 4.17. Serum concentration of Trastuzumab and fusion antibody in tumour bearing mice.  A-B. 
Mice (n=5) were inoculated IV on day -11 with 6x105 B14.3 Luc HER2 cells. Mice were treated with 
40µg of either Tr, Tr-LL37 or Tr-LL37 + CpG on day 0 (arrow). Serum was collected before treatment 
and at days 1, 4 and 7 post-treatment (syringe symbol). C, D. Mice (n=5) were inoculated IV on day -
11 with 9x105 B14.3 Luc HER2 cells. Mice were treated with three doses of 40µg of either Tr, Tr-LL37 
or Tr-LL37 + CpG (arrows). Serum was collected before treatment and at days 3 and 7 post-treatment 
(syringe symbol). B, D. Concentration of antibody or complexes was measured using ELISA with 
immobilized human HER2 and anti-human IgG1 detection antibody. Each graph shows means ± SD of 








In this chapter we fused LL37 at the heavy chain C-terminus of Trastuzumab. We showed that 
efficient separation of heavy chain C-terminus and LL37 via a rigid linker with at least two 
EAAAK repeats is required to enable expression of the fusion antibody (Fig. 4.6). We have 
further shown that both antigen binding (Fig. 4.15) and LL37 function are conserved (Fig. 
4.13). This strategy can be used to generate and efficiently express other functional fusion 
antibodies with heavy chain C-terminus moieties and to enable other research projects. 
In vitro generated LL37-nucleic acid complexes were visualised by other groups using 
confocal microscopy or scanning electron microscopy, as complexes are aggregated and 
condensed structures (Ganguly et al. 2009; Lande et al. 2007). Here we have shown that Tr-
H3-LL37 + CpG complexes can be easily visualised using absorption at wavelengths higher 
than 320nm (Fig. 4.11), an assay which is less descriptive, but more rapid to perform and less 
prone to visual interpretation bias. The size and morphology of complexes has not been 
determined, nor do we know if and how this influences immunoactivity. Future experiments 
are required to correlate the conditions for complex formation to complex size and 
immunoactivity.  
We evaluated Tr-H3-LL37 + CpG complexes in vivo as well. Trastuzumab is a human IgG1 
antibody and therefore shows an extended half-life of days in the mouse system (Hurst et al. 
2014). This is crucial for activity, as it takes time for the antibody to concentrate at the tumour 
site (Palm et al. 2003; Lee and Tannock 2010). In our experiments, Tr persisted in serum of 
tumour-bearing mice for days. In contrast, both Tr-H3-LL37 and Tr-H3-LL37+CpG 
complexes were rapidly cleared from serum within one day from IV administration (Fig. 4.17). 
This indicates that systemic delivery of Tr-H3-LL37+CpG complexes cannot achieve targeted 
delivery of NA TLR agonists to the tumour tissue.  
Tr-H3-LL37 serum concentration was determined using an antibody against the Fc region of 
human IgG1. This indicates that the entire fusion antibody was removed from circulation and 
not just LL37. The same stands for Tr-H3-LL37 + CpG (Fig. 4.17). The mechanism for this 
rapid clearance remains unclear. It is possible though, that the membrane-permeating 
properties of LL37 and LL37 complexes lead to rapid clearing by blood cells. In the context 
of skin infection, as well as autoimmune diseases such as lupus or psoriasis, LL37 is produced 
locally and acts on neighbouring cells. It might be that the function of LL37 can be harnessed 
for paracrine use, but not for systemic use.  The question remains about the use of LL37 fusion 
antibodies for other routes of administration. 
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To summarise this chapter, data so far indicates that Tr-H3-LL37 fusion antibodies are not 
appropriate means for targeted delivery of NA TLR agonists and other strategies should be 












Chapter 5 - Results 
 








Chapter 5: Antibody conjugates for targeted delivery of CpG ODN 
 to the tumour microenvironment  
Introduction 
Antibody conjugates are typically generated through biochemical conjugation of a payload to 
a tumour-targeting antibody, most often using heterobifunctional cross-linkers (Beck et al. 
2017). In this chapter, we asked if biochemical conjugation technologies used in the field of 
antibody drug conjugates (ADC) can be applied to generate antibody conjugates with 
endosomal TLR agonists. 
The model antibody we used for generation of conjugates was recombinantly expressed 
Trastuzumab, as described in chapter 4. In terms of cross-linkers and conjugation chemistries, 
we primarily used succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC). 
This linker contains N-hydroxysuccinimide (NHS) esters, the most often employed group for 
conjugation of primary amines and maleimide, to functionalise thiol groups. This allows for 
two-step conjugation reactions. SMCC is non-cleavable, conferring superior conjugate 
stability compared with many other linkers (McCombs and Owen 2015). Therefore, we 
considered SMCC a valuable candidate for our conjugation reactions. 
In terms of payloads for conjugate generation, these molecules should be soluble, stable and 
amenable to conjugation without loss of function (McCombs and Owen 2015). CpG molecules 
are highly potent, nuclease resistant oligonucleotides (ODN), with robust in vitro and in vivo 
stability and relatively low molecular weight (Krieg 2006), and can be ordered with a terminal 
amino or thiol group for conjugation. We considered them, therefore, suitable payloads for 
conjugation to antibodies. 
Other endosomal TLR agonists that would be interesting for targeted deposition in the tumour 
tissue were, however, most likely not feasible for this biochemical conjugation approach. 
Resiquimod (R848) and other small molecules agonists of TLR7, contain a primary amine in 
their structure, indispensable for the molecule’s activity, that is targetable by most commercial 
cross-likers (Ignacio et al. 2018). Therefore, conjugation of Resiquimod with such linkers is 
not appropriate, since it is expected to lead to complete loss of function.  PolyUs21, a TLR7 
agonistic oligonucleotide is rapidly degraded by RNases and is unstable in serum unless 
complexed with cationic molecules (Diebold et al. 2006). This implies that the polyUs21 
molecule conjugated via one chemical group to an antibody is likely to be rapidly degraded by 
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RNases as well. Polyinosinic-polycytidylic acid (poly I:C), a TLR3 agonist of 1.5-8 kilobases 
and undefined molecular weight also requires complex formation of high-molecular weight 
species of poly I:C for activity (Zhou et al. 2013). Moreover, the molecular weight of poly I:C 
is expected to be problematic due to sterical hindrance and this agonist cannot be purchased 
with thiol or amine modifications, rendering it unsuitable for conjugation. Hence, in terms of 
harnessing antibody conjugates for targeted delivery of endosomal TLR agonist, for this 
project we only focused on CpG, due to its greater potential for conjugation.   
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5.1 Identifying suitable CpG ODN molecules for the project 
CpG ODN molecules are typically considered species-specific, although this does not apply 
to all CpG ODNs (Roberts et al. 2005). To directly compare activity of different CpG ODNs 
on mouse and human TLR9, we performed in vitro activation assays (Fig. 5.1). CpG ODNs 
were titrated on mouse GM-CSF bone marrow-derived DCs (BMDC), which contain a mixed 
population of inflammatory DCs, macrophages and neutrophils (Inaba et al. 1992; Helft et al. 
2015) (Fig. 5.1 A) and Flt3L BMDCs which contain a mixed population of primary DC 
including conventional DC (cDC) and pDC (Brawand et al. 2002; Gilliet et al. 2002) (Fig. 5.1 
B). To evaluate activation of human TLR9, primary human DCs were enriched from PBMCs 
(Fig. 5.1 C). Each preparation of DCs was analysed by flow cytometry to confirm the expected 
cell populations (see Appendices K, L, M). In response to treatment with TLR9 agonists, 
signalling through MyD88 induces activation of DCs, which simultaneously upregulate MHC 
class II and costimulatory molecules and produce proinflammatory cytokines such as IL-12, 
IL-6 and TNF-α (Medzhitov 2001; Diebold 2008a). We used IL-6 production by ELISA as a 
robust and specific marker for DC activation for comparing the potency of several CpG ODNs.  
We directly compared CpG 1668, a class B mouse TLR9 agonist (Kreutz et al. 2012) with 
CpG 2006, which was originally designed as a human TLR9 agonist (Hartmann and Krieg 
2000). We also included CpG C274, a class C CpG, with reported human and mouse activity 
(Marshall et al. 2003). In all assays we included negative control ODN GpC 1668, which lacks 
the TLR9 stimulatory activity of CpG 1668. As expected, GpC-ODN induced only minute 
amounts of IL-6 in both mouse and human cells (Fig. 5.1). Stimulation of DCs with increasing 
doses of CpG ODN typically induce a bell-shaped cytokine response. Reportedly, high 
concentrations of CpG (or other TLR ligands) lead to increased production of the anti-
inflammatory cytokine IL-10 which inhibits DC functionality via an autocrine negative 
feedback loop and results in lower levels of proinflammatory cytokines (Waibler et al. 2008; 
Chang, Kunkel, and Chang 2009; Couper, Blount, and Riley 2008). In our hands, all CpG 
molecules induced IL-6 in a dose-dependent manner and with different potencies in mouse 
versus human cells. For each CpG ODN, the maximal IL-6 level was obtained at different 
concentrations for mouse GM-CSF or Flt3L derived BMDCs. This is likely due to differences 
in cell composition and/or differences in TLR9 expression levels in the two distinct DC 
cultures. CpG 1668 and CpG C274 induced strong levels of IL-6 in mouse BMDCs generated 
with either GM-CSF (Fig. 5.1 A) or Flt3L (Fig. 5.1 B). We also measured levels of IL-12p40 
in supernatant of GM-CSF derived BMDCs and found them to be in line with the IL-6 results 
(data not shown). As expected, human DCs enriched from PBMCs produced higher levels of 
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IL-6 in response to human CpG ODN 2006 (Fig. 5.1 D), which was originally designed as a 
human TLR9 agonist. Notably, although less potent, CpG 1668 also shows human TLR9 
activity. CpG C274 showed substantial activity on both mouse and human cells (Fig. 5.1). We 
decided to start our conjugation experiments using CpG 1668, since it had been used for 
antibody-ODN conjugate generation and investigation of anti-tumour immunity induction in 
melanoma mouse model in our laboratory before (Kreutz et al. 2012). To test conjugates in a 
humanised mouse model, we would have to generate conjugates using CpG 2006 or CpG 
C274.  
We also investigated the use of RAW 264.7, a murine macrophage cell line for in vitro 
evaluation of CpG ODN activity (Fig. 5.1 C). RAW 264.7 cells were shown to produce 
cytokines such as IL-6 and IL-12 when stimulated with CpG-ODNs, including CpG 1668 in 
similar conditions with our assay set-up (Chen et al. 2015; Yeo et al. 2003; Yi et al. 2002). 
However, in our experiments with RAW 264.7 cells stimulated with various doses CpG ODNs 
that efficiently activate mouse DC, the levels of IL-6 (Fig. 5.1 C) and IL-12p40 (data not 
shown) induction were comparatively low with less than 10ng/ml or less. Also, unlike for DC 
a clear dose dependent respond in activation was not observed. The data show that using RAW 
264.7 cells results in poor resolution of the activation assay, making it difficult to distinguish 
small differences in CpG ODN activity. For this reason, we continued to use BMDCs, derived 
either with GM-CSF or Flt3L for the evaluation of the stimulatory activity of antibody-CpG 
conjugates in in vitro activation assays. 




Figure. 5.1. In vitro potency of CpG ODN molecules in activating human and mouse dendritic cells. 
CpG-ODN molecules and control GpC were used for overnight stimulation of: 2x105 mouse GM-CSF 
derived BMDC (A), mouse Flt3L derived BMDC (B), human DC enriched from PBMC (D), 0.5x 106 RAW 
264.7 cells (C).  CpG ODN concentrations used were: 0.3µg/ml, 1µg/ml, 3µg/ml, 10µg/ml. IL-6 levels 
were measured in cell supernatant after overnight culture to quantify DC activation. Data are 
representative of two independent experiments.  
5.2 Trastuzumab-CpG conjugates generated by conventional conjugation with SMCC 
5.2.1 Generation of conjugates 
In terms of conjugation chemistries, traditional approaches involve the use of a 
heterobifunctional linker. These methods are often named conventional and the resulting 
conjugates are often referred to as conventional or traditional conjugates in the literature (Beck 
et al. 2017; Sochaj, Swiderska, and Otlewski 2015; Zhou 2017). 
To begin our experiments, Tr was conjugated to CpG 1668 using the heterobifunctional cross-
linker SMCC, containing an NHS (N-hydroxysuccinimides) ester and a maleimide, separated 
by a cyclohexane ring (chemical formula included in Fig. 5.3 A). We have employed this 
conjugation strategy as it is a validated method, which was previously used to generate 
Trastuzumab-DM1 (Kadcyla®) conjugates, approved for clinical use (Chari et al. 1992; 
Lambert and Chari 2014). Additionally, our lab used this crosslinker to successfully generate 
antibody-CpG 1668 conjugates for a previous study (Kreutz et al. 2012).  
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An overview of the conjugation reactions is shown in Fig. 5.2. In a first step, primary amines 
in lysine residues on the surface of Tr were modified with SMCC to generate maleimide-
activated Tr. This first reaction can be performed in PBS, at neutral pH, or in borate buffer in 
mild alkaline conditions (pH of about 9). After purification from unbound cross-linker, thiol-
CpG 1668 or thiol-GpC 1668 were reacted in PBS + 2mM EDTA (pH=7.1-7.3) with 
maleimide-activated Tr, generating Tr-MCC-CpG or Tr-MCC-GpC. After CpG conjugation, 
10x molar excess of cysteine was added for 10 min. In maleimide conjugation reactions, thiol-
containing small molecules, including cysteine, are typically used at high molar excess after 
payload conjugation to cap residual maleimide groups (Kim et al. 2008; Tiwari et al. 2009; 
Christie et al. 2017). An additional purification step was performed to separate the conjugate 
from unreacted ODN and cysteine. The resulting conjugates were analysed for Tr and CpG 
composition. The protein concentration was determined by BCA assay with a bovine gamma 
globulin (BGG) standard curve. CpG 1668 concentration in the conjugate preparation was 
determined using spectrophotometry. We measured A260 and calculated the concentration of 
CpG 1668 by interpolation on a standard curve generated with a constant concentration of Tr 
mixed with a dilution series of CpG 1668. Following this, the payload (CpG 1668) to antibody 
molar ratio was determined for purified conjugates.  
 
Figure 5.2. Schematic representation illustrating the reaction steps for conjugation of Trastuzumab 
with CpG using the heterobifunctional crosslinker SMCC.  
5.2.2 Composition of resulting Tr-MCC-CpG conjugates  
The IgG scaffold contains over 80 lysine residues, typically with around 20 residues at sites 
that are accessible for conjugation (McCombs and Owen 2015). Conjugation of SMCC to 
certain lysine residues on proteins depends on pH and SMCC molar excess, with different 
conditions resulting in distinct distribution of the payload added in the second step (Madler et 
al. 2009; Kalkhof and Sinz 2008; Smith 2006). To exemplify, α-amines at the N-terminus of 
heavy and light chains, usually deprotonated at pH=7, may be favoured for NHS modification 
at neutral pH, while ε-amines, which are lysine residues on the antibody surface and are usually 
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deprotonated at pH around 9, may be favoured for conjugation in mild alkaline conditions 
(Koniev and Wagner 2015). Payload molar ratio added in the second step of the reaction also 
impacts the final conjugate. It has been previously shown, that higher degrees of conjugation 
can impair antibody functionality and this depends on antibody structure and conjugation 
conditions (Thomas, Teicher, and Hassan 2016). To identify suitable conjugation conditions 
for the generation of functional Tr-MCC-CpG conjugates, we titrated both SMCC and CpG 
1668 molar ratios to antibody and performed conjugations with either Tr or Herc, at neutral 
pH (7.1-7.3) in PBS or alkaline pH (8.9-9.1) in borate buffer (Table 5.1).  
Antibody 
Buffer for 








CpG to antibody molar ratio 
of resulting conjugate 
Herc PBS 34 10 7.55 
Herc PBS 34 6 3.61 
Herc PBS 34 3 2.88 
Herc PBS 10 3 0.97 
Tr PBS 34 10 9.16 
Tr PBS 34 6 6.12 
Tr PBS 34 3 3.09 
Isotype PBS 34 6 2.87 
Herc Borate buffer 30 5 2.72 
Herc Borate buffer 20 5 2.13 
Herc Borate buffer 10 5 1.08 
Tr Borate buffer 30 4 2.02 
Tr Borate buffer 10 4 0.81 
Tr Borate buffer 5 4 0.40 
Isotype Borate buffer 20 5 1.82 
Herc Borate buffer 20 5 1.86 
Tr Borate buffer 20 5 2.12 
Table 5.1. Antibodies and conditions used to generate conventional conjugates using SMCC. CpG to 
antibody molar ratio of resulting conjugate is depicted.  
As mentioned before, CpG C274 is a potent human and mouse TLR9 activator and of interest 
for generating conjugates. However, when we attempted to generate conjugates using CpG 
C274 the conjugate precipitated heavily (data not shown). This is not surprising, considering 
that class C CpG molecules tend to spontaneously form intermolecular duplexes (Pohar et al. 
2015), each duplex containing thiol groups on each strand. Upon conjugation, this most likely 
lead to crosslinking of antibodies by CpG C274 duplexes and precipitation. Therefore, all 
conjugates we describe in this chapter were generated with CpG 1668 or the negative control, 
GpC 1668.     
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To confirm conjugation and characterise the conjugates in terms of structure and molecular 
weight, we employed two methods, size exclusion chromatography (SEC-HPLC) and SDS-
PAGE analysis.  
SEC-HPLC analysis (Fig. 5.3 A) of Tr (black), monitoring absorption at 214nm, shows a 
symmetrical peak corresponding to monodisperse antibodies and two peaks with considerably 
lower area, one with shorter retention time (RT), suggestive of aggregates and one with longer 
RT, characteristic for antibody fragments. Relative area under the curve calculated for each of 
the peaks was 3.50% for aggregates, 95.43% for monodisperse antibodies and 1.07% for 
fragments. When Tr-MCC-GpC was analysed by HPLC (pink), the peak corresponding to 
monodisperse conjugates (RT=26.4 s) eluted faster than the corresponding peak for Tr 
(RT=27.95 s), indicating an increased MW. Elution peak of Tr-MCC-CpG was shorter and 
wider than elution peak of Tr and slightly asymmetric, despite injecting the same quantity of 
each analyte, which is suggestive of increased heterogeneity. Importantly, peaks representing 
higher MW species and monomeric Tr-MCC-GpC were poorly resolved and hence the 
measurements are imprecise. The relative area of the shoulder corresponding to higher MW 
species was 8.95%, while the area for the second peak, representing monodisperse conjugates 
was 90.09%. We propose that the column used, TSK G4000SWXL separating molecules of 
20 – 7 000 kDa, was not ideal for the purpose. For future experiments and another column, 
TSK G3000SWXL, separating molecules of 10 – 500 kDa would be more suitable to achieve 
better resolution in the assay. 
Tr and Tr-MCC-CpG conjugates we analysed by SDS-PAGE as well (Fig. 5.3 B). The gel was 
stained successively with ethidium bromide to visualise CpG / GpC content (upper Fig. 5.3 B) 
and Simply Blue for protein content (lower Fig. 5.3 C). This allowed us to visualise co-
migration of CpG with Tr, confirming successful conjugation and show that conjugates with 
higher molar ratio of CpG migrate slower corresponding to their increased MW (Fig. 5.3 B).  
Staining for protein illustrated that Tr preparations only contained a small amount of higher 
MW species migrating slower on the gel (Fig. 5.3 B lower) and a very faint band representing 
fragments (data not shown). This was in line with HPLC data (Fig. 5.3 A). Analysis of Tr-
MCC-GpC conjugates by SDS-PAGE efficiently separated monomeric conjugates from 
higher MW species (Fig. 5.3 C lower). The presence of multiple bands suggested that higher 
MW species were heterogenous in composition.  
Data from both HPLC and SDS-PAGE analyses confirm increased MW of conjugates via 
attached CpG or GpC and the presence of higher MW species generated via conjugation. SDS-
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PAGE analysis showed overall superior resolution and we only used this method for analysis 
of future batches of conjugates.  
 
Figure 5.3. Characterisation of Tr-MCC-CpG conjugates by SEC-HPLC (A) and SDS-PAGE (B). A. HPLC 
analysis of Tr and Tr-MCC-GpC conjugate eluted on a TSK G4000SWXL column. Purified Tr-MCC-GpC 
had a GpC to Tr ratio of 6.28. Overlaid chromatograms from one experiment. B. SDS-PAGE analysis in 
non-reducing conditions of Tr and Tr-MCC-CpG conjugates and sequential staining with Ethidium 
Bromide (upper) for CpG and SimplyBlue (lower) for Tr. CpG to Tr molar ratio in purified conjugates is 
shown. Data representative of 5 independent experiments. 
Importantly, higher MW species of Tr-MCC-CpG (or GpC) conjugates cannot be separated 
from monomeric conjugate using commercially available ultrafiltration columns and we used 
conjugate preparations as shown for downstream experiments. Other purification methods, 
such as size exclusion chromatography, may be useful to separate monomeric conjugates from 
higher MW species. 
Next, we investigated whether the conjugation process affected the immunostimulatory 
activity of CpG or the functional properties of Trastuzumab.   
5.2.3 In vitro immunostimulatory activity of Tr-MCC-CpG conjugates 
To investigate whether conjugation of CpG to Trastuzumab affected its stimulatory activity, 
we performed in vitro activation assays. GM-CSF derived BMDCs were stimulated overnight 
with free or conjugated CpG. In addition, BMDCs were cocultured with B14.3 Luc HER2 
cells pre-incubated with conjugates or their controls. We knew from previous experiments that 
maximum GM-CSF derived BMDC activation were obtained with CpG 1668 doses in the 0.3-
1 µg/ml range (see Fig. 5.1 A). Therefore, we incubated cells with a dose of either 0.25 or 0.5 
µg/ml ODN, normalising samples for ODN content. Free Tr was normalised to Tr content in 
Tr-MCC-CpG. IL-12p40 and IL-6 were measured in cell supernatant by ELISA. As expected, 
vehicle, Tr, free GpC nor Tr-MCC-GpC conjugates did not induce cytokine production by 
BMDCs. Tr-MCC-CpG induced similar, if not slightly superior levels of IL-12p40 (Fig. 5.4 
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A) or IL-6 (Fig. 5.4 B) compared to CpG or Tr in the presence of free CpG. This pattern was 
also was observed when conjugates were pre-adsorbed on HER2 positive tumour cells before 
incubation with BMDCs (Fig. 5.4 C, D). Interestingly, GM-CSF derived BMDCs produced 
approx. two times higher levels of IL-6 when stimulated alone, compared to the tumour cell 
co-culture (e.g. 53.11 ng/ml induced by Tr-MCC-CpG vs. 23.43 ng/ml). In contrast, the IL-
12p40 response of GM-CSF BMDC to CpG ODN was unaffected by the presence of tumour 
cells. The same trend was observed in other experiments, where Herc-MCC-CpG conjugates 
were used instead (data not shown). Our data shows that Tr-MCC-CpG maintain 
immunostimulatory CpG activity, even when adsorbed on B14.2 Luc HER2 cells.  
 
Figure 5.4. In vitro dendritic cell activation assay evaluating functionality of conjugated CpG. 0.2x105 
GM-CSF BMDC were stimulated overnight alone (A and B) or in the presence of 4x105 tumour cells (C 
and D) with 0.5ug/ml (open symbols) and 0.25ug/ml (lined fill pattern) of CpG, either free (white) or 
conjugated with SMCC to Tr (light blue). Tr-MCC-GpC conjugates were used as negative controls. Read-
out for DC activation levels of IL-12p40 (A and C) and IL-6 (B and D) measured by sandwich ELISA. Data 
are mean ± SD of three technical replicates and is representative of three independent experiments 
with different batches of conjugates. 
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5.2.4 Conventional conjugates generated with SMCC have altered HER2 binding 
Since it was reported that conjugation reactions can impair antibody function, including 
binding to antigen and Fc function (Bakhtiar 2016; Thomas, Teicher, and Hassan 2016), we 
investigated the properties of conjugated Tr in comparison to the parent antibody.  
First, we evaluated the binding properties of the conjugates using ELISA with immobilised 
human HER2. For this assay, we determined that both Tr and the commercial version 
Herceptin® bound HER2 in a dose dependent manner, while the isotype control did not (Fig. 
4.2 B). Isotype-MCC-CpG conjugates did not bind to plate-bound HER2, indicating that CpG 
does not interfere with the assay (Fig. 5.5). All tested conjugates had markedly altered human 
HER2 binding compared with the parent antibody. Typically, there was a negative correlation 
between the number of CpG molecules incorporated into the conjugates and the binding 
affinity of the conjugates to human HER2. This was observed with both Tr and Herc-based 
conjugates (Fig. 5.5 A, B). Conjugates with CpG to Tr ratio of approx. 1 (green) showed 
strikingly improved binding over counterparts with CpG to Tr of 2 (blue) (Fig. 5.5 B). 
Considering that each antibody has two antigen binding sites, the data indicates that 
conjugation occurs preferentially in the vicinity of the antigen-binding site, with one CpG 
molecule hindering binding much less than 2 conjugated CpG molecules.  
In our hands, conjugating in borate buffer compared to PBS only minimally improved the 
binding of the conjugates (Fig. 5.5 C). This minimal advantage of borate buffer is difficult to 
appreciate, as the antibody to CpG molar ratio of each batch of conjugates is slightly different, 
and in our experience, this was the factor most influencing binding to human HER2. 
Interestingly, conjugation in borate buffer showed higher consistency in terms of antibody to 
CpG molar ratio among independently conjugated batches (data not shown).  
Ideally, we would want to deliver more than one CpG per molecule to the tumour tissue. 
Conjugates with CpG/Tr ratio of approx. 2 showed altered binding to human HER2, although 
this was better than for conjugates with higher CpG/Tr ratios. Therefore, in all downstream 
experiments, we conjugated either Tr, Herc or Isotype control in borate buffer with 20x molar 
excess SMCC, then 4x molar excess CpG, generating conjugates with 1.68-2.13 molecules of 
CpG bound to one molecule of antibody.  




Figure 5.5. Impact of conjugation conditions on antigen binding properties of resulting conjugates. Tr 
(A) or Herceptin (B) were conjugated in either PBS (A) or borate buffer (B) at various SMCC and CpG 
molar excess. Either different antibody to CpG ratios resulting from SMCC and CpG titrations (A and 
B) or different buffers (C) were compared. Payload to antibody (PAR) molar ratio of the resulting 
conjugate depicted in the legend. ELISA plates were coated with human HER2. Antibodies and 
conjugates were detected using anti-human IgG Fc monoclonal antibody. Binding curves were 
generated using non-linear regression (variable slope) function in GraphPad Prism. Each binding curve 
is representative of one batch of conjugate. 
Next, we asked if the impaired antigen binding of Tr-MCC-CpG conjugates was payload-
specific and if other antibodies are affected as well. CpG 1668 is a large molecule of approx. 
6345 Da. Other groups have conjugated small molecules, with molecular weight (MW) under 
1 000 Da to Tr without marked loss in antigen binding affinity (Arlotta et al. 2018). We 
hypothesised that the altered HER2 binding we have observed is due to sterical hindrance 
mediated by the increased MW of CpG conjugated close or in the antigen binding site.  
To test this, we used cysteine, an amino acid of 121.16 Da, as alternative payload instead of 
CpG (Fig. 5.6). Tr was conjugated with 20x molar excess of SMCC in borate buffer and then 
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with either 4x molar excess CpG followed in the last 10 min of reaction by 10x molar excess 
cysteine (to quench unreacted maleimide) or cysteine only. The resulting Tr-MCC-CpG 
conjugates showed CpG/Tr ratio of approx. 1.6. Tr-MCC-cysteine conjugates incorporated 3 
molecules of cysteine per Tr molecule, as measured by Ellman’s assay. Conversely, Tr-MCC-
CpG conjugates (Fig. 5.6 B), but not Tr-MCC-cysteine conjugates (Fig. 5.6 A), showed 
considerably poorer binding to human HER2 compared to Tr. To confirm our observation on 
Tr-MCC-CpG conjugate binding, we used another antibody for detection, namely a polyclonal 
antibody recognising the κ light chain (Fig. 5.6 C). Independent of detection antibody, the 
binding curve of Tr-MCC-CpG was dramatically shifted to the right, with marked differences 
compared to Tr curve in lower asymptote and slope region. Higher concentrations of conjugate 
in the assay are needed to evaluate differences in upper asymptote. However, despite this 
shortcoming, the data indicates that conjugation with SMCC impairs binding of conjugates to 
human HER2 in a payload-dependent manner. This effect was observed when conjugates were 
generated with either Tr (Fig. 5.4 A-C) or Herc (data not shown).  
When Cetuximab (anti-human EGFR) was used to generate conjugates as described above, 
ELISA binding assay showed the same trend observed for Tr, although binding of Cetuximab-
MCC-CpG conjugate was affected to a lesser degree (Fig. 5.6 D).  
Collectively, these data indicate that the properties of CpG ODN, most likely MW, sterically 
hinder binding of Tr-MCC-CpG conjugates to human HER2, while the magnitude of the effect 
is antibody specific. The major limitation in the depicted binding assay is that the ELISA has 
not been designed to calculate affinity. To quantify the diminished binding of Tr-MCC-CpG 
conjugates, methods such as surface plasmon resonance or isothermal titration calorimetry 
should be employed in the future to determine binding kinetics and constants. 




Figure 5.6. Conventional conjugation with SMCC hinders antigen binding properties of conjugates, 
which is payload dependent and antibody specific. A-C. Tr was conjugated using SMCC under identical 
conditions with either cysteine (A) or CpG 1668 (B, C). D. Cetuximab was conjugated with either 
cysteine (purple) or CpG (blue). After conjugation, payload to antibody (PAR) molar ratio was approx. 
1.7 for all CpG conjugates or about 3 for all cysteine conjugates. Resulting conjugates were analysed 
using ELISA with immobilised human HER2. ELISA was developed using either a monoclonal antibody 
against human IgG Fc and the biotin-streptavidin system (A, B, D), or a polyclonal antibody against 
human kappa chain (C) and the HRP system. The data was fitted using a four-parameter logistic model 
(sigmoid curves) with log transformation of dose, performed with GraphPad Prism. Data 
representative of 3 independent experiments with Tr and 2 experiments with Cetuximab.     
The therapeutic activity of Tr is partly determined by the ability to inhibit growth of human 
HER2 over-expressing tumours. This can be evaluated in vitro, by assessing proliferation of 
HER2 over-expressing and using HER2 minimal cells as control. Inhibition of proliferation is 
dependent on human HER2 binding, which prevents activation of downstream signalling 
pathways sustaining proliferation (Hudis 2007). Treatment with Tr inhibited proliferation of 
the human HER2 over-expressing tumour cell lines BT474 and OE-19, but not of triple-
negative MDA-MB-231 cell line, frequently used for negative control in such assays (Fig. 
5.7). By comparison, Tr-MCC-CpG was less efficient in inhibiting proliferation. A shift to the 
right of the dose-response curve was observed independent of the HER2 overexpressing cell 
line used (Fig. 5.7 A, B). Log10IC50 for Tr-MCC-CpG stood at 0.2718 on BT474 cells and 
0.431 on OE19 cells, much higher than log10IC50 for Tr, 0.1820 and -0.08813, respectively. 
With the set-up of this assay IC50 values are difficult to determine accurately, with wide, at 
times incalculable confidence intervals. Half log or even narrower serial dilutions and 
additional repeats of the assay are required to accurately determine IC50 values and compare 
Tr and Tr-MCC-CpG for statistical significance.  
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These results, however, align with the ELISA data to confirm altered human HER2 binding of 
Tr-MCC-CpG conjugates, which translates into diminished direct anti-proliferative effect on 
human HER2 over-expressing cells. 
 
Figure 5.7. Tr-MCC-CpG conjugates show reduced anti-proliferative effect compared to Tr, as 
measured in vitro by MTS assay. HER2 over-expressing Trastuzumab-sensitive human cancer cell lines 
(A and B) and HER2 minimal cell line (C) were incubated with increasing concentrations of Tr (black), 
Tr-MCC-CpG (light blue), isotype (grey dots) or isotype-CpG (grey squares). Tr-MCC-CpG had a PAR of 
~ 1.7. After 48h MTS substrate was added to the wells and signal was measured after 30 min 
incubation. Data was expressed as percent of untreated controls. Dose-response curves generated 
with non-linear fit equation with variable slope in GraphPad. Data are means ± SEM of three technical 
replicates and is representative of two independent experiments. 
5.2.5 Tr-MCC-CpG conjugates maintained ADCC activity 
The immune system contributes to the therapeutic effects of Tr, through mechanisms such as 
antibody-dependent cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADCP), 
mediated by the antibody Fc region (Bianchini and Gianni 2014). To evaluate the impact of 
CpG conjugation on Fc-mediated effects, we performed antibody-dependent cytotoxicity 
assays (ADCC). We performed a calcein-release assay with human PBMCs as effector cells 
(E) and BT474 cells as targets (T), with E:T ratio of 25:1. Within the set-up of our assay, 
vehicle (PBS), isotype control antibody or CpG 1668, either free or conjugated to the isotype 
control antibody only induced minimal levels of cytotoxicity, which was expected. 
Surprisingly, ADCC activity of Tr-MCC-CpG conjugate was comparable to Tr-mediated 
ADCC, despite decreased HER2 binding, within the described set-up (Fig. 5.8).  
Literature reports indicate that CpG enhances ADCC responses (Schettini et al. 2012; van Ojik 
et al. 2003; Hiramatsu et al. 2015), likely through an indirect mechanism that involves IFN-α 
and IL-12 produced by dendritic cells (Askew et al. 2000; Fernandez et al. 1999). It is unclear 
at this stage if CpG augmented ADCC in our in vitro assay. To elucidate the impact of 
conjugation on ADCC activity, at least two sets of future experiments are required. Altered 
Chapter 5 Results 
 
178 
HER2 binding is expected to lead to decreased ADCC activity. This impact of conjugation 
reactions should be evaluated in the future using a homogenous, preferably TLR9 negative 
effector cell population. The CD16 176V NK-92.05 cell line might be suitable for this 
experiment (Campbell 2012). Additional antibody dilutions, as well as incubation times before 
read-out are also required to ensure that the system is not saturated. To investigate the impact 
of CpG on ADCC using human cells, future experiments with a larger dilution series are 
required using CpG 2006 instead, which is more efficient in triggering TLR9. Since results 
from in vitro ADCC assays do not necessarily translate in vivo, a humanised mouse model 
should be considered.  
 
Figure 5.8. Evaluating ADCC function of conjugates. BT474 cells loaded with 11.2µM calcein were 
incubated with 0.1µg/ml (A) or 1µg/ml (B) antibodies or conjugates. Concentrations of conjugated 
CpG were 31.75ng/ml (A) and 317.5ng/ml (B), respectively. The same concentrations were used for 
the free CpG and Iso-MCC-CpG controls. PBMCs from 3 healthy donors were added at E: T=25 and the 
co-culture was incubated for 16 h. Afterwards, calcein released in the media was measured. Means ± 
SD of data generated with PBMCs from 3 healthy donors collected in 2 independent experiments. For 
each experiment, a different batch of Tr-MCC-CpG with CpG to Tr ratio of approx. 1.8-2 was used. 
Student’s t test for statistical analysis. 
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5.3 Generation of conjugates using cyanuric chloride (CC) 
To find an alternative for SMCC conjugates which showed altered HER2 binding, we 
generated conjugates using another heterobifunctional cross-linker, cyanuric chloride or 2,4,6-
trichloro-1,3,5,-triazine (CC) following a previously published protocol (Abuknesha et al. 
2009) with our modifications. Chemically, chlorine atoms of CC react with nucleophilic 
groups such as amino, thiol and hydroxyl to form covalent bonds. The first chlorine reacts at 
RT and neutral pH, the second chlorine requires alkaline pH and higher (37°C) temperature, 
while the third chlorine is almost unreactive, requiring very high temperatures and strong 
alkaline conditions, which are detrimental to proteins and avoided in the lab (Abuknesha et al. 
2005). As such, this cross-linker can be used to first activate CpG by reacting with hydroxyl 
groups of deoxyribose and then conjugate CpG to primary amines on antibodies. To us, the 
cross-linker is interesting as it would allow us to conjugate nucleic acid TLR agonists without 
Thiol modifications, such as polyUs21, a TLR7 agonist.   
Since Tr and Herc have identical amino acid sequence and conjugation of CpG using SMCC 
of either Tr or Herc generated conjugates with very similar properties, we presumed that the 
two antibodies are very similar in terms of availability of functional groups. To generate CpG-
containing conjugates with CC, we used Herceptin (Hudis 2007), since this antibody was more 
readily available for these tests and unlike Tr, did not have to be produced by ourselves in 
Freestyle 293 cells.  
The steps of the conjugation reaction are shown in Fig. 5.9 A. Firstly, CpG was conjugated 
with high molar excess of CC at neutral pH at room temperature. CpG was purified from 
unbound CC and then added to the antibody in mild alkaline pH at 37ºC. The conjugate was 
further purified from unbound CpG. Determined CpG/antibody molar ratio of purified Herc-
CC-CpG conjugate was 1.2.  
Upon SDS-PAGE analysis, the conjugate showed positive staining with ethidium bromide 
confirming conjugation with CpG. Also, the conjugate sample showed multiple bands 
migrating slower on the gel indicating the presence of higher MW species generated through 
conjugation (Fig. 5.9 C). 
When binding to human HER2 was assessed by ELISA, Herc-CC-CpG conjugates showed 
reduced binding compared to Herc (Fig. 5.9 B). This effect was similar to what we have 
observed for other conventional conjugates, Tr-MCC-CpG, where the antibody was wither Tr 
expressed in our lab or the commercial Herceptin (Fig. 5.5 B). 
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We concluded that conjugation with CC leads to Herc-CC-CpG conjugates with altered human 
HER2 binding and large fraction of higher MW species in the suspension. Since these 
conjugates did not show superior in vitro profile to SMCC generated conjugates, we have not 
pursued the method further.  
Collectively, the in vitro profile of conventional conjugates generated with either SMCC or 
CC in mild conditions and with low CpG to antibody molar ratio, indicates that linkage of the 
larger molecule CpG inhibits binding to human HER2 via steric hindrance, independently of 
the cross-linker used. Therefore, conventional conjugation methods are not suitable strategies 
to conjugate CpG to Tr and we considered site-specific conjugation methods as alternative 
approach. 
 
Figure 5.9. Generation and properties of Herc-CC-CpG conjugates. A. Schematic representation 
illustrating conjugation of CC-activated CpG 1668 to Herceptin. B. HER2 binding ELISA evaluating the 
Herc-CC-CpG as compared to the parent antibody. C. SDS-PAGE analysis in non-reducing conditions of 
Tr and Tr-CC-CpG conjugates on a 4-20% gel sequentially stained with Ethidium Bromide (top) to 
visualise the CpG content and SimplyBlue (bottom) for antibody content. Data was collected in one 
experiment. PAR = payload to antibody molar ratio in purified conjugates.  
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5.4 Trastuzumab-CpG site-specific conjugates 
5.4.1 Generation and composition of site-specific Trastuzumab-CpG conjugates using 
THIOMAB technology 
A large body of literature describes the many payload-independent limitations of conventional 
SMCC conjugation for generation of therapeutic antibody conjugates (see section 1.3.3). The 
resulting conjugates are heterogenous products, with various payload to antibody molar ratios. 
Also, unconjugated antibody in the preparation competes for antigen binding sites, while 
highly loaded conjugates show rapid degradation and loss of function (Hamblett et al. 2004). 
Conjugate heterogeneity has been shown to contribute to poor therapeutic activity (Dan et al. 
2018; Beck et al. 2017). Considering these limitations, paired with our own observations of 
altered antigen binding of Tr-MCC-CpG conjugates, we decided to explore site-specific 
conjugation methods.  
In addition to unaltered binding properties, site-specific conjugates promise higher payload to 
antibody homogeneity and in vivo stability, influencing both safety and therapeutic efficacy of 
conjugates (Zhou 2017). Among site-specific conjugation methods, we chose to use 
THIOMAB technology, which involves engineering cysteines at specific sites in the structure 
of Trastuzumab and specifically conjugating our payload of choice via a maleimide-containing 
linker to the thiol groups of these cysteines (Bhakta, Raab, and Junutula 2013). Cysteine 
residues in the structure of non-reduced IgG antibodies form disulphide bonds under native 
conditions, stabilising the tertiary structure of the antibody and need to be reduced to become 
available for conjugation (Sochaj, Swiderska, and Otlewski 2015; Behrens and Liu 2014). 
It has been shown that SMCC-mediated conjugation of modified Trastuzumab in which valine 
has been exchanged with cysteine at position 205 in the light chain (hence labelled LC-V205C) 
yields conjugates with superior in vivo stability and enhanced therapeutic function (Shen et al. 
2012). Moreover, this strategy avoids steric hindrance of the payload, which is conjugated at 
a distance from the antigen-binding site of the antibody.  
To exploit this strategy for the generation of Trastuzumab-CpG conjugates, we have 
engineered cysteines at LC-V205C in Trastuzumab and generated Trastuzumab THIOMAB, 
henceforth referred to as Tr(TH). To achieve site-selected mutagenesis, we used PIPE cloning 
as described in methods section 2.2.3. Full sequences are shown in appendix F. PIPE cloning 
fragments were generated and purified (Fig. 5.10 A), then transformed in competent bacteria. 
Following the workflow described in section 4.1, we have evaluated 3 clones of pVITRO-
Trastuzumab(TH) IgG1 with correct sequence for expression levels in FS 293 cells. Compared 
to the parent antibody Tr, expression of Tr(TH) clones #1 and #2 was similar, or even slightly 
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increased, respectively (Fig. 5.10 B). Purified Tr(TH) clone #2 migrates on a PAGE gel in a 
similar fashion with the parent antibody, corresponding to their expected molecular weights 
(Fig. 5.10 C). We have used this clone in all subsequent experiments. 
 
Figure 5.10. Generation of Tr(TH) antibody. A. Agarose gel analysis of PIPE cloning fragments 
introducing the LC-V205C mutation, showing purified bands of expected size (postV205C – 1657bp, 
fragment C – 2031, anteV205C - 4916). B. Expression levels of Tr(TH) clones. FS 293 cells were 
transfected with each of the plasmids and supernatant was harvested on day 5. Human IgG1 levels 
were assessed by ELISA. Clone Tr(TH)#2 (dark grey bar) was chosen for further experiments. C. SDS-
PAGE analysis of Tr(TH) in non-reducing conditions.  
To conjugate CpG to Tr(TH), we have optimised a previously published protocol (Nunes et 
al. 2017). During antibody expression, thiol groups of cysteines in the structure form 
disulphide bonds with other thiol-containing amino acids, named adducts, either intracellular 
or in the cell expression medium. To remove the adducts, we reduced the antibody in TCEP, 
then purified the resulting heavy and light chains by ultrafiltration. In a following step, heavy 
and light chain disulphide bonds were reoxidated using the accelerator dhAA for 3h RT (Fig. 
5.11 A). Efficient reduction and reoxidation was verified by SDS-PAGE analysis (Fig. 5.11 
B). Engineered cysteines are surrounded by positively charged amino acids and hence 
reoxidise at a much lower rate, remaining available for conjugation in the timeframe.  
CpG 1668 synthesised with an NH2 group at the 3’ end was conjugated with SMCC, to obtain 
maleimide-activated CpG using an adaptation of a previously published protocol (Williams 
and Chaput 2010). After purification from excess crosslinker, maleimide-activated CpG was 
conjugated to reoxidated Tr(TH) (Fig. 5.11 A). CpG payload to Tr molar ratio of resulting 
Tr(TH)-CpG conjugates was consistently in the 1.51-1.89 range. This was determined by 
measuring Tr(TH) content by BCA assay and CpG content by spectrophotometry as described 
before (see section 2.16.2).  
To visualise the CpG and Tr(TH) content, conjugates were run on a 4-12% SDS-PAGE gel, 
which was sequentially stained for CpG with SYBR Gold and antibody with SimplyBlue 
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SafeStain (Fig. 5.10 C). In contrast with conventional Tr-MCC-CpG conjugates (see Fig. 5.3 
B), Tr(TH)-CpG conjugates only showed minimal multimer content (Fig. 5.11 C).  
 
Figure 5.11. Generation of Tr(TH)-CpG conjugates. A. The process of conjugating maleimide-activated 
CpG 1668 to engineered cysteines (LC-V205C) of Tr(TH) is schematically represented. B. SDS-PAGE 
analysis of Tr(TH) in native, reduced and reoxidated form on 4-20% gel stained with SimplyBlue.  C. 
SDS-PAGE analysis in non-reducing conditions of Tr(TH)-CpG conjugates on a 4-12% gel sequentially 
stained with SYBR Gold (top) to visualise the CpG content, then with SimplyBlue (bottom) for protein 
content. Data representative of three independent experiments.  
5.4.2 Tr(TH)-CpG conjugates show CpG mediated immunoactivity in vitro 
To investigates the effect of conjugation to Tr(TH) on CpG immunostimulatory activity, we 
performed in vitro dendritic cell activation assays. Briefly, GM-CSF derived BMDCs (1x 
105/well) were stimulated with free or conjugated thiol-modified CpG and controls (Fig. 5.12 
A, B). Samples were normalised for CpG content. Tr and Tr(TH) content in samples was 
normalised to the Tr(TH) content of the conjugate. Additionally, conjugates and controls were 
pre-incubated with B14.3 Luc HER2 tumour cells for 20-30 min, then GM-CSF derived 
BMDCs were added (Fig. 5.12 C, D). As expected, GpC 1668 did not induce cytokine 
production by DCs, nor did vehicle (PBS), Tr or Tr(TH). When compared with free CpG, 
conjugated CpG induced production of comparable levels of IL-12p40 by dendritic cells, 
either alone (Fig. 5.12 B), or even slightly higher in the presence of tumour cells. Interestingly, 
as observed with conventional conjugates, free CpG induced slightly lower levels of IL-12p40 
(Fig. 5.12 C) or IL-6 (Fig. 5.12 D) in the presence of tumour cells, compared to BMDCs only 
(Fig. 5.12 A and B, respectively). Notably, GM-CSF BMDCs produced higher levels of IL-6 
when cultured alone, with maximum IL-6 values induced by Tr(TH)-CpG of 8.18ng/ml (Fig. 
5.12 B), compared to tumour cell co-cultures, where the maximum value IL-6 values induced 
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by Tr(TH)-CpG of 4.05ng/ml. Taken together, these data illustrate that conjugation with 
Tr(TH) does not impair CpG function in vitro, even in the presence of human HER2-
expressing cells.  
 
Figure 5.12. Assessing immunostimulatory properties of Tr(TH)-CpG in vitro. 1x105 GM-CSF derived 
BMDCs were stimulated overnight with CpG-NH2, free (white) or conjugated to Tr(TH) (red) or 
controls. BMDCs were stimulated alone (A, B) or in the presence of 3x 105 B14.3 Luc HER2 H2 tumour 
cells (C, D). For markers of DC maturation, IL-12p40 (A, C) and IL-6 (B, D) were measured in cell 
supernatant. Samples were normalised for concentration of CpG of 0.5µg/ml (line fill pattern) or 
0.5µg/ml (open fill). Data are mean ± SD of three technical replicates and is representative of two 
independent experiments.  
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5.4.3. Human HER2 binding is comparable for Tr and Tr(TH)-CpG conjugates 
To investigate the binding properties of Tr(TH)-CpG to human HER2, we performed ELISA 
with recombinant human HER2 immobilised to the plate. Antibody and conjugates binding to 
the immobilised HER2 was detected using an anti-human IgG Fc biotinylated antibody. 
Neither isotype control antibody nor isotype-CpG conjugate bind human HER2 in this assay, 
suggesting that CpG does not mediate unspecific binding of conjugate. As expected, Tr(TH) 
binding is comparable with Tr. The conjugate only showed minimal differences in binding, 
noticeable in the linear part of the curve, but not the upper asymptote (Fig. 5.13).  
Furthermore, direct inhibition of proliferation was assessed using an MTS assay. Proliferation 
of human HER2-overexpressing, Tr sensitive cells was decreased in vitro in the presence of 
Tr (Fig. 5.14 A, B), while proliferation of the negative control cell line MDA-MB-231 was 
not impacted (Fig. 5.14 C). Proliferation was not influenced by CpG. Treatment with Tr(TH)-
CpG inhibited proliferation of HER2 overexpressing tumour cell lines to the same degree as 
Tr, with only very small differences noticeable between the two curves. Log10IC50 for Tr and 
Tr(TH)-CpG were also comparable, 0.06446 vs -0.1311 respectively for BT474 cells and -
1.250 vs -0.8609 respectively on OE19 cell (Fig.  5.14 A, B). The confidence intervals for 
these values however are wide. 
Collectively, the two assays showed that HER2 binding was only slightly lower for Tr(TH)-
CpG compared to Tr. Differences were evident in ELISA data, since the assay had superior 
resolution to the cell-based proliferation assay. In this second assay the variability between 
replicates was much higher. 
 
Figure 5.13. Tr(TH)-CpG binds human HER2 comparably with Tr in vitro. ELISA with immobilised 
recombinant human HER2 was performed. CpG/Tr(TH) molar ratio of conjugates was approx. 1.7. 
Curves generated using nonlinear regression function with variable slopes of GraphPad prism of. Data 
representative of 4 independent experiments with individual batches of conjugates. 

























Figure 5.14. Tr(TH)-CpG maintains the anti-proliferative effect of Tr measured in vitro by MTS assay. 
Human HER2 overexpressing, Tr sensitive human tumour cell lines BT474 (A), OE19 (B) and the 
negative control MDA-MB-231 (C) were cultured for 48 h with 1/2 log dilutions of Tr, Tr(TH)-CpG, 
isotype or isotype-CpG. CpG/Tr(TH) molar ration for all conjugates was approx. 1.6. The MTS substrate 
was added to asses proliferation. Data was normalised to vehicle (PBS) treated cells and expressed as 
percent proliferation. Data are representative of two independent experiments with individual 
batches of conjugates.       
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5.5 Evaluating endotoxin contamination of conjugates 
To ensure that the immune responses triggered by conjugates are mediated by CpG, and not 
by an endotoxin contamination, we tested the antibodies used for conjugation as well as the 
resulting conjugates for endotoxin. As discussed in section 4.2.3, although it has been shown 
that mice tolerate much higher doses of endotoxin without inflammatory responses (Copeland 
et al. 2005), we wanted keep the endotoxin levels as low as possible. For a 20g mouse receiving 
single dose per day of 0.1ml, the calculated limit based on recommendations from the 
European Pharmacopoeia is 1 IU/ml. Keeping to this limit would allow us to assess conjugate 
effects on human cells, either in vitro or in vivo using a humanised mouse model in the future 
without having to change our current protocols. 
To ensure the antibodies we used for conjugations are endotoxin-free, we tested individual 
preparations using the limulus amoebocyte lysate (LAL) gel-clot assay. Tr(TH) was diluted to 
0.4mg/ml for the test, as this was the concentration of mouse IV inoculum. All preparations 
tested had undetectable endotoxin levels, under 0.3 IU/ml. Similar results were observed for 
Tr as well (Table 4.2). As discussed in section 4.2.2, we took ample precautions to avoid 
endotoxin contamination in our purification workflow and no endotoxin contamination was 
expected. 
Next, we tested finished conjugates as well. The LAL gel clot assay is semiquantitative and 
the results are expressed as intervals and not discrete values. The results for our assay set-up 
fall under the following intervals: <0.3 IU, 0.3-3 IU, 3-30 IU, 30-300 IU etc. Surprisingly, the 
gel-clot assay showed levels of endotoxin in the interval of 30-300 IU/ml in all six tested 
conjugate samples, including conventional and site-specific conjugates. A similar conjugation 
protocol and plastic-ware were used in our lab for another project, where conjugates showed 
only low endotoxin levels, as measured by the chromogenic LAL assay instead of the gel-
clotting method (Kreutz et al. 2012). Literature reports that multiple factors can interfere with 
the LAL gel-clot assay and it is likely that not all have been identified yet (European 
Pharmacopeia 2019). Among them, the synthetic nucleic acid poly I:C was shown to induce 
clotting, as a consequence of intrinsic polarity of nucleic acids, leading to false-positive results 
(Elin and Utter 1980). We consider that CpG may have a similar effect and the gel-clot LAL 
assay may be inappropriate to measure endotoxin levels in CpG containing samples. 
To assess if our CpG conjugates contain endotoxin or just interfere with the LAL gel-clot 
assay, we decided to perform an additional assay using the same samples and using the same 
NIBSC endotoxin standard. The monocyte activation assay is accepted as sensitive and 
accurate for pyrogen detection including endotoxin (European Pharmacopeia 2017). This 
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assay can be performed using a variety of cell populations, including whole blood, PBMCs or 
monocytic cell lines (Franco et al. 2018). In our lab we have experience in working with 
monocyte-derived DCs and have confirmed that the cells respond to TLR4 activation by LPS 
(Brencicova et al. 2017), but not to TLR9 stimulation in response to CpG ODN (data not 
published). Therefore, we decided to evaluate endotoxin contamination of Tr-CpG conjugates 
in a monocyte-derived DC activation assay (Fig. 5.15). Monocyte-derived DCs were incubated 
overnight with endotoxin or conjugates or controls. Final concentration was 0.4mg/ml for Tr 
and 30µg/ml for CpG, either free or conjugated. These are the concentrations we intend to use 
in mouse experiments. 3-7 different batches of conjugate were pooled and tested as one 
sample. As expected, endotoxin induced IL-6 production in a dose-dependent manner, while 
CpG did not. Neither of the conjugate samples induced IL-6 production, indicating that 
endotoxin levels in these preparations were lower than 1 IU/ml.    
To summarise the in vitro data, we were able to generate conjugates using a traditional 
conjugation method and SMCC and a novel, site-specific method, the Thiomab technology. 
Traditional conjugation methods resulted in CpG conjugates with altered human HER2 
binding, while site-specific conjugates did not. Conjugated CpG maintained 
immunostimulatory activity comparable to unconjugated CpG. The conjugate preparations 
were low in endotoxin if not entirely endotoxin-free and importantly, these pooled samples 
provided sufficient material to move into in vivo investigations.   
 
Figure 5.15. Monocyte-derived dendritic cell activation assay to detect endotoxin (LPS) contamination 
in conjugate preparations. Monocytes were enriched from health donor PBMCs and differentiated 
into DCs using 20ng/ml human GM-CSF and 20ng/ml IL-4. 1x 105 monocyte derived DCs were cultured 
overnight with the indicated conjugates and controls. Tr, either free or conjugated was 0.4 mg/ml, 
while CpG, either free or conjugated was approx. 30µg/ml. Read-out was human IL-6 production 
measured by ELISA. Data are mean ± SD of technical duplicates from one experiment and are 

































































Chapter 5 Results 
 
189 
5.6 In vivo evaluation of Trastuzumab-CpG conjugates 
5.6.1 Impact of treatment with Trastuzumab-CpG conjugates on tumour growth 
To evaluate the in vivo profile of Trastuzumab-CpG conjugates, we used the B14.3 Luc HER2 
clone H2 pseudo-metastasis model described in Chapter 3. Importantly, the tumour cells 
themselves do no express TLR9 (Appendix I) and do not respond to treatment with Tr (Fig. 
3.14). Upon inoculation in mice, tumour cells maintain a moderate degree of human HER2 
expression (Fig. 3.13).  
In this model, tumour cells were injected IV to generate pulmonary tumours (Fig. 5.16 A). 
Mice were treated with 2mg/kg body weight (40µg for a 20g mouse) of Trastuzumab and this 
was normalised across samples. We chose this dose as it is in the range of clinical used doses 
(Nemeth et al. 2017) and preclinical mouse in vivo imaging studies showed successful 
accumulation of Tr dosed in this range in HER2-expressing tumours (Dennis et al. 2007; 
McLarty et al. 2009). 40µg of Tr(TH)-CpG carried approx. 2.5µg of conjugated CpG at a 
CpG/Tr molar ratio of ~1.8. This CpG dose was also kept constant across treated groups. Tr-
MCC-CpG conjugates were generated for in vivo experiments to achieve CpG/Tr molar ratio 
of 1.8-2 and showed altered HER2 binding (Fig. 5.3 A, B). Therapeutic treatment was initiated 
on day 4 post tumour-inoculation and repeated twice, on day 8 and day 11 (Fig. 5.16 A). We 
chose this schedule because many studies showing CpG efficacy in tumour immunotherapy, 
administered CpG repeatedly, usually biweekly, with at least 3 doses administered for effect 
(Kunikata et al. 2004; Kawarada, Ganss, Garbi, Sacher, Arnold, and Hammerling 2001; 
Chavez et al. 2018; Rakhmilevich et al. 2017; Sagiv-Barfi et al. 2018; Wang et al. 2016; 
Westwood et al. 2014; Yin et al. 2016; Gallotta et al. 2018). The timing of dosing is in line 
with transcriptional data of splenocytes from CpG treated mice, showing that CpG-mediated 
gene regulation drops 3 days after treatment (Bode et al. 2011). Importantly, all our in vivo 
experiments include a direct comparison of targeted CpG in the form of conjugates with 
untargeted CpG, alone or in combination with unconjugated Tr.  In vivo imaging was 
employed for non-invasive monitoring of tumour burden at days 3, 7, 10, 15 (☼). Endpoint 
was at day 18, when lungs were harvested and fixed in Fekete solution to enable counting of 
tumour nodules. (Fig. 5.16 A). 
Importantly, tumour-bearing mice do not respond to treatment with Tr, making this a Tr-
resistant mouse model (Fig. 5.16 B and D). Within this schedule of treatment, CpG alone did 
not inhibit tumour growth compared to vehicle (PBS) treated mice, as illustrated by the tumour 
nodules count (Fig. 5.16 B) and by in vivo imaging and (Fig. 5.16 D). To the contrary, tumour 
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burden was slightly higher for Tr and for CpG treated mice. Compared to these 2 controls, 
treatment with unconjugated Tr + CpG synergised to delay tumour growth, with differences 
that were significant in terms of lung nodule count (Fig. 5.16 B), but not in terms of 
luminescence intensity (Fig. 5.16 F).  
In terms of conjugates, mice treated with Tr-MCC-CpG conventional conjugates only showed 
minimally decreased tumour burden, compared to mice treated with equimolar doses of either 
Tr or CpG, which did not achieve significant differences in terms of lung nodules nor 
luminescence profile across time (Fig. 5.16 B, E, respectively). No differences were observed 
for the isotype control (Fig. 5.16 B and E). In contrast, mice treated with Tr(TH)-CpG 
conjugates had significantly lower numbers of lung tumours at day 18 (Fig. 5.16 B). The delay 
in tumour growth was more pronounced from day 10 after tumour inoculation onwards, when 
luminescence intensity plateaued at around 106 photons/s of mice treated with Tr(TH)-CpG, 
but increased steadily close to 107 photons/s for CpG treated mice (Fig. 5.16 G). 
Representative images of luminescence signal (Fig. 5.16 H) and mouse lungs after bleaching 
in Fekete solution to highlight melanoma tumour nodules (Fig. 5.16 C) are shown. This 
indicates that site-specific conjugation of anti-HER2 antibody with CpG improves efficacy of 
Tr therapy in the mouse model. Interestingly, when Tr(TH)-CpG treatment group was 
compared with vehicle treated mice, the differences were not statistically significant in terms 
of lung nodules, nor luminescence intensity of tumours. The same was observed for the Tr + 
CpG treated group as well. The reasons for this are unclear and larger treatment groups may 
be required to obtain a robust data set and to establish statistical significance over all 
experimental groups. 
Collectively, the data indicate that treatment with site-specific conjugates (Tr(TH)-CpG), but 
not conventional conjugates (Tr-MCC-CpG) delays tumour growth in mice with B14.3 Luc 
HER2 pulmonary tumours. Tr(TH)-CpG conjugates showed a therapeutic benefit compared 
to Tr alone, as well as compared to untargeted CpG. However, efficacy of Tr(TH)-CpG was 
not superior to a unconjugated combination of Tr and CpG. This was rather surprising and 
indicates that in this mouse model, combination of Tr with CpG is of therapeutic benefit, but 
that targeted delivery of CpG via Tr(TH)-CpG conjugates was either suboptimal, or does not 
bring an additional benefit. As described in chapter 1, in this model, tumour cells only show 
mild to moderate human HER2 expression in vivo. Further work evaluating the efficacy of 
Tr(TH)-CpG is required, including the use of an additional tumour mouse model to overcome 
the limitations of the used tumour model.   






Figure 5.16. Continued on next page. 





Figure 5.16. Repeated treatment with Tr(TH)-CpG only minimally decreases tumour burden in mice 
with pulmonary B14.3 Luc HER2 mice, but is not superior to unconjugated Tr + CpG. A. Mice (n=10 for 
all groups, except vehicle where n=9) were inoculated with 9x 105 B14.3 Luc HER2 clone H2 cells on 
day 0 and treated at days 4, 8 and 11 (arrows) with 40µg Tr or isotype control, with or without 3µg 
CpG 1668 either unconjugated or conjugated to antibody via the stochastic or site-specific (Thiomab) 
method. Tumour burden was monitored using in vivo imaging on days 3, 7, 10, 15 and 18 post-tumour 
inoculation (☼). B. Number of pulmonary nodules counted on the lung surface at day 18 post-tumour 
inoculation (end point). Each data point and mean are shown. Mann-Whitney T test; * p<0.05; ns – 
not significant. C. Representative images of mouse lungs bearing B14.3 Luc HER2 clone H2 tumours at 
day 18 post tumour inoculation (endpoint). D-G. Tumour growth profiles represented as luminescence 
signal of mice imaged at the indicated time-points. Data are shown as mean ± SEM. Groups were 
compared using CGGC permutation test with 10 000 permutations. H. Representative images of 
tumour burden monitored by measuring luminescence signal in vivo. Data are pooled from 3 
independent experiments. 
  
Chapter 5 Results 
 
193 
5.6.2 Serum concentration of conjugates over time 
CpG containing conjugates show additional binding to dendritic cells via the CpG moiety 
(Kreutz et al. 2012). This is likely accounted for by specificity of CpG ODN for scavenger 
receptors, expressed by dendritic cells and macrophages (Jozefowski et al. 2006; Kissick et al. 
2014). Since these and possibly other mechanisms could impact on serum persistence of Tr 
and Tr-derived CpG-containing conjugates, we investigated this parameter by ELISA.  
In this assay, human HER2-specific antibodies or conjugates were captured on human HER2-
coated plates and subsequently detected with an anti-human IgG1 Fc antibody. A standard 
ladder of Tr or conjugate was used to calculate the respective serum concentration. In our 
ELISA set-up, serum form mice treated with CpG or isotype-MCC-CpG treatment did not 
increase assay background, suggesting that neither free nor conjugated CpG interfered with 
the assay (data not shown). Since we observed that Tr(TH)-CpG conjugates were more 
efficient than Tr-MCC-CpG conjugates in delaying tumour growth, we primarily focused our 
efforts toward understanding the profile of Tr(TH)-CpG conjugates.  
First, we determined serum concentration after one dose of treatment. Mice were inoculated 
with B14.3 Luc HER2 tumour cells at day 0. At day 10 the presence of tumour burden was 
confirmed using in vivo imaging. Mice were treated with one dose of either Tr(TH) or Tr(TH)-
CpG on day 11. Serum was collected at day 1, 4 and 7 after IV treatment, which represents 
day 12, 15 and 16 after tumour inoculation, respectively (Fig. 5.17 A). Among tested time-
points, serum concentration of Tr(TH) was greatest on day 1 at 21.16±5.97 µg/ml, then 
decreased progressively and dropped to 6.78±0.458 µg/ml on day 7 post-treatment. These 
results were comparable to Tr results (Figure 4.17 B). Serum concentration of Tr(TH)-CpG 
was comparable to Tr(TH) on day 1 and day 7, at 23.14±1.76 µg/ml and 6.28±1.27 µg/ml, 
respectively. Serum concentration on day 4 however, was decreased for Tr(TH)-CpG 
(12.18±4.69 µg/ml) compared to Tr (18.11±3.61 µg/ml). Notably, standard deviations are high 
(Fig. 5.17 B). Considering that we observed high variability in tumour burden within groups 
and that tumour cells are involved in antibody metabolism, high variability in serum 
concentrations of antibody are not surprising for our set of samples. 
Secondly, we investigated whether there is a difference in serum concentration of Tr and 
conjugates at day 14 and 18 in mice treated repeatedly with a total of 3 doses on days 4, 8 and 
11 (Fig. 5.18 A). In this experiment, we observed a mild delay in tumour growth in mice 
treated either with Tr + CpG or Tr(TH)-CpG compared to controls (Fig. 5.16). Tumour burden 
was markedly variable within groups (Fig. 5.18). Serum concentration of Tr or conjugates was 
also highly variable within groups (Fig. 5.18 B-D). Serum concentration of Tr stood at 
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29.46±11.25 µg/ml on day 3 and decreased to 17.08±11.78 µg/ml on day 7 post treatment 
(days 14 and 18 of the experiment, respectively). Addition of CpG to the Tr treatment did not 
influence the serum concentration of Tr (Fig. 5.18 B). The conventional conjugate Tr-MCC-
CpG showed statistically significant lower serum concentration on both day 3 and day 7 post-
treatment (Fig. 5.18 C). This could be due to more rapid up-take of the conjugate by myeloid 
cells via the CpG moiety or rapid up-take of the higher MW species in the heterogenous 
mixture of conjugates. Surprisingly, serum concentration of Tr(TH)-CpG however, was only 
slightly lower than for Tr at both time-points, and differences did not reach statistical 
significance (Fig. 5.18 D). 
Taken together, our data indicates that metabolism of Tr(TH)-CpG conjugates is similar to Tr 
after three doses of treatment, as demonstrated by comparable serum concentration across 
time. In contrast, serum concentration of Tr-MCC-CpG was significantly decreased and may 
have contributed to the lack of impact on tumour burden observed for these mice (Fig. 5.16). 
The experimental set-up was limited in terms of time-points and therefore we cannot establish 
the maximum serum concentration or calculate pharmacokinetic parameters such as terminal 
half-life.   




Figure 5.17. Serum concentration over time of Tr(TH) and Tr(TH)-CpG after single IV administration. 
A. Mice (n=5) bearing B14.3 Luc HER2 tumours were treated once at day 0 with 40µg Tr(TH) or Tr(TH)-
CpG. Blood sampling was performed at day 1, 4 and 7 post-treatment. B. Tr(TH) (black) and Tr(TH)-
CpG (red) were detected on ELISA with immobilised human HER2 and anti-human IgG Fc detection 
antibody, then serum concentration was calculated using the respective standard ladder in the linear 
range. Data are mean ± SD and were generated in one experiment. 
 
Figure 5.18. Serum concentration over time of Tr or conjugates after administration of 3 doses. A. 
Mice bearing B14.3 Luc HER2 tumours (n=10) were treated 3 times with 40µg Tr, Tr-MCC-CpG, or 
Tr(TH)-CpG. Serum samples were harvested at day 3 and day 7 after the last round of treatment. B-D. 
Antibody or conjugate serum concentration was determined by ELISA using an antibody or respective 
conjugate standard curve. Data are shown as mean ± SD and are pooled from 3 independent 
experiments.    
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5.6.3 Treatment with Tr(TH)-CpG promotes anti-tumour T cell responses  
One of the major effects of CpG-mediated TLR9 signalling is instructing adaptive immune 
responses towards a Th1 phenotype with strong cytotoxic T cell effector functions (Iwasaki 
and Medzhitov 2015). Therefore, we investigated T cell responses induced by treatment with 
CpG alone, with Tr or in the form of conjugates. 
Mice were treated with three doses as previously described in Fig. 5.18. In these experiments, 
treatment with Tr(TH)-CpG and Tr + CpG showed a minor benefit in terms of tumour burden 
(Fig. 5.16). At endpoint, spleens were harvested, and single cell suspensions were generated. 
Splenocytes were stained with the following T cell markers: CD3, CD4, CD8, CD44 and 
CD62L and analysed by flow cytometry (Fig. 5.19 A). CD44 is a marker for activated T cells. 
Double staining with CD44 and CD62L allows for separation of activated T cells in the spleen 
into central memory T cells (CD44+CD62L+) and effector memory T cells (CD44+CD62L-) 
(Sallusto, Geginat, and Lanzavecchia 2004). Mice showed comparable numbers of CD4+ and 
CD8+ T cells across treatment groups (data not shown). Most CD44+ activated T cells were 
also CD62L+, indicating a central memory phenotype (representative plots in Fig. 19 B and 
C). This was expected, as these T cell responses were investigated at the experiment endpoint, 
which was 14 days from treatment initiation and 7 days since the last dose. Percentages of 
CD44+CD62L+ cells in the CD8+ T population were significantly higher in mice treated with 
CpG compared to mice treated with vehicle or Tr, and this was independent of the therapeutic 
format of CpG, either alone, with Tr or conjugated (Fig. 5.19 D). The same trend was observed 
for counts of CD44+CD62L+ CD8+ T cells and differences were statistically significant, except 
for counts of CD44+CD62L+ CD8+ T cells in spleens of mice treated with Tr-MCC-CpG or Tr 
+ CpG (Fig. 5.19 E). In these groups, standard deviations were much higher. A statistically 
significant increase in CD44+CD62L+ population was observed for CD4+ T cells as well, in all 
groups receiving treatment with CpG, either conjugated or not (Fig. 5.19 F, G).  





Figure 5.19. Treatment with 3 doses of CpG increases number of activated, central memory (CD44+, 
CD62L+) T cells. Splenocytes from mice treated 3 times with the indicated drugs, were harvested at 
day 18, stained and analysed by flow cytometry. A. Gating strategy used to analyse CD4+ and CD8+ T 
cells separately. B-C. Representative plots of CD8+ T cells from mice treated with Tr (B) or Tr(TH)-CpG 
(C) with gating for CD44 and CD62L. Percentages (D, F) and counts (E, G) of CD44+CD62L+ cells in the 
CD8+ T cell population (D, E) and CD4+ T cell population. Each symbol represents a mouse with n=5 for 
vehicle, Iso-MCC-CpG, Tr-MCC-CpG and Tr(TH)-CpG; n=8 for Tr and n=7 for Tr + CpG. Means 
(represented by bars) ± SD of samples from 2 independent experiments. Mann-Whitney two tailed 
test; *p<0.05; **p<0.01; ns – not significant.  
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Next, we asked if the observed T cell responses are tumour specific. To evaluate this, 
splenocytes were labelled with CFSE, which is typically diluted with each cell division, and 
then cocultured for three days with dendritic cells presenting a variety of tumour-specific 
antigens. The percentage of proliferating T cells was determined by flow cytometry. Tumour 
specific proteins and peptides included the extracellular domain of human HER2, the class I 
peptide SIINFEKL of OVA antigen and multiple predicted class I and class II peptides of 
TRP-1 and TRP-2, which are melanocyte-specific proteins present in B14.3 tumours.  
Proliferation of activated (CD44+) T cells upon tumour antigen re-encounter was measured in 
splenocyte populations from mice treated at day 11 with one dose of Tr, CpG or Tr(TH)-CpG 
(Fig. 5.20 A). Gating strategy is shown in Fig. 5.20 B. Representative histograms for 
CD44+CD8+ gated T cells from mice treated with Tr(TH) or Tr(TH)-CpG are shown in Fig. 
5.20 C. In this assay, our negative control consisting of cells from untreated mice that had not 
received tumour cells showed a degree of proliferation as well, with values of 20.3 ± 7.42 for 
activated CD8+ T cells (Fig. 5.20 D) and 14.3 ± 3.3% for activated CD4+ T cells (Fig. 5.20 E). 
After one dose of treatment, mice treated with either Tr, CpG or Tr(TH)-CpG showed 
increased percentages of proliferating activated CD8+ T cells (Fig. 5.20 D) and activated CD4+ 
T cells (Fig. 5.20 E). Treatment with Tr(TH)-CpG only minimally increased the percentage of 
tumour specific T cells in comparison to the other treatment groups and this was observed for 
both CD8+ and CD4+ T cell subtypes (Fig. 5.20 D and E).  





Figure 5.20. Effect of treatment with one dose of Tr(TH)-CpG in promoting anti-tumour T cell 
responses. A. Mice were treated once at day 11 with Tr(TH)-CpG (n=4) comprising 40µg Tr and 2.5µg 
CpG or normalised controls: Tr(TH) (n=3), CpG (n=5). Spleens were harvested at day 18. B. Splenocytes 
were labelled with CFSE and cultured for 3 days with GM-CSF derived BMDCs loaded with tumour 
specific proteins and peptides: extracellular domain of human HER2, SIINFEKL (class I OVA-peptide), 
and multiple class I and class II TRP-1 and TRP-2 peptides. Incubated splenocytes were stained for CD3, 
Chapter 5 Results 
 
200 
CD4, CD8, CD44 and analysed by flow cytometry. FMO controls were used for gating.  C. The 
percentage of CFSE diluting cells was calculated and served as a marker of proliferation. 
Representative histograms of activated CD8+ T cells from Tr(TH) and Tr(TH)-CpG treated mice. D. 
Percent proliferating activated CD8+ T cells. E. Percent proliferating activated CD4+ T cells. Each data 
point represents cells from an individual mouse. Mean ± SD are shown. Mann-Whitney two tailed test; 
ns – not significant. Data from one experiment.    
T cell antigen specific recall responses were also measured in splenocyte samples from mice 
treated repeatedly, with three doses of conjugates or controls. Spleens were also harvested at 
day 18 (Fig. 5.21 A). The experiment and analysis were performed as described above. 
Proliferation of activated T cells was observed for vehicle treated mice as well and stood at 
17.5 ± 3.1% for activated CD8+ T cells (Fig. 5.21 B) and 31.3 ± 5.9% for activated CD4+ T 
cells (Fig. 5.20 H). In the absence of tumour antigens, only low levels of proliferation were 
observed. Treatment with either Tr or CpG significantly increased the percentage of 
proliferating CD8+ T cells (Fig. 5.21 B), but only a subtle effect was observed for CD4+ T cells 
(Fig. 5.21 C). The increase in tumour specific T cells by treatment with Tr has been described 
in the literature before and has been attributed to Fc mediated facilitated uptake of tumour cells 
by DCs (Bianchini and Gianni 2014). Compared to the Tr or CpG controls, treatment with 
Tr(TH)-CpG, but not Tr-MCC-CpG, Iso-MCC-CpG or Tr + CpG was superior in promoting 
tumour antigen specific T cells even further, for both the CD8+ and CD4+ T cell populations 
(Fig. 5.21 B, C). Differences between Tr(TH)-CpG treatment and Tr treatment did not reach 
statistical significance for CD8+ T cells (Fig. 5.21 B), but were significant for CD4+ T cells 
(Fig. 5.21 C). When percentages for Tr(TH)-CpG group were compared to unconjugated CpG 
controls, differences were statistically significant for both CD8+ (Fig. 5.21 B) and CD4+ T cell 
(Fig. 5.21 C) populations. In this assay proliferation of vehicle treated mice was not compared 
to tumour-free mice and it is currently unclear if there is a difference in the background levels 
of these two controls.  
Together, these two experiments indicate that treatment with Tr or CpG moderately increase 
the percentage of tumour specific T cells. Treatment with Tr(TH)-CpG is substantially 
superior in this respect, even when compared to unconjugated Tr + CpG. This suggests that 
distinct mechanisms are responsible for the partial tumour growth control we observed in mice 
treated with Tr(TH)-CpG or Tr + CpG. Repeated treatment is required to increase the levels 
of tumour specific T cells by conjugate. This was observed for both CD8+ T cell and CD4+ T 
cell responses.  




Figure 5.21. Repeated treatment with Tr(TH)-CpG promotes anti-tumour T cell responses. A. Mice 
were treated 3 times with Tr(TH)-CpG comprising 40µg Tr and 2.5µg CpG and normalised controls, or 
with Tr-MCC-CpG. Splenocytes were incubated with peptides and analysed as described above. B. 
Proliferation of activated CD8+ T cells in percentage. C. Proliferation of activated CD4+ T cells in 
percentage. Each data point represents an individual mouse (n=4 or 5). Bars show mean, lines show 
SD. Mann-Whitney two tailed tests; *p<0.05; ns – not significant. Data from one experiment. 
Additional experiments are needed in the future to confirm these observations. Measuring 
other markers of proliferation such as Ki67 and IL-2 levels in cell supernatant would be useful 
to increase the power in future experiments. 
It is unclear at this stage if these T cell responses are directed mostly against the foreign antigen 
HER2, against OVA or the melanoma-associated antigens TRP-1 and TRP-2. The resolution 
of the proliferation assays is far from ideal and it does not seem to permit such investigations. 
Experiments using multimeric MHC / peptide complexes for detection of specific T cell 
receptors (TCR), however, might be better suited. Pentamers or dextramers detecting anti-
human HER2 specific mouse TCRs are not yet commercially available, but pentamers staining 
for SIINFEKL specific T cell receptors are and we employed them to detect anti-OVA specific 
T cells (Fig. 5.22). 
Splenocytes were collected at day 18 from tumour inoculation of mice treated with three doses 
of conjugates or controls as described above (Fig. 5.21 A). Splenocytes were cultured for 3 
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days with SIINFEKL peptide loaded onto GM-CSF derived DCs, then stained for CD8 
expression and with H-2Kb-SIINFEKL pentamer. Representative plots of Tr or Tr(TH)-CpG 
treated mice are shown (Fig. 5.22 A). Negatively selected lymph node OT-1 CD8+ T cells, 
which are specific for the OVA-peptide SIINFEKL (Hogquist et al. 1994) were used for 
positive control, to confirm assay performance (Fig. 5.22 B). No changes in the percentage of 
SIINFEKL binding CD8+ T cells were detected for any of the treatment groups, with all means 
standing between 0.15 and 0.20% (Fig. 5.22 C). This indicates that the tumour-specific T cells 
detected at higher levels in tumour-bearing mice treated with Tr(TH)-CpG (Fig. 5.21) are 
unlikely to be specific for the OVA model antigen (Fig. 5.22). 
Further investigations of the specificity of anti-tumour T cell responses promoted by treatment 
with Tr(TH)-CpG are required to better understand the effects of treatment.  
 
Figure 5.22. Anti-tumour CD8+ T cell responses are not specific for OVA-peptide SIINFEKL. A. 
Representative plots of splenocytes incubated for 3 days with 1µM of the OVA-peptide SINNFEKL 
presented by DCs and stained for CD8 and SIINFEKL specific TCR with pentamer.  B. Percent OVA-
specific CD8+ T cells. Each data point represents an individual mouse (n=5 per group). Mean ± SD are 
shown. Multiple Mann-Whitney two tailed tests showed no statistically significant differences. Data 
collected from one experiment. 
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5.6.4 In vivo antibody responses to treatment with conjugates 
Humoral anti-tumour responses were evaluated as well. We focused on groups of mice treated 
with Tr(TH)-CpG or Tr + CpG as we observed a small delay in tumour burden in these mice, 
and included their controls, mice treated with either vehicle, Tr or CpG. We assessed total 
serum antibody titres pre- and post-treatment (Fig. 5.23) and subsequently investigated if 
antibodies present in day 18 were raised against tumour-specific antigens (Figure 5.24). 
 
To assess total antibody titres, serum was harvested from tumour-bearing mice on day 1 after 
tumour inoculation (pre-treatment) and on days 14 and 18 after tumour inoculation, which are 
3- and 7-days post-treatment (Fig. 5.23 A). The treatment schedule and doses were previously 
described in section 5.6, while the tumour-burden response to treatment of these mice is shown 
in Fig. 5.16. The Mouse Immunoglobulin Isotyping Panel from BioLegend was used to 
measure total serum levels. Serum from tumour-free mice was measured as well (green 
symbols). Tr or derived conjugate (human IgG1 isotype) did not cross-react with mouse 
immunoglobulin isotyping panel (data not shown). Variability within mouse treatment groups 
as well as among treatment groups at pre-treatment baseline (day 1) was observed in this assay. 
Across antibody isotypes, day 1 serum from all treatment groups contained lower levels of 
antibodies, at comparable, or slightly higher levels than tumour-free mice. Apart from IgA 
(Fig. 5.23 F), serum levels of all other measured isotypes were increased at day 14 and 18 
post-tumour inoculation compared to day 1. This trend was observed for vehicle (PBS) treated 
mice as well, suggesting that the tumour cells, which were human HER2-transgenic, OVA-
GFP transgenic and luciferase-transgenic, induced a humoral immune response on their own.  
Levels of mouse IgG1 (Fig. 5.20 B) were comparable among all treatment groups. Mouse IgM 
(Fig. 5.23 G) levels were highest for CpG treated mice. Mouse IgG2c (Fig. 5.23 C), IgG2b 
(Fig. 5.23 E), IgG3 (Fig. 5.23 D) levels were higher in mice treated with either Tr, CpG, Tr + 
CpG or Tr(TH)-CpG compared to vehicle treated group. Treatment with Tr(TH)-CpG (red 
symbols) did not substantially influence serum levels of any of the determined antibody 
isotypes when compared to Tr, CpG or Tr + CpG treated mice. These data show increased 
serum antibody levels in tumour-bearing mice, which are moderately elevated by treatment 
with either Tr(TH)-CpG, unconjugated Tr + CpG, Tr or CpG alone.  




Figure 5.23. Serum mouse immunoglobulin titres. Total antibody levels were measured in serum 
harvested from tumour-free mice (green symbols) or tumour-bearing mice treated with conjugates or 
controls at different time-points (A) after tumour inoculation using the LEGENDplex Mouse 
Immunoglobulin Isotyping Panel (BioLegend). Serum levels of mouse antibody isotypes IgG1 (B), IgG2c 
(C), IgG3 (D), IgG2b (E), IgA (F), IgM (G) were detected. At time-point day 1 (pre-treatment), mouse 
serum within treatment groups was pooled and analysed together, as one sample per group per 
experiment. For time-points day 14 and day 18, serum from individual mice was analysed separately, 
with n=10 for each treatment group. Data pooled from two independent experiments is shown as 
mean ± SEM. 
Additionally, we asked whether the observed antibody responses were directed at B14.3 Luc 
HER2 tumour-specific antigens (Fig. 5.24), such as human HER2 and ovalbumin (OVA). For 
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this, day 18 serum was analysed by ELISA with immobilised human HER2 (Fig. 5.24 A, C, 
E) or immobilised OVA (Fig. 5.24 B, D, F). Anti-mouse IgG1 (Fig. 5.24 A, B), IgG2c (Fig. 
5.24 C, D) or IgM (Fig. 5.24 E, F) biotinylated antibodies were used to detect mouse antibody 
isotypes. We verified that neither of the detection antibodies used in this assay cross-reacted 
with human IgG1 isotype (data not shown). Serum from tumour-free mice (green) did not 
increase OD 450 readings over background in the mouse IgG1 (Fig. 5.24 A, B) or IgG2c (Fig. 
5.24 C, D) ELISA. In terms of T cell dependent antibody responses, B14.2 HER2 Luc tumour-
bearing mice developed anti-human HER2 mouse IgG1 (Fig. 5.24 A) and mouse IgG2c 
antibodies (Fig. 5.24 C) and treatment with Tr(TH)-CpG or controls did not influence levels 
of these antibodies. No mouse IgG1 (Fig. 5.24 B) or mouse IgG2c (Fig. 5.24 D) responses 
were detected for OVA antigen. To confirm the performance of the OVA-specific mouse 
antibody ELISA, a purified anti-OVA mouse IgG1 antibody (Sigma) was used as positive 
control.  
IgM responses, which do not require T cell help, were detected against both human HER2 
(Fig. 5.24 E) and OVA antigen (Fig. 5.24 F) and interestingly, albeit at lower levels, in the 
serum from tumour-free mice as well. This observation might be explained by the presence of 
natural antibodies in these healthy, antigen-free mice (Maddur et al. 2019), or might just be 
background. Anti-HER2 and anti-OVA IgM levels were indistinguishable between tumour-
free and B16-bearing mice (data not shown). Surprisingly, Tr(TH)-CpG treated mice had 
lower levels of anti-HER2 or anti-OVA IgM antibodies than vehicle or CpG treated mice at 
day 18 post-tumour inoculation. Ideally, tumour antigen-specific antibody responses would 
have been investigated in dynamic, at different time-points. In terms of localisation of humoral 
responses, further experiments evaluating germinal centre B cells and plasma cells in tumour 
tissue, tumour draining lymph nodes and spleen of these mice are required. 
Together, these data indicate that there is a humoral immune response to B14.3 Luc HER2 
tumour cells, which includes anti-human HER2, but not anti-OVA antibodies. Treatment with 
either Tr(TH)-CpG, Tr + CpG, Tr or CpG alone moderately increases total serum levels of 
mouse IgG2c, IgG2b and IgG3. When compared to vehicle, the increased serum IgG2c did 
not contain higher levels of anti-HER2 or anti-OVA IgG2c. At this stage, it is unclear whether 
the increased pool of antibodies of multiple isotypes are specific to other tumour antigens we 
did not test for or mouse self-antigens.     




Figure 5.24. Detecting anti-human HER2 and anti-OVA specific antibody responses in mouse serum. 
Serum was collected from tumour-free mice and from tumour-bearing mice at day 18 post-tumour 
inoculation, which is 7 days after the last dose of treatment with either vehicle, Tr, CpG, Tr + CpG or 
Tr(TH)-CpG. Serum was pooled from n=5 mice per treatment group or n=2 for tumour-free mice and 
was analysed on ELISA with immobilised human HER2 (A, C, E) or OVA (B, D, F). Mouse IgG1 (A, B), 
IgG2c (C, D) and IgM (E, F) were detected with specific antibodies. Purified anti-OVA mouse IgG1 
diluted at 15ng/ml was used as positive control (B). Mean ± SEM of data from two independent 
experiments. 
5.6.5 In vivo cytokine response to treatment with conjugates 
TLR9-mediated response to CpG ODN include the production of proinflammatory cytokines 
by innate immune cells, such as TNF-α and IL-6 (Krieg 2000). Overstimulation with CpG can 
induce IL-10 production (Waibler et al. 2008). Treatment with CpG induces maturation of 
dendritic cells and polarisation of CD4+ T cells towards a Th1 phenotype promoting CTL 
responses (Iwasaki and Medzhitov 2015). Activated T cells in turn produce IL-2 and IFN-ɣ 
and CTLs can produce TNF-α as well (Mehta, Gracias, and Croft 2018). We investigated 
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serum cytokine levels in mice treated with free or conjugated CpG or controls using the 
LEGENDplex mouse Th1 panel from BioLegend (Fig. 5.25). The panel included IFN-ɣ, TNF-
α, IL-2, IL-6 and IL-10. Serum was harvested from mice treated three times with 40µg Tr or 
Iso, free or conjugated with approx. 2.5-3µg CpG as shown in Fig. 5.25 A. Blood sampling 
were performed either 3 or 7 days after the last round of treatment.  
Serum levels of TNF-α and IL-2 were below the assay detection limit at both time-points (data 
not shown). Only minute amounts of IL-6 were detected at day 3 post-treatment (Fig. 5.25 D), 
which seemed slightly higher at day 7 (Fig. 5.25 E). IL-6 levels were not influenced by 
treatment.  
Mice treated with CpG, either free or conjugated to Tr or Iso showed increased IFN-ɣ levels 
at day 3 post-treatment, which achieved statistical significance, with the exception of the 
Tr(TH)-CpG group (red) (Fig. 5.25 B). IFN-ɣ levels dropped massively by day 7 (Fig. 5.25 
C). This indicates that the systemic inflammatory response induced by CpG was lowest in 
mice treated with Tr(TH)-CpG conjugates. 
At day 3 post-treatment, serum of vehicle (PBS) treated mice showed a mean of 
71.99±27.53pg/ml of the immunosuppressive cytokine IL-10 (Fig. 5.25 F). This is in line with 
other studies using B16 or B16F10 melanoma tumours (Sato et al. 2011; Liu et al. 2013) and 
is a marker of the immunosuppressive tumour microenvironment. Treatment with CpG only 
minimally if at all decreased serum IL-10. Serum from mice treated with Tr(TH)-CpG showed 
the lowest IL-10 values, but no statistical significance was achieved (Fig. 5.25 F). Notably, 
the variability within treatment groups was high. At day 7 post-treatment, we could not detect 
IL-10 in serum (Fig. 5.25 G). Importantly, the detection limit for this assay stood at 82.35 
pg/ml and IL-10 levels could have been just slightly under the threshold, resembling day 3 
levels.  
Together, these data indicate that treatment with CpG induces moderate serum IFN-ɣ levels, 
but not TNF-α or IL-2 or IL-6 at day 3 post-treatment. Since CpG-induced gene transcription 
has been shown to decrease in mice after 3 days from treatment (Bode et al. 2011), for future 
experiments, an earlier time-point would be beneficial, especially for evaluating TNF-α, IL-6 
and IL-10 levels. Notably, serum IFN-ɣ was lower in mice treated with Tr(TH)-CpG. 
Decreased levels of IFN-ɣ in systemic circulation may point to an improved safety profile of 
Tr(TH)-CpG compared to unconjugated CpG.  
  





Figure 5.25. Serum cytokine levels induced by treatment with conjugates. A. Mice were inoculated 
with 9x 105 B14.3 Luc HER2 clone H2 cells on day 0 and treated at days 4, 8 and 11 (arrows) with 40µg 
Tr or isotype control, with or without 3µg CpG 1668 either unconjugated or conjugated to antibody 
via the stochastic or site-specific (Thiomab) method. Blood samples were collected before treatment, 
3 (day 7) and 7 (day 18) days after the last dose of treatment (syringe symbol). B-G. Cytokines were 
detected in serum collected 3 days after treatment (day 14) or 7 days after treatment (day 18) using 
the LEGENDplex cytokine kit. Data are mean ± SD of n=10 mice for all day3 post-treatment groups, 
except for vehicle group where n=5 and Tr group where n=7. For day 7 post-treatment, n=3 in all 
groups, except Tr-MCC-CpG, where n=2. Mann-Whitney test; *p<0.05; **p<0.01; ***p<0.001; ns – not 
significant; < - below detection limit.  
  




In this chapter, we explored antibody drug conjugation techniques to generate Trastuzumab-
CpG conjugates. We showed that conjugates generated using site-specific conjugation 
chemistry were superior to non-specific, conventional conjugates in both in vitro and in vivo 
assays, and warrant further investigation. 
Non-specific, stochastic conjugation of CpG with SMCC to lysine residues on Trastuzumab 
(Tr) impaired binding affinity of Trastuzumab to human HER2 (Fig. 5.5). This impairment 
was payload specific, with CpG, an oligo of approx. 6.5kDa, inducing a much more 
pronounced effect than the amino acid cysteine of 0.1 kDa (Fig. 5.6). The results for 
Trastuzumab-cysteine conjugates are in line with results from other groups reporting that 
SMCC conjugation of Trastuzumab with other small molecules did not impair HER2 binding 
(Arlotta et al. 2018; Abedi et al. 2019). Antigen binding was affected after conjugation with 
CpG for both Trastuzumab and another human IgG1 antibody, Cetuximab, although the 
impairment was more substantial for Trastuzumab (Fig. 5.6). Another study employing a rat 
antibody (anti-DEC205) conjugated via SMCC to CpG 1668 showed only a mild decrease in 
antigen binding of the resulting conjugate (Kreutz et al. 2012), supporting our findings that 
the magnitude of the effect is antibody-specific. 
SMCC non-specific conjugation of Trastuzumab was reported by other groups, with various 
payloads. Since the method was employed to generate the approved conjugate Trastuzumab-
emtansine (Kadcyla®), the stability and efficacy of the conjugation method was extensively 
studied. The consensus is that non-specific, conventional conjugations methods yield 
conjugate preparations that are structurally heterogenous, with antibodies that bear no payload 
and antibodies that are conjugated to a degree that abolishes their activity (Behrens and Liu 
2014; Bakhtiar 2016; Chau, Steeg, and Figg 2019). Moreover, serum stability is poor, due to 
linker maleimide exchanges from the conjugate to thiol groups in serum proteins such as 
albumin (Alley et al. 2008). One of the reported elegant solution to these shortcomings is site-
specific conjugation using Thiomab technology (Junutula et al. 2008; Shen et al. 2012). Here, 
we showed that this conjugation chemistry results in Tr(TH)-CpG conjugates with HER2 
binding properties comparable to Tr (Fig. 5.13).  
In terms of CpG activity, this did not seem to be affected by either method of conjugation 
(Fig.5.4 and Fig. 5.12). For in vivo evaluation of Trastuzumab-CpG conjugates, we used a 
human HER2 expressing mouse model generated with HER2-transgenic B14.3 luciferase cells 
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transplanted into immunocompetent mice. This model allows for the evaluation of adaptive 
anti-tumour immune responses.  
Overall, we used only two in vivo experimental set-ups. In one set-up, mice received only one 
dose of treatment at day 11 post-tumour inoculation. Since mice were treated at a stage of 
substantial tumour burden and only once, we cannot expect much in terms of tumour growth 
control. The set-up allowed for direct comparison of serum concentration of Tr(TH)-CpG with 
the unconjugated antibody Tr(TH). Just one dose of Tr(TH)-CpG, which persisted in the serum 
comparably to Tr(Th) (Fig. 5.17), mildly increased the number of tumour antigen specific T 
cells over the unconjugated antibody in mouse spleens 7 days after treatment (Fig. 5.20). 
In further experiments, mice received three doses of treatment, starting with day 4 post-tumour 
inoculation, at 3-4 days interval. With this set-up, when compared with the parent antibody Tr 
or even unconjugated CpG, in mice treated with Tr(TH)-CpG but not with Tr-MCC-CpG 
conjugates we observed a mild delay in tumour growth (Fig. 5.16) and tumour antigen specific 
T cell responses in the spleens of (Fig. 5.21). These results were expected, since there is ample 
literature reporting the efficacy of CpG in promoting anti-tumour T cell responses, which 
controlled tumour growth (Kawarada, Ganss, Garbi, Sacher, Arnold, and Hammerling 2001; 
Kunikata et al. 2004; Wang et al. 2016; Lonsdorf et al. 2003). The mentioned studies were 
performed using CpG injected directly into the tumour and the T cell responses were much 
more robust. Further studies are needed to establish if the anti-tumour T cell responses we 
observed can be enhanced using increased doses of conjugated CpG while avoiding increased 
levels of immunotoxicity observed for high doses of unconjugated CpG. The mouse model we 
used only expressed moderate levels of human HER2 in vivo (Fig. 3.13). It would be 
interesting to evaluate the effects of treatment with Tr(TH)-CpG in a HER2-overexpressing 
mouse model. Direct comparison between intratumoral injection and targeted delivery using 
Tr(TH)-CpG would help establish the efficiency of the conjugate. To achieve this, we would 
require either a human HER2 transgenic mouse or a humanised mouse model bearing a HER2 
overexpressing xenograft.  
Notably, tumour growth was delayed in mice treated with unconjugated Tr + CpG comparably 
with mice treated with Tr(TH)-CpG. Considering that Tr was shown to promote anti-tumour 
T cell responses on its own (Bianchini and Gianni 2014), and this effect is well documented 
for CpG (Krieg 2007), it is not surprising for treatment with Tr + CpG to synergise. 
Interestingly, Tr(TH)-CpG conjugates induced increased levels of anti-tumour T cell 
responses compared to unconjugated Tr + CpG. This indicates that distinct immune activation 
profile may be responsible for the observed delay in tumour growth and importantly, it is likely 
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that multiple cell populations contribute to the effect. For instance, treatment with CpG has 
been shown to boost Tr mediated antibody-dependent cytotoxicity that delayed tumour growth 
of a Tr resistant tumour (Damiano et al. 2009). In this study, we have only analysed splenic T 
cells in different treatment groups. For the future, it would be important to analyse immune 
responses in the tumour microenvironment, to further unravel the effects of different 
treatments.   
Importantly, when drugs are administered IV the first capillary bed reached is in the lung 
(Chao et al. 2010). It is therefore possible, that the anatomic location of the tumours in our 
mouse model favours activity of Tr + CpG. Another study using subcutaneous B16F10-OVA 
tumours showed that when combined with cryosurgery IV CpG has anti-tumour effects as 
well, although intratumoral CpG is much more potent. The B14.3 Luc HER2 cells we used to 
generate pulmonary nodules generate variable tumour burden when transplanted 
subcutaneously, with some mice rejecting the tumours completely (Fig. 3.16). Another mouse 
model for subcutaneous tumour implantation would be required for accurate comparison of IV 
delivery of Tr + CpG and conjugated Tr(TH)-CpG versus intratumoural application of Tr 
+CpG.  
In addition to investigating tumour growth and T cell responses in mice treated thrice with 
Tr(TH)-CpG or controls, we also investigated antibody responses. Importantly, titres of serum 
IgG isotypes increased with time (Fig. 5.23) and implicitly, with tumour growth. This confirms 
our suspicions that the B14.3 Luc HER2 cells are recognised by the immune system of 
C57/BL6 mice. Interestingly, anti-human HER2 mouse antibodies, but not anti-OVA mouse 
antibodies were detected in B14.3 Luc HER2-bearing mice and no treatment substantially 
influenced levels (Fig. 5.24). These results indicate that human HER2 is more immunogenic 
in the mouse system than OVA model antigen and explain the spontaneous tumour growth 
control we have observed for B14.3 Luc HER2 tumours (Fig. 3.10) which was not encountered 
for B14.3 tumours expressing OVA but not human HER2 (Kreutz et al. 2012; Rajagopal et al. 
2010). The role of the Firefly luciferase in this was not investigated by us. Literature reports, 
however, that Firefly luciferase is immunogenic in mice of the C57/BL6 background (Liao et 
al. 2015). 
Notably, most studies combined CpG with other therapies (Krieg 2007). This suggests that the 
effects of CpG are not regarded sufficient for effective tumour treatment. One of the emerging 
regimens is combining treatment with CpG with immune checkpoint inhibitors. While the role 
of CpG is to promote anti-tumour immune responses, immune checkpoint inhibitors are used 
to alleviate T cell dysfunction mediated by the tumour microenvironment. This strategy is 
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currently explored both in vivo (Sato-Kaneko et al. 2017; Wang et al. 2016) and in the clinic 
(Ribas et al. 2018). In terms of our experimental setting, it remains to be determined if synergic 
effects of Tr and CpG, at higher doses then what we used, administered under various routes 
are sufficient to treat HER2 expressing, tumour-bearing, immunocompetent mice and induce 
long term protection.  
To summarise the findings in this chapter, conventional conjugation of CpG to Trastuzumab 
results in conjugates with poor binding specificity, accelerated clearance from serum and no 
anti-tumour effect. Site-specific conjugates generated using the THIOMAB technology were 
highly specific for human HER2 and promoted tumour specific T cell responses in vivo. These 
T cell response were more pronounced in mice treated with Tr(TH)-CpG, than in mice treated 
with unconjugated Tr and CpG. Both treatments, however, delayed tumour growth in mice 
bearing tumours with moderate HER2 expression in a comparable way.  
 






In this study we explore antibody-based targeted delivery of endosomal TLR agonists to the 
tumour tissue for the promotion of anti-tumour immunotherapy. Presently, the interest of the 
scientific community in using endosomal TLR agonists to boost anti-tumour immunity is 
increasing (Tang et al. 2018; Tang, Shalabi, and Hubbard-Lucey 2018). For activity, 
endosomal TLR agonists need to concentrate to the tumour microenvironment. Additionally, 
concentration at the tumour site has the potential to minimise activation of immune cells in the 
healthy tissue, thus preventing immune-mediated side-effects (Murthy, Minehart, and Sterman 
2017; Marabelle et al. 2018). In light of the current landscape, exploring targeted delivery 
approaches for endosomal TLR agonists becomes a relevant research avenue. Successful 
targeted delivery of endosomal TLR agonists would enable their investigation in patients with 
metastatic disease that is not safely accessible to direct injection. 
In this project, one strategy for targeted delivery of nucleic acid endosomal TLR agonists 
employs complex formation of these nucleic acids with LL37 cationic peptides, fused with the 
anti-human HER2 antibody Trastuzumab. In terms of the fusion antibody, we show that 
efficient recombinant expression requires a suitable linker to separate the cationic LL37 from 
the CH3 domain of the antibody, which requires homodimerization mediated by ionic 
interactions to ensure appropriate antibody folding. Among tested linkers, H3 linker was found 
to facilitate highest levels of antibody expression. In the current scientific context, where 
fusion proteins and especially fusion antibodies are being extensively explored as therapies, 
these findings are significant, identifying a linker that allows recombinant expression of full-
length fusion antibodies with a LL37, a peptide with strong cationic charge. In addition to 
allowing for efficient recombinant expression, the linker H3 enabled maintained function of 
each moiety. Trastuzumab-H3-LL37 showed comparable HER2 binding affinity to the parent 
Trastuzumab, and similar nucleic acid binding affinity with the LL37 synthetic peptide.  
Typically, significant concentration of anti-tumour monoclonal antibodies at the tumour site 
can be observed after hours to days from intravenous administration (Massicano, Marquez-
Nostra, and Lapi 2018). In stark contrast with Trastuzumab, the fusion antibody Trastuzumab-
H3-LL37 is undetectable in serum after one day since injection and we believe this is an effect 
of the LL37 moiety. The same is true for Trastuzumab-H3-LL37 complexed with CpG. These 
results are important, as they highlight that Trastuzumab-H3-LL37 antibodies or CpG 
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complexes are highly unlikely to concentrate to the tumour tissue. This implies that the 
properties of Trastuzumab-H3-LL37 + CpG make this approach unsuitable for systemic 
administration. Local administration to the tumour site, on the other hand, may be efficient in 
inducing anti-tumour immune responses and is worth investigating. Considering that LL37 
facilitates access of nucleic acid TLR agonists to the endosomal compartment, and nucleic 
acid TLR agonists are powerful adjuvants, LL37, either alone or fused with other proteins, 
may be a useful tool in developing vaccines. 
A previous study demonstrates that LL37 can deliver nucleic acids intracellularly using lipid 
rafts, in a process that depends on glycans on the cell surface (Sandgren et al. 2004). Other 
studies showed that LL37 interacts with various cell receptors (Kahlenberg and Kaplan 2013), 
and even changes the physico- chemical state of the cell membrane (Di Nardo et al. 2007; 
Perregaux et al. 2002; Zughaier, Shafer, and Stephens 2005). It is therefore possible, that cells 
in the blood consume LL37 rapidly through mechanisms that are not yet well understood, 
leading to low serum availability. We believe that further exploring the behaviour of LL37 in 
serum is valuable, as it may inform on how to potentially harness LL37 efficiently for therapy. 
In addition to generating fusion antibodies, this study also explored biochemical conjugation 
technologies to generate Trastuzumab conjugates with the TLR9 agonist CpG. To generate 
conjugates, both conventional and site-specific conjugation methods were used. CpG can be 
synthesised either with a 3’ terminal thiol group, and used to generate conventional conjugates, 
or with a terminal 3’ amino group to be used in generating THIOMABs. In both cases, 
functionality of CpG is maintained post-conjugation, supporting other reports of maintained 
CpG activity upon conjugation at the 3’ end (Kramer, Young, and Walker 2017; Kandimalla 
et al. 2002). Furthermore, we show that for CpG conjugates, the conjugation chemistry heavily 
impacts the functionality of resulting purified conjugates in vitro. In contrast with site-specific 
conjugates generated using THIOMAB technology, conventional conjugation using the 
SMCC linker results in Trastuzumab-MCC-CpG conjugates with markedly reduced binding 
affinity compared to Trastuzumab. This study highlights that linking nucleic acid molecules 
such as CpG to monoclonal anti-tumour antibodies such as Trastuzumab is technically 
challenging and requires advanced technologies such as THIOMAB generation. In our 
experience, the process is labour intensive as well. 
To investigate the effects of conjugates in vivo, we have developed a mouse model with human 
HER2 transgenic B16 cells in immunocompetent mice. In our mouse model, tumour growth 
can be tracked over time by measuring luminescence activity and experimental turn-around is 
rapid for a tumour mouse model, of 18 days. Using this mouse model, we demonstrate that 
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biochemical conjugates have longer persistence in serum than complexes. Interestingly, 
Tr(TH)-CpG site-specific conjugates, generated using THIOMAB technology, persist in 
circulation at higher concentrations than conventional conjugates. Moreover, these site-
specific conjugates delay tumour growth in immunocompetent mice bearing pulmonary 
human HER2-transgenic B16 tumours, even when HER2 expression is at moderate levels. The 
conjugates, however, are not superior in this respect to soluble Trastuzumab + CpG. 
Importantly, we show that treatment with Tr(TH)-CpG promotes tumour-specific T cell 
responses, which are more pronounced than for treatment with Trastuzumab + CpG or either 
of the components. In light of these results, it remains to be confirmed if treatment with 
Tr(TH)-CpG is in any way superior to treatment with unconjugated Trastuzumab + CpG in 
mice with pulmonary tumours. Another important question that remains to be answered in the 
future is how the two treatments compare in mice with tumours localised at other sites, which 
unlike the lung, are not the first reached capillary bed. Importantly, it remains to be determined 
if higher doses are more efficient, and if other routes of administration are more suitable. These 
experiments would help establish if the conjugates are more efficient than co-injection of the 
components. 
It is now accepted that CpG directly activates B cells and results in increased antibody 
responses of IgM and IgG isotypes (Alugupalli et al. 2007; Browne 2012; Hua and Hou 2013). 
In our experimental set-up, there is little evidence that B cells are specifically activated by 
treatment with CpG, in either therapeutic format, as evidenced by similar levels of antibodies 
against tumour antigens compared to vehicle treated mice.  
Importantly, our study did not address changes in immune responses at the tumour site. Since 
it is well known that the tumour microenvironment is immunosuppressive and leads to T cell 
dysfunction (Anderson, Stromnes, and Greenberg 2017), it would be good to investigate the 
tumour T cell infiltrate and activation levels. There are other studies showing that treatment 
with CpG expands anti-tumour T cells, but the immune suppression of the tumour 
microenvironment precludes optimal function, and this can be alleviated by concomitant 
treatment with an immune checkpoint inhibitor (Wang et al. 2016; Sato-Kaneko et al. 2017). 
It would be interesting to investigate if a similar pattern is observed after treatment with 
Tr(TH)-CpG or controls.  In addition to evaluating T cell responses, it would be interesting to 
investigate if other immune cells in the tumour microenvironment are activated by treatment 
and contribute to tumour growth control. To exemplify, it has been shown that NK cells induce 
ADCC contributing to tumour growth control (Lo Nigro et al. 2019), and that these responses 
may be enhanced by cytokines induced by CpG stimulation of dendritic cells (Asselin-Paturel 
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and Trinchieri 2005; Marshall et al. 2006). Flow cytometry could be used to define tumour 
infiltrating cell populations and their activation status. Another interesting experiment would 
be to evaluate local cytokine production as a function of treatment, for instance using RT PCR. 
While this study focuses largely on the generation and initial characterisation of conjugates, 
their adverse effects are an important question to be addressed. It is now accepted that systemic 
administration of endosomal TLR agonists can be dangerous, with several clinical trials being 
stopped due to immune mediated adverse effects. It remains to be determined if conjugation 
to antibodies such as Trastuzumab achieves sufficient concentration to the tumour site while 
sparing other tissue from unintended inflammation. We know from previous publications as 
well as experience in our lab that CpG can bind to membrane receptors on myeloid cells 
(Kreutz et al. 2012), likely scavenger receptors (Jozefowski et al. 2006; Kissick et al. 2014). 
It is currently unclear to what extent site-specific conjugates are taken up in myeloid cell rich 
tissues such as the spleen and if this leads to adverse effects. Future experiments are required 
to establish tissue distribution of conjugates as well as immune activation in those tissues. 
From our limited set of in vivo experiments, we can point out that treatment with CpG, alone, 
with Tr or conjugated to a THIOMAB increases the numbers of activated T cells in the spleen. 
Only a fraction of these cells, however, proliferate in the presence of tumour-specific peptides, 
raising the question about the specificity of the rest of the population and the potential for 
adverse effects.  
In terms of evaluating adverse effects, a good future step would be to investigate immune 
responses at multiple time-points during treatment. This would allow us to investigate T cell 
responses at their peak and better delineate their specificity. Additionally, serum cytokines 
should be measured as well. The experiments we have already performed for cytokine 
responses are suboptimal in terms of set-up, with serum harvested at only one time-point, late, 
at day 3 after the last dose of treatment. This time-point is not appropriate to measure levels 
of cytokines produced by innate immune cells in response to CpG activation such as IL-12, 
IL-6 and TNF-α. Future experiments measuring levels of a variety of cytokine would be 
helpful in investigating safety of treatment with free and conjugated CpG, since it is accepted 
that high serum levels of cytokines such as TNF-α and interferons are indicative of systemic 
immune activation leading to adverse effects (Tisoncik et al. 2012; Clark 2007).  
For this study, we used Trastuzumab, which is a human IgG1 isotype antibody in a mouse 
system. There is a good degree of cross-talk between human IgG1 and mouse innate immune 
cells, and decent levels of antibody-mediated effects are observed (Overdijk et al. 2012). 
However, Fc interactions could be further improved by using another isotype and by using 
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mouse antibodies in mouse systems or human antibodies in humanised mouse systems. Recent 
reports show that antibodies targeting tumour antigens of the IgE isotype are superior in 
mediating antibody-dependent effects, as well as recruiting other immune cell populations 
against tumours, and are more efficient in controlling tumour growth in rat tumour models 
(Josephs et al. 2015; Josephs et al. 2017) and humanised mouse models bearing patient derived 
xenografts (Cheung et al. 2018). It would be very interesting for our project compare the IgG 
with an IgE antibody in the composition of conjugates. 
In terms of the mouse model, we identified a few important limitations in the course of the 
study. For one, human HER2 expression is significantly diminished in vivo in 
immunocompetent mice compared to levels of in vitro cultured cells. This is relevant, since it 
impacts accumulation of conjugates at the tumour site. It would be interesting to study the 
effect of Tr(TH)-CpG conjugates compared with the unconjugated components in mice 
bearing HER2 overexpressing tumours. This may be achieved by using human HER2 
transgenic mice as host for the B14.3 Luc HER2 cells to enable HER2 tolerance (Piechocki et 
al. 2003). Another option would be to use humanised mouse models engrafted with human 
immune cells and bearing HER2 xenografts. These humanised mouse models, however, have 
their own limitations, which include lymph nodes that are not fully developed and incomplete 
reconstitution of certain cell populations (Morton et al. 2016; De La Rochere et al. 2018).  
Another significant limitation is that some mice spontaneously control tumour growth. We 
demonstrated that mice bearing B14.3 Luc HER2 tumours have increased levels of serum 
antibodies compared to tumour-free mice. Anti-HER2 IgG antibodies, but not anti-ovalbumin 
antibodies can be detected in the serum of these tumour-bearing mice. We know from previous 
work in our lab that B14.3 tumours, which are ovalbumin transgenic, are not spontaneously 
controlled by mice, we can assume that human HER2 is a more powerful antigen in the mouse 
system, either because it is a human protein, or due to the extracellular domain, or both. It 
would be of interest to us to explore the use of human HER2 transgenic mice as hosts for the 
B14.3 Luc HER2 cells (Piechocki et al. 2003) and evaluate immune responses in the presence 
and absence of treatment.   
Effective evaluation of Tr(TH)-CpG in vivo is further complicated by distinct TLR9 
expression patterns in the mouse and human immune system. Rodent macrophages and 
myeloid dendritic cells express TLR9, while human macrophages do not (Anwar et al. 2019). 
This is especially relevant in the context of tumours, which contain high numbers of tumour 
associated macrophages which modulate the tumour microenvironment (Pollard 2004). An 
ideal tumour animal model, therefore, would be reconstituted with both human antigen-
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presenting cells and T cells. This may be difficult to achieve using humanised mouse models, 
since tissue-resident dendritic cell populations are not easy to reconstitute efficiently. 
Currently, literature reports that for efficient DC reconstitution, treatment of NSG mice with 
specific growth factors such as Flt3L is required (Ding et al. 2014). Additionally, engraftment 
with human CD34 stem cells, but not PBMCs is required for generation of DCs, significantly 
increasing the cost of the model and the reconstitution time from 2 to 12-16 weeks (Skelton, 
Ortega-Prieto, and Dorner 2018).  
Importantly, TLR9, as well as other endosomal TLRs can be expressed by tumour cells as well 
and may be functional, leading to tumour growth (Gao et al. 2018; Shahriari et al. 2017; Ren 
et al. 2007; Cen, Liu, and Cheng 2018). These finding are important, and the effects of CpG 
in growth of TLR9 expressing tumour cells should be tested in the experimental setting. In 
terms of The B16 cells we used to develop our mouse model, we know that they are TLR9 
negative, and we expect CpG to only trigger TLR9-expressing immune cells.   
To conclude, we demonstrate that generation of Trastuzumab-CpG conjugates with retained 
antibody specificity and CpG immunoactivity is feasible using site-specific conjugation and 
the THIOMAB technology. Current in vivo data highlights the difficulty and complexity in 
evaluating the effects of the conjugate. However, the approach has merit and it is worth 
exploring further in the aforementioned mouse models. This would further inform on the 
potential and limitations of Tr(TH)-CpG conjugates, as well as enable defining the 
requirements of a more effective targeted delivery method of endosomal TLR agonists to the 
tumour tissue for the promotion of anti-tumour immunity. 
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Vector map of pcDNA3-HER2WT 
(Addgene # 16257; http://n2t.net/addgene:16257; RRID:Addgene_16257)  
Sequence downloaded from: 
https://www.addgene.org/browse/sequence/43248/ 









































































































































































































































Vector map of pSIN-SFFV-luc2.1 (from Kam Zaki)  



































































































































































































































































Vector map of pVITRO1-Trastuzumab-IgG1/κ  
(Addgene plasmid # 61883; http://n2t.net/addgene:61883; RRID: Addgene_61883) 
Sequence downloaded from 
https://www.addgene.org/browse/sequence/212721/ 











Sequence of pVITRO plasmid encoding Trastuzumab IgG1/κ as recovered from 

































































































































































































Heavy chain sequence 
Variable region exchanged to generate isotype controls     
Linker sequence  
LL37 sequence 
Stop codon 
Light chain sequence 
Variable region exchanged to generate isotype controls     
Valine at position 205 (Kabat numbering) exchanged with Cysteine (codon TGT) to 








Sequences introduced in the pVITRO1-Trastuzumab-IgG1/κ 
to generate Trastuzumab-linker-LL37 
 
LL37:  








1. Hinge region of human IgG2 
Nucleotide sequence – 57bp: 
GAGCGCAAATGTTGTGTCGAGTGCCCACCGTGCCCAGCACCACCTGTGGCA
GGACCG 
Amino acid sequence - 19aa: ERKCCVECPPCPAPPVAGP 
2. G4S  
Nucleotide sequence - 15bp: GGAGGTGGAGGTTGT 
Amino acid sequence – 5aa: GGGGS 
3. (G4S)x2 
Nucleotide sequence – 30bp: GGTGGAGGCGGTTCAGGCGGAGGTGGCTCT 
Amino acid sequence – 10aa: GGGGSGGGGS 
 
4. (G4S)x3 
Nucleotide sequence – 45bp:  
GGTGGAGGCGGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCG 






5. H1– LEAEAAAKALE 
Nucleotide sequence – 33bp: CTGGAAGCTGAGGCAGCGGCCAAGGCCCTTGAG 
Amino acid sequence – 11aa: LEAEAAAKALE 
 
6. H2 – LEA(EAAAK)2ALE 
Nucleotide sequence - 48bp: 
CTGGAAGCTGAGGCAGCGGCCAAGGAAGCTGCAGCCAAGGCCCTTGAG 
Amino acid sequence - 16aa: LEAEAAAKEAAAKALE 
 
7. H3 – LEA(EAAAK)3ALE 
Nucleotide sequence - 60bp: 
CTGGAGGCCGAGGCCGCCGCCAAGGAGGCCGCCGCCAAGGAGGCCGCCGC
CAAGCTGGAG 
Amino acid sequence - 20aa: LEAEAAAKEAAAKEAAAKLE 
 
8. H4 – LEA(EAAAK)4ALE 
Nucleotide sequence - 78bp: 
CTGGAAGCAGAGGCGGCTGCAAAGGAGGCTGCAGCCAAAGAGGCCGCTGC
TAAAGAAGCCGCCGCCAAGGCCCTCGAA 








Sequences of variable regions exchanged in pVITRO1-Trastuzumab-IgG1/κ 
plasmid to generate isotype controls for Trastuzumab, Trastuzumab-LL37 or 
THIOMAB 
 
























Expression of endosomal Toll-like Receptors (TLR) in steady-state  
mouse tumour cell lines 
 
 
Figure I. Expression of endosomal TLR in steady-state mouse tumour cell lines. A. Semi-quantitative RT-
PCR where control cells are enriched CD11c splenocytes. B. Real time PCR levels (Ct) are shown relative 
to the house keeping gene GADPH. Data are representative of 2 independent experiments. Data were 








Validation of human IgG1 isotype controls  
expressed from pVITRO-1F6/Mac IgG1 plasmids 
 
Figure J1. Human IgG1 isotype controls generated in our lab analysed by SDS-PAGE in non-reducing 
conditions. Compared to the human IgG1 antibody Trastuzumab, all isotype control antibodies, including 
clone 1F6/Mac #8 (red), migrated similarly. The gel was stained with SimplyBlue. 
 
Figure J2. Isotype control 1F6/Mac hIgG1 shows similar, if not lower background staining than the 
commercial antibody UltraLEAF hIgG1. Mouse splenocytes (A), human PBMCs (B), DNGR1+ B3Z cells (C), 
mouse melanoma cell lines (D) and human cancer cell lines (E) were stained with either the commercial 
UltraLEAF isotype control (open blue histogram), 1F6/Mac hIgG1 (filled grey) or Trastuzumab hIgG1 
(green) for positive control, then an anti-human IgG secondary. Mouse splenocytes (A) and human PBMCs 
(B) were also stained with the indicated surface markers. Cells were analysed by flow cytometry. 













Figure K. Analysis of mouse GM-CSF derived BMDCs by flow cytometry. Cells were harvested, stained and 
analysed at day 6 of culture. All gating was performed according to full minus one + isotype (FMO) 
controls. CD11c+ MHC II+ Gr-1- cells comprising macrophages and dendritic cells contain a CD86+ subset. 
Granulocytes are defined as Gr-1+ CD11c- cells and were confirmed MHC II– and CD86-. Data representative 




















Figure L. Analysis of mouse Flt3L-derived BMDCs by flow cytometry. Unstimulated cells were harvested, 
stained and analysed at day 10 of culture. All gating was performed according to full minus one + isotype 
(FMO) controls. Plasmacytoid DC (pDCs) were defined as CD11c+ B220+ CD11b- cells. Conventional DCs 
were defined as CD11c+ CD11bhigh B220- CD24- cells. CD8α-like DCs were defined as CD11c+ CD24+ CD11blow 







Cell populations in panDCs isolated from human PBMCs  
 
 
Figure M. Flow cytometry analysis of panDCs isolated from human PBMCs. panDCs were isolated using 
the EasySep® Human panDC Enrichment Kit and Silver Magnet (Stem Cell Technologies). Cells were 
stained for surface markers and analysed on BD Canto II. Full minus one (FMO) controls were employed 
for gating. Plasmacytoid DC (pDCs) were defined as BDCA-2+ HLA-DRhigh, CD19- cells. Myeloid DCs type 1 
(mDC1) were defined as BDCA-1+ HLA-DRbright CD14- CD19- cells. Myeloid DCs type 2 (mDC2) were 
defined as BDCA-3+ HLA-DRhigh CD14- CD19- cells. Data representative of two independent experiments 
with cells from individual donors. 
 


















S1. Toll-like receptors (TLR) - general structure 
Toll-like receptors (TLRs) are membrane bound proteins that recognise pathogen-associated 
molecular patterns (PAMPs), triggering immune responses (Medzhitov 2007). TLRs are type I 
transmembrane glycoproteins, each containing extracellular, transmembrane and intracellular 
signaling domains (Gay and Gangloff 2007). As described in section 1.2 of this thesis, TLRs 
localise either to the cell surface, recognising molecular motifs present on the surface of microbes 
(lipids, lipoproteins, glycans), or in the endosomal compartment, recognising nucleic acid 
molecules (Iwasaki and Medzhitov 2015).  
Despite the broad spectrum of motifs recognised by TLRs, the ligand-binding domains of these 
receptors are surprisingly similar. The extracellular domain (ECD) of all TLRs consists of tandem 
repeats of leucine-rich repeats (LRR) motifs. Each LRR motif is typically 22-29 residues long. 
The extracellular domain of all TLRs adopt a horseshoe shape with glycans distributed throughout 
the structure, except for the N-terminal ascending loop (Fig. S1 A), which is most often non-
glycosylated, leaving it free to bind ligands and be involved in dimerization (Fig. S1 B). While 
the general structure of TLR ECDs follows the same principles, these structures cannot be 
superimposed due to differences in curvature (Botos, Segal, and Davies 2011).  
Importantly, ligand binding induces dimerization of TLRs, forming an m-shape with the C-
termini in immediate proximity, and this induces dimerization of the intracellular domains 
triggering receptor signaling. In terms of endosomal TLR agonists, crystallography experiments 
determined the structures of multiple TLR-ligand complexes. For TLR9 activation, it was shown 
that a single CpG molecule interacts with both the N-terminus (LRR1–10) of one TLR9 ECD, as 
well as a C-terminal ECD region (LRR20–22) of an adjacent TLR9 molecule, inducing formation 
of an m-shaped dimer (Ohto et al. 2015). Similarly, each TLR3 contains two binding sites for 
dsRNA, and ligand binding induces TLR3 dimerization (Liu et al. 2008). Both TLR7 and TLR8 
ECDs contain a binding site for nucleosides, labelled site 1 and a binding site for 
oligoribonucleotides, labelled site 2. Site 1 interfaces contribute most to receptor dimerization. 
For site 1, TLR7 prefers guanosine, while TLR8 prefers uridine. The similarities in structure of 
guanosine and uridine, as well as potent small antiviral molecules such as imidazoquinolines 




imiquimod and resiquimod, explain to a degree how these ligands can activate both TLR7 and 
TLR8 (Tanji et al. 2015; Zhang et al. 2016; Zhang, Ohto, and Shimizu 2017). 
In terms of the transmembrane domains of TLR receptors, these mostly consist of hydrophobic 
residues and differ in sequence for cell membrane TLRs and endosomal TLRs. The 
transmembrane domain of endosomal TLRs interact with the multispan transmembrane protein 
UNC93B, and traffic to the endosomal compartment (Brinkmann et al. 2007), while other TLRs 
do not, trafficking directly to the cell membrane. 
The signaling domain of TLRs share homology with signaling domains of IL-1 receptor family 
and are hence called Toll IL-1 receptor (TIR) domains (O'Neill and Bowie 2007). Importantly, 
dimerization of the ECDs induces dimerization of the signaling TIR domains, which in turn recruit 
adaptor proteins, of which MyD88 is most often employed (Jin and Lee 2008). For details on the 
signaling cascade of endosomal TLRs and differences between TLR3 and TLR7/8/9 signaling, 
please see section 1.2.1.   
 
Fig. S1. Schematic structure of TLRs. A. Structure of TLR monomers. N-terminus, extracellular domain 
(red), transmembrane (green) and signalling domains (grey) are labelled. B. Schematic representation of 
ligand induced dimerization of TLR receptors, exemplified for TLR9 and CpG molecules (blue).  
S2. Approved immunotherapies containing endosomal TLR agonists 
Presently, only two TLR agonist preparations are approved as immunotherapies for cancer: 
bacillus Calmette–Guérin (BCG) and imiquimod.  
Bacillus Calmette–Guérin (BCG) is an immunotherapy approved for the treatment of superficial 
bladder cancer. The delivery method is by intravesical instillation (Guallar-Garrido and Julian 
2020). Essentially, BCG is a live attenuated preparation of Mycobacterium bovis, containing high 




levels of unmethylated CpG motifs and peptidoglycans, which simulate primarily TLR9, TLR2 
and TLR4 (Kaczanowska, Joseph et al. 2013). While the mechanisms leading to tumour growth 
control and protection from recurrence have not been completely elucidated, it has been shown 
that the inflammation resulting from TLR triggering is responsible for efficacy, with CD4 and 
CD8 T cells playing an important role (Biot, Rentsch et al. 2012). Despite being first reported as 
an efficient therapy for superficial bladder cancer in 1976 (Morales 1976) and approved for 
clinical use by the Food and Drug Administration (FDA) in 1990 (Morales 2017), intravesical 
BCG remains one of the most often used and efficient therapies for treating high-risk superficial 
bladder cancer. Importantly, treatment with BCG offers protection from recurrence and 
progression of disease (Guallar-Garrido and Julian 2020).  
There are, however, numerous limitations to BCG immunotherapy. These include poor efficiency 
for invasive bladder cancers, a possibility of infection due to BCG, and adverse effects (Guallar-
Garrido and Julian 2020). The EORTC trial showed that 70% of patients experienced adverse 
effects, milder ones including flu-like symptoms and bladder discomfort, while 8% of patients 
discontinued treatment due to the severity of adverse effects (Brausi, Oddens et al. 2014).   
The only other approved TLR agonist for cancer immunotherapy is Imiquimod. This lipophilic 
small molecule from the class of imidazoquinolines (Fig. S2) is an agonist of human TLR7 and 
TLR8 (Schon and Schon 2008). Imiquimod is approved for topical treatment, in the form of a 
cream, of a range of cutaneous lesions, including superficial basal cell carcinoma (Scarfi et al. 
2020) and melanoma in situ (stage zero melanoma) (NICE Pathways 2020). The mechanism of 
action involves TLR 7/8 activation at the tumour site, inducing an inflammatory response 
characterised by cytokine production (IL-1, IFN-α, IFN-γ, and TNF-α), CD4 and CD8 T cell 
responses (Urosevic et al. 2003). Additionally, research also showed that accumulation of 
activated plasmacytoid dendritic cells (pDCs) into the tumour tissue contributes to the therapeutic 
effect in patients (Dummer et al. 2003).    
 
Fig. S2. Chemical structure of the imidazoquinoline derivative Imiquimod. 




A 5% imiquimod cream was shown to induce clinical and histological clearance of superficial 
basal cell carcinoma with a 3 year of success rate of 83.6% (Williams et al. 2017). Treatment with 
imiquimod is an approved alternative for patients with skin tumours at sites where surgical 
excision is not feasible or for patients that would no undergo surgical treatment. Notably, 
treatment with imiquimod has only been shown to be effective for superficial, low-risk skin 
tumours (Love, Bernhard, and Bordeaux 2009; Scarfi et al. 2020). In terms of side effects, the 
most common ones are local and include pruritus, pain and burning at the site of application. 
Rarely, back pain, sinusitis or even upper respiratory tract infections were noted in patients. 
Typically, adverse effects are quite mild, and only rarely result in stopping the treatment (Geisse 
et al. 2004; Love, Bernhard, and Bordeaux 2009).  
To summarise, both TLR-based immunotherapies currently approved for treatment of cancers are 
delivered locally to the tumour tissue to induce anti-tumour immune responses. Their broader use 
is currently limited by both side effects, and the requirement for the drug to spatially co-localise 
with the tumour tissue.  
S3. Potential for utilising cross-linking reagents beyond SMCC 
In this thesis we explored two types of conjugation strategies to generate Trastuzumab-CpG 
conjugates. Both strategies, namely conventional biochemical conjugation to amines on 
Trastuzumab and site-specific conjugation using THIOMAB technology made use of the SMCC 
cross-linker (Fig. S3 A). The justification for using this reagent was presented at length in Chapter 
5 - Introduction. In short, SMCC is a non-cleavable linker, allowing for conjugation of primary 
amines via the NHS ester and conjugation to thiol groups via the maleimide. The two functional 
groups are separated by a cyclohexane ring spacer, which is 8.3 angstrom long. This cyclohexane 
ring confers added stability to the maleimide group by decreasing its rate of hydrolysis (Brinkley 
1992; Mattson et al. 1993). When used to generate Trastuzumab-DM1 conjugates, SMCC 
provided higher serum stability to conjugates compared to other cross-linkers (Lewis Phillips et 
al. 2008). This linker is also well described in literature, and commercially available.  
One of the limitations of this study is that only one cross-linker was used to generate conjugates. 
Other cross-linkers containing an NHS ester and a maleimide group are available, with different 
spacers, that confer different properties to the cross-linker, and may in turn influence the 
properties of the conjugate. For instance, the cross-linker LC-SMCC (Fig. S3 B) is a variation of 
SMCC containing a long cyclohexane-stabilised spacer arm of 16.2 angstroms (Masuko 2003; 
Mattson et al. 1993). The presence of the longer cyclohexane bridge maintains the advantage of 




stabilising the maleimide group, while offering better spatial separation of CpG from the antibody. 
This may improve access of conjugated CpG to TLR9 in the endosome.  
For the conventional conjugates, we have shown that binding to human HER2 is impaired as a 
result of conjugations CpG, but not smaller molecules such as cysteine. Using cross-linkers with 
longer spacers may lead to conjugates with superior HER2 binding affinity. To fully explore the 
degree of separation between the functional groups of the cross-linker that leads to Trastuzumab-
CpG conventional conjugates with better HER2 binding, SM(PEG)n (Fig. S3 C) linkers could be 
used. These linkers consist of an NHS ester and a maleimide separated by polyethylene glycol 
(PEG) spacers of 2-24 ethylene glycol units, with lengths varying from 17.6 to 95.2 angstroms 
(Bidast et al. 2020; Shukla et al. 2015). In addition to the benefit of longer spacers, PEG-
containing reagents have been shown to provide additional advantages including better solubility, 
lesser potential for precipitation, and may mask the conjugate from enzymatic degradation, which 
is why PEGylation is widely used to improve the properties of various protein therapies such as 
PEG-interferon (Gupta et al. 2019). The availability of anti-PEG antibodies opens additional 
avenues for detection of conjugates in assays (Kozma et al. 2020). While using PEG-containing 
linkers is expected to improve the therapeutic potential of Trastuzumab-CpG conjugates, whether 
generated using conventional biochemical conjugation, or THIOMAB technology, the expected 
disadvantage is that these linkers may render the maleimide group, and therefore the conjugate, 
less stable in serum.  
In summary, different cross-linkers, such as LC-SMCC or SM(PEG)n can be explored to further 
optimise the therapeutic potential of Trastuzumab-CpG conjugates. 
 
Fig. S3. Chemical formulas of: A. SMCC, B. LC-SMCC, C. SM(PEG)n, n=2-24. 
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